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Abstract
The pro-inflammatory cytokine IL-1 induces the synthesis of many genes during 
inflammation. The signalling mechanisms triggered by IL-1 include activation of 
several distinct parallel MAP kinase pathways. The p38 MAP kinase pathway is 
activated particularly strongly by this cytokine. MAPKAP kinase-2 (MAPKAPK-2) is 
one of several p38 substrates that are regulated by direct phosphorylation. Few 
MAPKAPK-2 substrates are known. One of these, the small heat shock protein 27 
(Hsp27), is rapidly phosphorylated following MAPKAPK-2 activation. In an attempt 
to delineate the role of MAPKAPK-2 in IL-1 signalling, IL-1 a  induced MAPKAPK-2 
activity was inhibited by stable overexpression of dominant negative (MAPKAPK-2 
K93R) and MAPKAPK-2 anti-sense RNA (MAPKAPK-2 A/S) in HeLa cells. IL-1 a  
strongly induced COX-2 protein in empty vector transfected cells. In contrast 
MAPKAPK-2 K93R and MAPKAPK-2 A/S overexpressing cells strongly inhibited 
COX-2 protein and mRNA In addition IL -la  induced IL-6 synthesis was also 
strongly inhibited by MAPKAPK-2 A/S. These results suggest that MAPKAPK-2 
may act as an effector molecule involved in IL -la  induced COX-2 and IL-6 
synthesis. In an attempt to identify new MAPKAPK-2 substrates, yeast two-hybrid 
screening of a human leukocyte cDNA library identified a novel protein interaction 
between MAPKAPK-2 K93R and a close homologue of the human polyhomeotic 2 
(HPH2) protein.
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Chapter 1
Introduction
1.1 General Introduction
Following injury, trauma or infection of a tissue, the host organism initiates a 
complex series of reactions in an effort to prevent ongoing tissue damage, to isolate 
and destroy the infective agent and to activate the repair processes that are necessary 
to return the organism to normal function. This cumulative homeostatic process is 
known as inflammation. The characteristics of the inflammatory response are that the 
area is reddened, swollen, hot and painful and that there is loss of function. The 
redness and heat are due to vasodilation and increased blood flow. The swelling is due 
to increased vascular permeability with leakage of fluid into the tissue and 
accumulation of inflammatory cells. The pain is due to stimulation of afferent nerves 
by chemical mediators and also the pressure from increased tension. The restriction, of 
movement in an inflamed joint or the narrowing of the airways with resulting 
breathing difficulties are examples of loss of function.
1.1.1 Initiation of the inflammatory response
The macroscopic inflammatory effects described above, are the result of an early and 
immediate set of reactions at the site of infection or trauma, which lead to the release 
of soluble mediators, including cytokines, that mobilise the metabolic response of the 
whole organism. The cells responsible for initiating the inflammatory and acute phase 
response are activated monocytes or tissue macrophages (reviewed by Baumann and 
Gauldie, 1994), which release the primary pro-inflammatory cytokines, interleukin-1
1
(IL-1) and tumour necrosis factor (TNF). These pro-inflammatory cytokines are 
released in response to stimuli which may be exogenous such as, bacterial endotoxin 
(LPS) and other bacterial products or mixtures of cytokines such as IL-2, IL-1, TNF, 
interferon-y and granulocyte-monocyte colony stimulating factor (reviewed by 
Dinarello, 1994). Both IL-1 and TNF have pleiotropic activity and may act 
individually or synergistically to trigger both local and systemic inflammatory 
processes. Locally, IL-1 and TNF act upon many cell types, such as epithelial cells 
and fibroblasts, which are stimulated to further produce IL-1 and TNF. These cell 
types are also responsible for the production of secondary pro-inflammatory 
cytokines, such as IL-6 and IL-8 and monocyte chemoattractant protein -1 (MCP-1). 
IL-6 regulates most of the acute phase plasma proteins from hepatocytes (reviewed by 
Baumann and Gauldie, 1994), whilst IL-8 and MCP-1 are highly chemotactic for 
neutrophils and mononuclear cells respectively (reviewed by Matsushima and 
Oppenheim, 1989) see Figure 1.1.
Blood
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Figure 1.1. Diagram illustrating cell and cytokine interactions In the inflammatory response 
(reviewed by Baumann and Gauldie, 1994).
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Interleukin-1 and TNF have a similar, broad range of physiological effects and 
provide crucial signals by which activated mononuclear phagocytes control functions 
of other cells. The most notable biological difference between them is that TNF has 
cytotoxic properties whereas IL-1 does not.
The activated endothelium plays a critical role in the communication between the site 
of inflammation and circulating leukocytes. Leukocytes can be selectively attracted 
to the inflammatory site to defend the host against invading pathogens or remove 
cellular debris. Stimulation by EL-1 and TNF induces the surface expression of 
adhesion molecules such, as intercellular adhesion molecule-1 (ICAM-1), endothelial 
leukocyte adhesion molecule -1 (ELAM-1), E-selectin and P-selectin.
Neutrophils appear early in the course of inflammation and are removed from the 
circulation by attaching to Surface adhesion molecules. At first they interact weakly 
through L-selectin binding to carbohydrates on endothelial glycoprotein receptors. 
Following further stimulation by chemokines the neutrophils adhere tightly through 
integrin and endothelial adhesion molecule interactions (reviewed by Proost et al.,
1996). Finally the cells migrate through the endothelial layer in response to a 
chemokine gradient and infiltrate the tissues by a process known as diapedesis. 
Neutrophil infiltration is usually followed by an influx of macrophages and together 
these cells release a wide range of pro-inflammatory substances including proteases, 
low molecular-weight reactive oxygen species and lipid mediators as well as IL-1 and 
TNF. These low molecular weight mediators, prostaglandins, leukotrienes and 
thromboxanes, are the products of arachidonic acid metabolism by 5-lipoxygenase 
and cyclooxygenase enzymes.
3
1.1.2 Cyclooxygenase enzymes and prostaglandin synthesis
As indicated above cyclooxygenase enzymes are responsible for the production of 
highly potent pro-inflammatory intermediates that prolong the actions of IL-l/TNF 
long after activation. Two cyclooxygenases, COX-1 and COX-2, also known as 
prostaglandin synthases (PGHS) 1 and 2 have been identified in humans. The 
enzymes, which are encoded by separate genes on different chromosomes, share 60% 
amino acid homology (DeWitt and Smith, 1988; Xie et al., 1991; Kujubu et al.,
1991). Both are haem-containing, 66 kDa homodimers that are heavily glycosylated, 
which results in the proteins migrating with an apparent molecular mass of 72 kDa 
(Sirois and Richards, 1992). Although structurally COX-1 and COX-2 are very 
similar, the crystal structures are virtually superimposable and the active sites differ 
by only a single amino acid (COX-2 V509/ COX-11509), the enzymes differ 
substantially in their patterns of expression and biology. COX-1 is constitutively 
expressed in most tissues and appears to be responsible for the production of 
prostaglandins that mediate normal physiological functions such as renal and vascular 
homeostasis (reviewed by Smith et al., 1996; reviewed by Smith and DeWitt, 1995). 
The regulation of COX-1 expression is poorly understood. However, like most other 
developmentally regulated housekeeping genes COX-1 lacks a TATA box, which is a 
characteristic feature of most inducible genes (Kraemer et al., 1992). In contrast to 
COX-1, COX-2 is not detectable in most mammalian tissues, but its expression can be 
induced rapidly (2-6 hr) by pro-inflammatory cytokines (Maier et al., 1990), tumour 
promoters (Kujubu etaL, 1991), growth factors (Habenicht et al., 1985) and 
oncogenes (Han et al., 1990). The rapid induction of COX-2 mRNA, which can be
4
superinduced by cycloheximide, mirrors the induction of immediate early genes such, 
as c-fos and has therefore resulted in COX-2 being classified as such.
Cyclooxygenases are bifunctional enzymes that catalyse the rate limiting step in 
prostaglandin synthesis. This reaction occurs in two stages; in the first, arachidonate is 
released from cellular membrane phospholipids by the action of phospholipase A% and 
converted by the cyclooxygenase activity to prostaglandin Gz (PGGz); secondly,
PGGz is reduced by the peroxidase activity of the enzyme to prostaglandin Hz (PGHz)
(see Figure 1.2). Once activated the levels of COX-2 protein within the cell remain
\
elevated for several hours and large amounts of prostaglandins are synthesized, in 
particular PGEz. In fact, many of the biological effects of IL-1 are due to increased 
PGEz, which can increase vasodilation resulting in leakage from the blood vessels, 
particularly at the post-capillary venules, resulting in swelling and in some cases 
redness. In addition prostaglandins can act synergistically with IL-1 to enhance the 
transcription of secondary pro-inflammatory cytokines such as IL-8, IL-6 and also DL- 
1 itself (Vannier and Dinarello, 1993; Vannier and Dinarello, 1994).
Ten chemical classes of prostaglandins have been recognised (PGA to PGJ) of which 
PGHz acts as a common precursor. Different cell types produce different 
prostaglandins and the conversion of PGHz to the end product is dependent upon 
which specific synthase is present in the cell. PGEz is produced mainly by 
macrophages, fibroblasts, monocytes and chondrocytes whilst, PGDz and PGIz 
(prostacyclin) are produced mainly by mast cells and endothelial cells respectively 
(reviewed by DeWitt and Smith, 1995).
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Figure 1.2: Diagram illustrating the bifunctional enzymatic properties of COX-2.
The role of COX-2 in inflammation and pain has been demonstrated and COX-2 is 
now regarded as an important therapeutic target (Seibert et al., 1994). Elevated 
prostaglandin levels have been linked to chronic and acute inflammatory disease 
(reviewed by Smith and DeWitt, 1996; Lipsky and Isakson, 1997) and colon cancer 
(reviewed by Mamett, 1992; Rao et al., 1995). The importance of inhibiting COX-2 
for anticancer therapy has been supported following a recent study, which 
demonstrated that selective inhibition of COX-2 caused nearly complete suppression 
of azoxymethane-induced colon cancer (Kawamori et al., 1998).
1.1.3 Inhibitors of cyclooxygenase enzymes
Cyclooxygenases are the main therapeutic target for non-steroidal anti-inflammatory 
drugs (NSAIDs) (reviewed by Smith et al., 1994). The most notable of these, being
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acetylsalicylic acid (aspirin), which permanently inactivates COX-1 by acetylating 
serine 530 at the cyclooxygenase active site (Loll et al., 1995). The unique long-lived 
effect of aspirin on platelet thromboxane A% formation, is a combined result of the 
covalent modification of COX-1 within these cells and that circulating platelets, 
unlike other cells, do not synthesize new COX-1. Other NSAIDs include ibuprofen, 
indomethacin, flurbiprofen and meclofenamate, which behave as competitive 
reversible inhibitors of arachidonate (Laneuville et al., 1994; reviewed by Smith and 
DeWitt, 1996).
Until recently all available NSAIDs inhibited both COX-1 and COX-2 by competing 
with arachidonate for binding to the cyclooxygenase active site. However, although 
these compounds are effective anti-inflammatory agents they have the particular 
disadvantage of gastrointestinal toxicity, caused by the inhibition of cytoprotective 
prostaglandins in the stomach and gut. The discovery that COX-2 is the relevant 
enzyme in inflammation (Seibert et al., 1994) and that COX-1 and not COX-2 is 
present in the stomach (Isakson P et al., 1995) has led to the development of COX-2 
specific inhibitors such as celecoxib (SC58635) and MK966 (L745337), which are 
active in animal models of inflammatory disease (Reitz et al., 1995; Penning et al.,
1997). Recently, a novel class of pyridinyl imidazole compounds have been shown to 
inhibit PGEz production in IL-1 stimulated human fibroblasts (Ridley et al., 1997), in 
LPS stimulated monocytes (Pouliot et al., 1997) and in IL-1 stimulated mesanglial 
cells (Guan et al., 1997). Prostaglandin Ez production in these studies has been shown 
to be due to decreased COX-2 synthesis and not inhibition of COX-2 activity. The 
biological target of these compounds is p38 MAP kinase an enzyme that is strongly 
activated by pro-inflammatory cytokines (Freshney et al., 1994; Raingeaud et al..
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1995). The mechanism of p38 MAPK activation, inhibition and the role of p38 
MÀPK in the regulation of COX-2 synthesis are discussed in later sections.
1.1.4 Interleukin -1 and tumour necrosis factor in disease states
As discussed in section 1.1.1, IL-1 and TNF play a key role in both the initiation and 
the progression of the inflammatory response. However, in some cases the 
inflammatory response occurs in an uncontrolled manner, resulting in the 
overproduction of either IL-1 or TNF. Consequently, much attention has been focused 
on these cytokines because of their critical role in the pathogenesis of inflammatory 
diseases. Both are implicated in acute and chronic inflammatory diseases, such as 
rheumatoid arthritis, osteoarthritis, inflammatory bowel disease and toxic shock 
syndrome and many of the pathological features observed in these disease states can 
be reproduced by infusion of IL-1 and TNF (reviewed by Dinarello, 1996). In humans 
IL-1 and TNF added intravenously mimic the systemic inflammatory symptoms of 
septic shock (Smith et al., 1992) and in rabbits the symptoms can be potentiated by 
co-infusion of both cytokines (Okusawa et al., 1988; Tredget et al., 1988). Infusion of 
IL-1 and TNF into joint space produces cellular and destructive changes indicative of 
acute arthritis, whilst elevated levels of both cytokines have been detected in the joint 
fluids in patients with rheumatoid arthritis (Miyasaka et al., 1988). Limiting or 
reducing the production of these cytokines has provided further evidence for IL-1 and 
TNF in such disease states. Antibodies to TNF have been given with success to 
patients with rheumatoid arthritis (Elliott et al., 1994; Elliott and Maini, 1995) and 
Crohns disease (van Dullemen et a l, 1995). Whilst naturally occurring specific 
inhibitors of IL-1 such as the interleukin-1 receptor antagonist (IL-IRa) have 
demonstrated therapeutic efficacy in clinical trials with patients with rheumatoid
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arthritis (Breshihan et al., 1996). Recently, inhibitors of p38 MAP kinase an enzyme 
that is involved in pro-inflammatory cytokine synthesis and signalling (Freshney et 
al., 1994; Lee et al., 1994) have, in animal models, demonstrated therapeutic benefit 
in some of the conditions described above (Badger et al., 1996).
1.2 Interleukin-1 and Tumour Necrosis Factor
1.2.1 Interleukin-1 family
The IL-1 gene family is composed of three members: IL-la, 1L-1(3 (March et al., 
1985) and the IL-1 receptor antagonist (IL-IRa) (Eisenberg et al., 1990; Carter et al., 
1990). The biological effects of IL-1 are mediated by IL -la  and IL-1 (3 whilst the IL- 
IRa acts as true antagonist of IL -la  and EL-Ip. IL -la  and IL-ip are first translated as 
31 kDa pro-forms (proIL-lo/P) that lack leader sequences. Unlike proIL-lp, proIL- 
l a  is biologically active and a percentage of this (10-15%) is myristoylated on 
specific lysine residues within the pro-piece and transported to the cell membrane 
where it is referred to as membrane IL-1. ProIL-lp is also myristoylated, but is not 
transported to the membrane (Stevenson et al., 1993).
ProLL-la is proteolytically cleaved to produce mature IL -la  (17 kDa) and a 16 kDa 
pro-piece, by activation of a calcium-dependent, membrane- associated cysteine 
protease called calpain (Kobayashi et al., 1990). ProIL-ip is cleaved by the 
interleukin-1 converting enzyme (ICE) to produce mature, biologically active IL-lp 
(17 kDa) and a 16 kDa pro-piece (Thomberry et al., 1992; Cerretti et al., 1992). 
Mature IL-lp is transported out of the cell through a putative membrane channel.
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whilst mature IL -la remains cytosolic and is not found in the circulation except in 
severe disease states, in which it may be released from dying cells or by proteolytic 
cleavage by calpains (Watanabe and Kobayashi, 1994). The exact role of IL -la  is 
unclear although evidence suggests that it may function as an autocrine intracellular 
messenger since IL -la and IL-1 receptor complexes have been identified inside the 
nucleus with a resulting increase in signal transduction (Curtis et al., 1990).
The third member of the IL-1 family is the IL-1 receptor antagonist (IL-IRa). Two 
forms of the IL-IRa exist, secreted IL-IRA (sIL-IRa) and intracellular IL-IRa (icIL- 
IRa) which are transcribed from alternate promoters (Haskill et al., 1991; Muzio et 
al., 1995). After stimulation by bacterial endotoxin, monocytes initially express 
pro(s)IL-lRa from the sIL-IRa promoter, which is translated in the endoplasmic 
reticulum and transported to the Golgi. After removal of the leader sequence, sIL-IRa 
is secreted from the cell After 24 hours the cell switches to the icIL-IRa promoter 
and icIL-IRa becomes the major transcript, which lacks a leader sequence and 
remains intracellular (Andersson et al., 1992).
1.2.2 Interleukin-1 receptor family
The IL-1 receptor family consists of two principal members: IL-1RI (Sims et al.,
1989) and IL-IRE (McMahan et al., 1991). Evidence suggests that IL-1RI binds IL- 
l a  with a higher affinity whereas IL-1R11 binds IL-1 (3 with higher affinity (Scapigliati 
et al., 1989). IL-1RI is a heavily glycosylated 80 kDa protein, constitutively 
expressed at low levels and expressed on most cell types. IL-1R11 (68 kDa) is also 
heavily glycosylated and is expressed primarily on neutrophils, monocytes and B- 
lymphocytes. Both receptors have three extracellular Ig-like domains that are 26-28%
homologous and they both contain a single transmembrane domain. However, the 
cytoplasmic domains of each receptor are very different. IL-1R1 has a cytosolic 
domain of 213 amino acids, whilst that of IL-1R11 is only 29 amino acids (Sims et al., 
1989; McMahan et al., 1991). It is therefore not surprising that most of the biological 
effects of IL-1 are mediated by IL-1R1, with IL-1R11 acting as a decoy receptor, which 
sequesters and binds IL-ip tightly thus preventing it binding and signalling through 
IL-1R1 (Colotta et al., 1993).
The cytosolic domain of IL-1R1 shares 45% homology with the cytosolic domain of 
the Drosophila protein Toll (Gay and Keith, 1991). Recently, Toll has been identified 
in a signalling pathway that is critical for anti microbial peptide production in adult 
flies (Lemaitre et al., 1996). Like Toll, the other components of this pathway share 
significant homology with their mammalian counterparts in the IL-1 signalling 
pathway, therefore implying that this signalling system is conserved between insects 
and mammals (reviewed by O’Neill and Greene, 1998).
1.2.3 IL-1 signalling
For IL-1RI to signal it must form a complex with the IL-1 receptor accessory protein 
(IL-lAcP) (Greenfeder et al., 1995). The IL-lAcP is essential for signalling since 
cells lacking this protein do not respond to IL-1 (Wesche et al., 1997b). Binding of 
IL-1 to the IL-1RI receptor induces heterodimerization with IL-lAcP resulting in a 
change from low to high affinity binding of IL-1, which may be the result of a 
conformational change within the complex (Greenfeder et al.r 1995) IL-lAcP then 
recruits MyD88, an adapter protein that functions to mediate interactions between the 
cytoplasmic domain of the receptor and a serine threonine kinase called, IL-1 receptor
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associated kinase (IRAK) (Cao et al., 1996a; Wesche et al.9 1997a). MyD88 contains 
an N-terminal death domain, related to those found within the cytoplasmic domains of 
TNFRSF members and a C-terminal Toll domain similar to that found in Toll/IL-1- 
like receptors. MyD88 coimmunoprecipitates with the EL-IRI complex in an IL-1 
dependent manner (Bums et cU., 1998). IRAK has been shown to complex with the 
IL-lAcP, but not IL-1RI (Huang et al., 1997; Volpe et al., 1997). IRAK then 
dissociates from the complex and interacts with TRAF6 (Cao et al., 1996b).
TRAF6 is a member of the TNF-receptor associated factors (TRAFs), but which 
paradoxically is not involved in TNF signalling. Members of this family of proteins 
are characterised by a conserved carboxyl-terminal TRAF-C domain o f -170 amino 
acids, a a-helical TRAF-N domain and with the exception of TRAF1, an amino 
terminal RING finger (Rothe et al., 1994). Immunoprécipitation studies have 
demonstrated that TRAF6 does not associate with IL-1RI, but with IRAK, implying 
that IRAK recruits TRAF6. This interaction is entirely dependent upon stimulation 
with IL-1 (Cao et a l, 1996b). Cotransfection studies using dominant negative mutants 
of IRAK and TRAF6 have demonstrated that both are critical intermediates in the 
pathways leading to IL-1 induced NFkB and JNK/p38 MAP kinase activation (Cao et 
al., 1996b; Baud et al., 1999). In addition over-expression of TRAF6 (or TRAF2, see 
section 1.2.6) is sufficient to activate signalling pathways leading to NF-kB and AP I 
in the absence of extracellular stimuli (Cao et al., 1996b). This latter observation may 
be explained by a recent study which has demonstrated using TRAP chimeras, that a 
critical event in TRAF-mediated IL-1 (TNF) signalling is ligand- induced TRAP 
oligomerisation (Baud et al., 1999). In this study the amino terminal halves of the 
TRAP proteins were fused to a threefold repeat of the immunophilin FKBP12 and
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oligomerised by incubating with the dimeric ligand FK1012. Once oligomerised, the 
TRAF-FKBP12 chimeras were able to induce the same set of genes that are normally 
induced by IL-1 (TNF). Oligomerisation of the TRAF amino terminal domains 
appears to facilitate binding to other effector molecules, such as MEKK which is a 
member of the MAPKKK family (Baud et al., 1999).
Recently, it has been demonstrated that TRAF6 interacts with TAK1 (TGFp activated 
kinase), which is also a member of the MAPKKK family (Ninomiya-Tsuji et al., 
1999). TAK1 requires TAB1 (TAK binding protein) for activation (Shibuya et al., 
1996) and both interact with TRAF6 in a process that is IL-1 dependent. TAK1 
phosphorylates and activates NIK (NF-KB inducing kinase), a critical component of 
the complex leading to NF-kB activation (Malinin et al., 1997). NF-kB dependent 
reporter gene assays linked to luciferase have demonstrated that NIK lies downstream 
of TAB1/TAK1, since dominant negative NIK is able to block TAB1/TAK1 induced 
NF-kB activation. Inactive TAK1 also inhibits IL-1 induced NF-kB activation in a 
dose dependent manner, but it has no effect on NIK induced activation. Dominant 
negative TAK1 is able to block IL-1 induced INK and p38 MAPK activation. 
However dominant negative NIK did not inhibit IL-1 or TAK1/TAB1 induced 
activation, indicating that bifurcation of the IL-1 signalling pathway occurs at TAK1 
(Ninomiya-Tsuji et al., 1999).
NIK, which also shares sequence similarity with MAPKKK members, was identified 
in a yeast two-hybrid study using TRAF2 a component of the TNF signalling pathway 
as bait (Malinin et al., 1997). NIK appears to represent a crucial convergence point 
for both the IL-1 pathway via TRAF6 (as described above) and the TNF pathway via
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TRAF2 (see section 1.2.6). NIK activates NF-kB when over-expressed and kinase 
inactive mutants of NIK can act as dominant negative inhibitors of TNF and IL-1 
mediated NF-kB activation, indicating that this enzyme is essential for IL-1 and TNF 
induced activation of NF-kB (Malinin et al., 1997).
1.2.4 Tumour necrosis factors
The tumour necrosis factors comprise of two closely related proteins, TNFa (also 
known as cachectin) and TNF[3 (also known as lymphotoxin). TNFa is produced by a 
variety of cell types including, neutrophils, activated lymphocytes, macrophages, NK 
cells, endothelial cells, astrocytes and some transformed cells. TNFp is produced by 
lymphocytes. The two proteins share about 30% amino acid homology and bind to 
the same cell surface receptors to elicit a wide range of similar, but not identical 
biological responses (Vilcek and Lee, 1991). Human TNFa can exist as a membrane 
bound pro-form (26 kDa) or soluble (17 kDa) form. Both forms have biological 
activity although the soluble form is more potent (Decoster et al., 1995). Membrane 
bound proTNFa is cleaved to release soluble TNFa by a membrane bound protease 
called TNFa converting enzyme (TACE) (Black et al., 1997; Moss et al., 1997). 
TNFP possesses a signal peptide sequence and is processed and secreted in the same 
manner as other secretory proteins. TNFP has a molecular weight of 25 kDa .The 
higher apparent molecular mass of TNFP is a result of extra amino acids at the amino 
terminus and N- glycosylation which are absent in TNFa (Vilcek and Lee, 1991). In 
their biologically active native forms TNFa and TNFp are found as tightly packed 
trimers (Jones et al., 1989; Eck et al., 1992).
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1.2.5 The TNF receptor family
TNF mediates its effects through two distinct receptors, TNFRI and TNFRH. TNFRI 
is a 55 kDa (455 aa) transmembrane glycoprotein that is present on the surface of 
virtually all nucleated cell types (Loetscher et al., 1990). Soluble TNFa and TNFP are 
able to bind to TNFRI with Kd values of 20-60 pM and 650 pM respectively (Marsters 
et al., 1992). The extracellular domain of TNFRI is 190 aa residues and contains four 
cysteine-rich motifs that are believed to be involved in binding (Marsters ef al., 1992). 
The transmembrane domain is 25 aa residues with the remaining 240 aa residues 
comprising the cytoplasmic domain (Loetscher et a l, 1990). Within the cytoplasmic 
domain there is an 80 aa residue "death domain" that can recruit accessory proteins to 
trigger either an apoptotic signal, anti-viral activity or induction of general 
inflam matory responses (Tartaglia et al., 1993a). Death domain motifs facilitate 
protein interactions and are a common feature of proteins involved in receptor 
mediated apoptosis. TNFRI is also able to transduce signals that lead to NF-kB 
activation although the mechanism determining the choice of pathways is not clear.
TNFRII is a 75 kDa (461 aa) transmembrane glycoprotein whose exact function is 
unclear (Smith et éd., 1990). TNFRII is expressed on many cell types such as 
macrophages, monocytes and endothelial cells. TNFRII does have a biological role 
since TNFa binding to TNFRII is able to induce apoptosis in skeletal muscle tumour 
cells and cell migration in Langerhan cells (Medvedev et al., 1994; Wang et al.,
1996). Another possible role for TNFRII, is that it may act as a co-receptor that 
presents TNF for binding to TNFRI (Tartaglia et al., 1993b). Although most 
biological responses are mediated through TNFRI, including activation of the 
transcription factors AP I and NF-kB, recent evidence suggests that this receptor may
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be most important for circulating TNFa, while TNFRII is more important for 
membrane bound TNFa (Grell, 1996). Since most of the biological properties of TNF 
are mediated through TNFRI, including activation of the transcription factors AP I 
and NF-kB, only signalling events initiated from this receptor will be discussed 
below.
1.2.6 TNF signalling
Binding of trimeric TNF to TNFRI induces receptor clustering and catalyses the 
recruitment of several downstream signal-transducing proteins to the cytoplasmic 
domains of the receptors (reviewed by Damay and Aggarwal, 1997). TRADD (TNF 
receptor associated death domain) (Hsu et al., 1995) is the first protein to be recruited 
to the TNFRI receptor. TRADD is a 34 kDa protein containing a C-terminus death 
domain that is essential for binding to TNFRI via its own cytoplasmic death domain. 
TRADD is able to serve as a platform and recruit at least three other proteins that 
mediate both the apoptotic signal as well as TNF induced AP I and NF-kB activation 
(Hsu et al., 1996). TRADD recruits a protein called RIP (receptor-interacting protein), 
which was identified by yeast two-hybrid screening using TRADD as bait (Hsu et al., 
1996). RIP binds to TRADD through death domain interactions and like TRADD is 
essential for activation of NF-kB and apoptosis. The TRADD-RIP complex is then 
able to recruit and bind either of two proteins, FADD (Fas associated death domain) 
or TRAF2 (Chinnaiyan et al., 1995; Rothe et al., 1994). FADD binding signals to 
apoptosis following binding of caspase-8 (FLICE) which initiates a proteolytic 
cascade of caspases (Boldin et al., 1996). TRAF2 binds NIK and signals to NF-kB 
activation via the IKK complex. In addition TRAF2 is also part of an NIK- 
independent signal transduction pathway that results in the activation of AP I through
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the JNK and p38 MAP kinase cascades (Natoli et al., 1997; Carpentier et a l, 1998). 
The signal transduction events from TRAF2 leading to AP I activation have not yet 
been elucidated although MEKK can interact with TRAF2 and induce TNF and IL-1 
responsive genes (Baud et al., 1999).
1.2.7 IL-1 and TNF signalling leading to AP I and NF- kB activation
Most of the pleiotropic effects of IL-1 and TNF are due to their unique abilities to 
increase the expression of a wide variety of genes in a multitude of target cells (Table 
1.1). This induction may be the result of either increased transcriptional activity or 
increased half-life (stabilisation) or both of the mRNA (reviewed by Dinarello, 1996; 
reviewed by Vilcek and Lee, 1991).
IL-1 and TNF activate several transcription factors. Of these, nuclear factor kB (NF- 
kB) and activating protein-1 (AP-1) are two of the most significant. Both transcription 
factors regulate the induction of many genes critical for the progression of normal 
immune and inflammatory responses (Table 1.1). NF-kB belongs to the Rel family of 
transcriptional activators and is composed of one RelA (p65) and one p50 subunit 
(reviewed by Huguet et al., 1997). The early intracellular events leading to the 
activation of AP-1 and NF-kB following IL-1 and TNF stimulation are illustrated in 
Figure 1.3.
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cytokines: IL-6, IFN, IL-8, IL-2, IL-IRa, TNF, IL-1 and GM-CSF
growth factors: PDGF, NGF
proinflammatory
mediators:
cyclooxygenase-2, cytosolic secretory 
phospholipase A2, iNOS
oncogenes: c-jun, c-fos, c-myc
tissue remodeling: collagenase-1, gelatinases, elastase 
stromelysin
adhesion molecules: ICAM-1, ELAM-1 VCAM-1, lymphocyte 
L-selectin
T u b le l . l ;  E xam p les u f gen es w h ose ex p ress io n  is  in creased  by  IL -1  a n d  T N F  (m od ified  fro m  a  
review article by Dinarello, 1996).
In addition to increasing the transcriptional activity of NF-xB, IL-1 and TNF also 
simultaneously activate the INK and p38 MAP kinase families (Figure 1.3), also 
known as stress activated protein kinases (SAPKs) (Kyriakis et al., 1994; Raingeaud 
et al., 1995). Both JNK and p38 MAP kinases contribute to the activation of AP-1 by 
activating the transcription factors (c-jun, ATF-2 and Elk-1) that induce c-jun and c- 
fos genes, the products of which form the AP-1 complex (reviewed Karin, 1995; 
reviewed Karin et al., 1997). The integral role of p38 MAP kinase in pro- 
inflammatory cytokine signalling has became apparent with the aid of the highly 
specific inhibitor, SB 203580 (Figure 1.5). SB 203580 has demonstrated that p38 
MAP kinase activity is rate limiting for a number of IL-1 and TNF responsive genes 
(Lee et al., 1994; Beyaert et al., 1996; Ridley et al., 1997; Pietersma et al., 1997).
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Figure 1.3: Schematic diagram illustrating the key protein interactions involved in IL-1 and TNF signalling 
leading to NF-kB and AP-1 activation.This figure is a modified version of an illustration in a review article by 
O’Neill and Greene, 1998.
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1.3 Mitogen activated protein kinase cascades
Mitogen activated protein kinase (MAPK) cascades are important mediators of signal 
transduction from the cell surface to the nucleus. MAPK pathways have been 
identified in yeast and in mammalian cells and exhibit a high degree of conservation 
(reviewed by Blumer and Johnson, 1994). These pathways are typically characterised 
by a MAPK module consisting of a MAPK kinase kinase (MAPKKK), a MAPK 
kinase (MAPKK) and a MAPK. The specificity of MAPK responses to given stimuli 
is achieved by activation of specific MAPKKK- MAPKK-MAPK modules. There is 
now emerging evidence that the specificity is achieved, in part, by the use of 
scaffolding or anchoring proteins that sequester and hold these modular components 
together (reviewed by Garrington and Johnson, 1999). Activation of MAPK cascades 
results in the sequential phosphorylation and activation of each of these components, 
culminating in the phosphorylation of the MAPK by a dual specificity kinase 
(MAPKK) (Figure 1.4). In mammalian cells three parallel MAPK pathways have 
been extensively studied. The MAPK members from each of these pathways are 
discussed below. However, for the purpose of this project emphasis will be given to 
the p38 MAP kinase family and its substrate MAP kinase activated protein kinase-2 
(MAPKAPK-2). The role of the p38 MAP kinase pathway in pro-inflammatory 
cytokine signalling and the biological effects of specifically inhibiting p38 MAP 
kinase will be discussed. Finally the potential of identifying other therapeutic targets 
within this pathway will be reviewed.
1.3.1 ERK (p42/p44) MAP kinases
The ERK kinases, also known as p42 (ERK1) and p44 (ERK2) were the first 
members of the MAPK family to be characterised and cloned (Boulton et aZ., 1990;
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Figure 1.4: Diagram illustrating the sequential activation of the ERK, JNK and p38 MAP kinases 
by mitogenic stimuli and cellular stresses respectively. As described in the text activation occurs 
following phosphorylation of threonine and tyrosine residues at the specific TXY motif.
Boulton et al., 1991). ERK kinases are activated following phosphorylation of the 
threonine and tyrosine residues at the T-E-Y activation motif (Figure 1.4) in response 
to mitogenic stimuli including; NGF in PC12 cells (Boulton et al., 1991), EGF in 
hepatocytes (Liu et al., 1996) and PDGF in smooth muscle cells (Graves et al., 1996). 
However in certain cell types they can also be activated by pro-inflammatory 
cytokines (IL-1 and TNF) (Saklatvala et al., 1993). Of the three principal MAP kinase 
pathways, the events leading to the activation of the ERK kinases are the best 
understood. Growth factors acting through tyrosine kinase receptors or seven 
transmembrane receptor coupled to G-proteins induce ERK activation via Ras 
GTPase/RaiTMAPK kinase (MEK) (Figure 1.4) (reviewed by Waskiewicz and 
Cooper, 1995). Several substrates for ERK1/2 have been identified including protein 
kinases, MAPKAPK-1 or ribosomal S6 kinase (p90r8k) (Sturgill and Wu, 1991) and 
MAPKAPK-2 in-vitro (Stokoe et al., 1992). Members of the ternary complex factor 
(TCF) sub-family of ETS-domain transcription factors, Sap-1 (Price et al., 1996), Elk- 
1 (Janknecht et al., 1993; Marais et al., 1993), are also phosphorylated by ERKs. 
Other proteins include cPLAz (Lin et al., 1993), cMyc (Gupta and Davis, 1994). 
Recently, several new ERK members, ERK3 (Cheng et al., 1996), ERK4 (Peng et al.,
1996) and ERK5 have been identified and with the exception of ERK3, which 
contains an S-E-G motif, all contain the characteristic T-E-Y activation motif. To date 
little is known about the physiological roles of these proteins.
1.3.2 JNK MAP kinases
The second MAP kinase family are the JNKs or SAPKs (stress activated protein 
kinases) which are predominantly activated by cellular insults such as, UV light, pro- 
inflammatory cytokines (IL-1 and TNF), sodium arsenite and hyperosmolarity
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(Derijard et al., 1994; Kyriakis et al., 1994). Activation occurs following 
phosphorylation of the threonine and tyrosine residues at the T-P-Y activation motif 
(Figure 1.4). The first member of the SAPK family, called p54, was isolated from 
livers of rats injected with cycloheximide (Kyriakis and Avruch, 1990). Tryptic 
peptide sequences of p54 were used to design oligonucleotides and the subsequent 
amplification of a cDNA probed Screening of a rat brain cDNA library isolated four 
classes of p54 cDNAs (al, an , p and y) which were highly homologous proteins (85- 
90%) of 54 kDa and 45 kDa (Kyriakis et al., 1994). Independently, JNK1 (jun N- 
terminal kinase 1) which is identical to the 45 kDa SAPKy protein and JNK2 which is 
identical to 54 kDa SAPKoH were cloned (Derijard et al., 1994). Recently a third 
member of the JNK (SAPK) family has been identified that also contains the long (54 
kDa) and short (46 kDa) forms (Gupta et al., 1996). To date, three distinct genes in 
humans (JNK1, 2 and 3), which can give rise to ten variants, have been identified 
(Gupta et al., 1996).
The precise upstream mechanisms that lead to JNK activation are not yet fully 
elucidated. In response to cellular stress two major JNK kinases have been identified, 
MKK4 (Derijard et al., 1995), also called SEK1 (Sanchez et al., 1994) or JNKK (Lin 
et al., 1995) and MKK7 (Moriguchi et al., 1997; Toumier et al., 1997; Yao et al.,
1997). Of these only MKK7 is specific for JNK and was found to be the only IL-1 
induced JNK activator in rabbit liver (Finch et al., 1997). The specificity of MKK4 is 
unclear. In COS cells MKK4 does not co-precipitate with p38 MAP kinase but does 
with JNK. In addition, overexpressed MEKK which is a strong MKK4 activator 
results in JNK but not p38 MAP kinase phosphorylation (Zanke et al., 1996). 
Contrary to these data Guan et al (1998) demonstrated that catalytically inactive
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MKK4 permanently expressed in rat mesangial cells inhibited IL-lp-induced 
phosphorylation of p38 MAP kinase.
Several transcription factors, c-jun (Derijard et al.91994), ATF-2 (Gupta et al., 1995), 
Elk-1 (Yang et al., 1998) have been identified as JNK substrates. Elk-1 is also a 
substrate of the ERK kinases and recent data suggests that ERK and JNK MAP 
kinases target over-lapping yet specific domains (Yang et al., 1998).
1.3.3 p38 MAP kinases
p38 MAPK is the archetypal member of the third MAPK-related pathway. Activation 
occurs after phosphorylation of the threonine and tyrosine residues at the activation 
motif, T-G-Y, following cellular insults including; pro-inflammatory cytokines, UV, 
chemical and osmotic shock (Figure 1.4) (Freshney et al., 1994; Raingeaud et al., 
1995; Rouse et al., 1994). However in certain cell types p38 MAP kinase can be 
activated by other stimuli including; N-formyl-Met-Leu-Phe in neutrophils (Krump et 
al., 1997), thrombin/collagen in platelets (Saklatvala et al., 1996), IL-2 and IL-7 in T- 
cells (Crawley et a l, 1997) and IL-10 (Foey et al., 1998). The details describing the 
characterisation and cloning of p38 MAP kinase are described in Chapter 3. To date 
four p38 MAP kinase isoforms p38a (p38/CSBP), p, y  and 8, encoded by separate 
genes have been identified (Lee et al., 1994; Jiang et al., 1996; Li et a l, 1996; Kumar 
et al., 1997). The sequence of p38 MAP kinase shares extensive homology with the 
yeast Saccharomyces cerevisiae high-osmolarity glycerol 1 (hogl) gene (Brewster et 
al, 1993). HOG1 is required by yeast to enable them to survive in hyperosmotic 
conditions. The mammalian homologue of HOG1, p38 MAP kinase (and JNK), was 
able to complement this enzyme by allowing growth in hyperosmotic conditions in a
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hogl deleted yeast strain (Han et al., 1994; Lee et al., 1994; Kumar et al., 1995; 
Galcheva-Gargova et al., 1994). This result led to the assumption that the HOG1 
MAP kinase kinase, PBS2, may be a homologue of the physiological MAP kinase 
kinase that activates p38 MAP kinase. With this aim Derijard et al. (1995) used the 
sequence of PBS2 to design degenerate oligonucleotides and subsequently amplified a 
cDNA probe. Screening of a human foetal brain cDNA library isolated two activators 
of p38 MAP kinase, MKK3 (also termed SAPKK2) and MKK4 (see JNK MAP 
kinases). Another p38 MAPK activator, MKK6 (also termed SAPKK3), has also been 
identified (Han et al., 1996; Moriguchi et al., 1996; Cuenda et al., 1996). Whilst both 
MKK3 and MKK6 have been shown to be specific for p38 MAPK activation 
(Raingeaud et al., 1996; Meier et al., 1996) the predominant activator of p38 MAPK 
by pro-inflammatory cytokines in epithelial cells and monocytes is MKK6 (Cuenda et 
al., 1996). The exact mechanisms leading to the activation of MKK3 and MKK6 
following pro-inflammatory cytokine stimulation are still unclear. However, the 
protein interactions illustrated in Figure 1.3 may explain some of the early signalling 
events that lead to the activation of potential MKK3 and MKK6 activators including; 
TAK1 (TGFp activated kinase) (Moriguchi et al., 1996), PAK (p21-activated kinase) 
(Frost et al., 1996) and MLK3 (mixed lineage kinase-3) (Tibbies et al., 1996).
Several substrates of p38 MAP kinase have been identified based on the results of 
overexpression studies, in-vitro kinase assays, reporter gene assay and selective 
inhibition of p38 MAP kinase. Among these are several protein kinases and 
transcription factors. Potential nuclear targets include members of the ETS-domain 
family of transcription factor Elk-1 (Raingeaud et al., 1996; Yang et al., 1998) and 
Sapl-a (Janknecht and Hunter, 1997) which interact and complex with the serum
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response factor and bind the serum response element in genes such as c-fos. MEF2-C, 
which is member of the myocyte-enhancer factor 2 group of transcription factors (Han 
et al., 1997), ATF-2 (Derijard et a l, 1995; Raingeaud et a l, 1996) and CHOP (Wang 
and Ron, 1996) have also been proposed as potential nuclear targets. Potential protein 
kinase substrates include PRAK (New et al., 1998), MNK1/2 (Fukunaga and Hunter, 
1997; Waskiewicz et al., 1997), MAPKAPK-3 (mitogen activated protein kinase 
activated protein kinase -3) (McLaughlin et al., 1996), MAPKAPK-2 (Rouse et al., 
1994; Freshney et al., 1994) and MSK1 (Deak et al., 1998). Although the exact 
physiological relevance of most of these substrates with regards to the biological 
activities p38 MAPK have yet to be defined some such as MAPKAPK-2 have been 
well characterised.
MAPKAPK-2 is a recognised physiological substrate of p38 MAPK that can also be 
phosphorylated in-vitro by p42/p44 MAPK (Stokoe et al., 1992). However, stimuli 
that strongly activate MAPKAPK-2 in-vivo such as pro-inflammatory cytokines and 
cellular stresses do not activate p42/p44 MAPK (Freshney et 'al., 1994; Rouse et al., 
1994). The first reported association of increased MAPKAPK-2 activity with pro- 
inflammatory cytokine signalling was made by Freshney et al. (1994). In this study, 
which also identified and associated p38 MAPK (termed p40) with IL-1 signalling, 
MAPKAPK-2 (termed p50) was purified to near homogeneity and its activity could 
be increased following incubation with purified fractions of IL-1 activated p40. 
MAPKAPK-2 was phosphorylated by p38 MAPK on threonine and serine residues 
and increased activity was associated with increased phosphorylation of the small heat 
shock protein 27 (Hsp27) (Freshney et a l, 1994). The physiological relevance of 
Hsp27 phosphorylation by activation of the p38 MAPK pathway is unclear. Hsp27 is
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a cytoplasmic protein homologous to a-crystallin. Two main roles of Hsp27 have 
been proposed. The first is that of a molecular chaperone aiding the correct folding of 
proteins (Jakob et al., 1993) and the second is to preserve the structural integrity of 
the cell by inhibiting actin polymerization (Lavoie et al., 1993). In unstressed cells 
Hsp27 forms large aggregates which dissociate upon phosphorylation after heat shock 
or other cellular stresses (Kato et al., 1994). Recent data in transfected L929 cells 
suggests that Hsp27 aggregates are necessary for chaperone action and protection 
against oxidative stress/TNF. Further phosphorylation of these complexes down- 
regulates these protective properties (Rogalla et al., 1999). Activated MAPKAPK-2 
has also been shown to phosphorylate lymphocyte-specific protein 1, LSP1 (Huang et 
al., 1997), cAMP response element-binding protein (CREB) and ATF-1 (Tan et al.,
1996).
1.4 Inhibitors of p38 MAPK
The prototype p38 MAPK inhibitor, SK&F 86002, was identified from a series of 
dual 5-lipooxygenase/cyclooxygenase inhibitors which also blocked the production of 
IL-1 and TNF both in-vitro and in-vivo (Lee et al., 1993). Recognition that the anti­
inflammatory properties of SK&F 86002 were independent of its inhibition of 
arachidonate metabolism led to the search for the molecular targets for this 
compound. Lee et al. (1994) designed a drug-binding assay using a radiolabelled 
derivative of SK&F 86002, SB 202190, and partially purified an enzyme from the 
cytosol of THP.l cells that tightly bound this compound. Tryptic peptide sequences 
were used to design redundant oligonucleotides, which were then used to screen a 
GM-CSF stimulated human monocyte library and isolate p38 MAPK. Subsequent
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work using p38 MAPK inhibitors has been carried out using SB 203580 (Figure 1.5) 
which is a more potent analogue of SB 202190.
Figure 1.5$ SB 203580
Recently, the biochemical and structural basis by which SB 203580 interacts and 
inhibits p38 MAPK activity has been elucidated. In competition assays, using GST- 
ATF2 as substrate with SB 203580 and a related tritiated pyridinyl imidazole 
SB202190, Frantz et aL (1998) showed that p38 MAPK had a particularly high Km 
value for ATP (25 |iM). SB 203580 competed with ATP for the active site of p38 
MAPK and inhibited LPS and TNF induced p38 MAPK activation in THP.l cells 
with an IC5 0  value comparable to the IC5 0  (50-100 nM) for inhibition of cytokine 
induction. Furthermore, SB 203580 was able to bind to the active and inactive forms 
of p38 MAPK with equal affinity, whilst ATP only competed with the tritiated 
inhibitor for binding to the active form. Together these results suggest that under 
physiological conditions p38 MAPK is not bound to ATP but upon activation its 
affinity for ATP is increased (Frantz et al., 1998).
Several groups have now published the crystal structure of p38 MAPK complexed 
with or without inhibitors (Wilson et a i, 1996; Wang et al., 1997; Tong et al., 1997;
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Wilson et al., 1997). These data support the biochemical results described above and 
reveal that pyridinyl imidazole compounds do bind to the ATP pocket of the inactive 
enzyme in a manner that resembles ATP binding. Site directed mutagenesis studies of 
amino acid residues within the ATP binding pocket have identified Met 109 and Thr 
106 as crucial for the potency and specificity of these compounds. Mutating Met 109 
to alanine results in a 6-fold drop in potency of SB 203580 (Lisnock et al., 1998) 
whilst Thr 106 associates with the fluorophenyl moiety of the inhibitor and induces a 
local conformational change in the enzyme (Wang et al., 1998). This interaction is 
crucial for conferring selectivity as has been demonstrated by mutagenesis studies. Of 
the four p38 MAPK isoforms that exist (a,|3,Ô and y) only the p38 MAPKa and P 
isoforms are sensitive to SB 203580 (Kumar et al., 1997) and a comparison of the 
nucleotide sequences of these isoforms reveals that Thr 106 is conserved. 
Significantly, mutating Thr 106 to the corresponding residue of the p38 MAPKy and 6 
isoforms (Met 106) results in complete loss of inhibition. Conversely, mutation of 
Met 106 in the p38 MAPKy and 8 isoforms to Thr 106 confers sensitivity to the 
inhibitor (Gum et al., 1998). The change in sensitivity to inhibition is not solely 
restricted to p38 MAPK family members since a similar mutation in JNK1 can also 
confer a degree of susceptibility to inhibition by pyridinyl imidazole inhibitors (Gum 
et al., 1998; Byers et al., 1998). Although the high degree of specificity of SB 203580 
towards p38 MAPK can be explained by structural differences, a degree of caution 
must still be exercised when interpreting data suggesting a biological role for p38 
MAPK in which chemical inhibitors have been used. Recently, it has been shown that 
certain isoforms of JNK, notably JNKlp and JNK2P (Clerk and Sugden, 1998) and c- 
Raf (Hall-Jackson et a l, 1999) are sensitive to SB 203580.
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1.4.1 Pharmacological activity of p38 MAPK inhibitors
Inhibitors of p38 MAPK have been shown to inhibit pro-inflammatory cytokine 
production from LPS-stimulated human monocytes (Lee et a/.,1994). In addition pro- 
inflammatory cytokine inhibition with concomitant beneficial effects has been 
demonstrated in animal models of inflammation. In a collagen-induced arthritis model 
in DBA/l LACJ mice, SB 203580 (50 mg/kg p.o., b.id.) possessed significant 
therapeutic activity as determined by reduced paw inflammation and serum amyloid 
protein levels. Evidence for disease modifying activity was indicated by improved 
bone mineral density as determined by foetal rat long bone assay and histological 
evaluation. In the foetal rat long bone assay, SB 203580 inhibited radio labelled 
calcium release from pre-radiolabelled foetal long bones with an I C 5 0  of 0.6 pM 
(Badger et al., 1996). It has previously been demonstrated using anti-TNF and anti- 
IL-1 antibodies that in this model of arthritis IL-1 and TNF contribute to the 
pathophysiology of disease (Williams et al., 1992; van de Berg et al., 1994). Thus the 
efficacy of p38 MAPK inhibitors in this disease model is entirely consistent with the 
regulation of IL-1 and TNF signalling by p38 MAPK.
The commercial availability of SB 203580 has meant that the role of p38 MAPK in 
response to pro-inflammatory cytokine signalling has been extensively studied in a 
variety of cell systems. These results have contributed greatly to our understanding of 
the underlying mechanisms by which p38 MAPK inhibitors, in particular SB 203580, 
may be efficacious in animal models of inflammation. In addition to the original 
observation that SB 203580 inhibited IL-1 and TNF production in human monocytes 
(Lee et al., 1994) it has also been shown to inhibit the synthesis of secondary pro- 
inflammatory cytokines such as IL-6 (Ridley et al., 1997; Beyaert et al., 1996) and
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IL-8 (Hashimoto et al., 1999). Both of these cytokines are involved in augmenting the 
inflammatory response (see section 1.1.1). Inhibition of matrix metalloproteinases 
(MMPs), collagenase-1 (MMP1) and stromelysin-1 (MMP3) by SB 203580 has also 
been noted (Ridley et al., 1997). Recently several reports have also shown that p38 
MAPK inhibitors can modulate the synthesis of prostaglandins in IL-1-induced 
fibroblasts (Ridley et al., 1997) and in LPS, IL-1, TNF and zymosan treated 
monocytes (Pouliot etal., 1997; Dean et al., 1999). As described in section 1.1.2, 
prostaglandins are potent pro-inflammatory mediators synthesised by 
cyclooxygenases from arachidonate. In the studies described above decreased 
prostaglandin production was shown to be due to direct effect of p38 MAPK 
inhibitors on COX-2 protein synthesis and not a result of blocking cytokine 
production per se, thus implicating p38 MAPK in the regulation of COX-2.
1.5 Molecular mechanisms
The exact role of p38 MAP kinase in the regulation of prorinflammatory cytokine and 
IL-1 inducible gene synthesis, such as COX-2, is still unclear. Gene expression is 
controlled at many levels and there is evidence for the involvement of p38 MAP 
kinase in transcription (possibly by activation of transcription factors), mRNA 
stabilisation or translational regulation. With the aid of specific p38 MAPK inhibitors 
the level(s) of regulation at which p38 MAPK can modulate the expression of some of 
the genes described above have been determined (Table 1.2). From this table it can be 
seen that p38 MAPK regulates the expression of different genes at different levels 
depending upon the cell type and the nature of the stimuli.
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Gene Agonist Cell Type Regulatory Mechanisms Reference
EL-1 LPS monocytes translational Lee et a l, 1994
TNT LPS monocytes translational Lee et al., 1994
EL-6 TNF murine L929 decreased mRNA 
(transcription 
and/or mRNA stability?)
Bayaert et al., 1996
IL-8 IL-l/TNF endothelial cells decreased mRNA 
(transcription 
and/or mRNA stability?)
Hashimoto et al., 1999
COX-2 IL-1 HeLa mRNA stability Ridley et oZ.,1998
COX-2 LPS monocytes transcription and mRNA 
stability
Dean et al., 1999
COX-2 LPS, IL-1 
zymosan
monocytes decreased mRNA 
(transcription 
and/or mRNA stability
Puuliut et al., 1997
MMP-1 IL-1 dermal fibroblasts decreased mRNA 
(transcription 
and/or mRNA stability
Ridley et al., 1997
IL-6 IL-1 synoviocytes mRNA stability Miyazawa et al, 1998
Table 1_2: Regulation of gene expression by p38 MAPK as determined using specific Inhibitors, 
1.5.1 Transcriptional regulation
Although several transcription factors have been identified as potential p38 MAPK 
substrates (see section 1.3.3) the physiological relevance of many of these remains to 
be determined. For instance ATF-2 can be phosphorylated by p38 MAPK in-vitro and 
ATF-2-dependent gene transcription can be increased by cotransfection with MKK3 
and MKK6 (Raingeaud et al., 1996). However SB 203580 does not inhibit ATF-2 
phosphorylation in-vivo when cells are stimulated with agonists that activate p38 
MAPK, therefore indicating that p38 MAPK is not rate-limiting for this process 
(Hazzalin et al., 1996). ETS domain transcription factors, Elk-1 and Sapl-a, have also 
been identified as potential p38 MAPK substrates that can be phosphorylated in-vitro
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and stimulate a c-fos SRE-driven luciferase reporter gene (Janknecht and Hunter,
1997). These transcription factors bind together with the serum response factor to the 
serum response element (SRE) in immediate early genes such as c-fos. Eos is then 
able to form a heterodimer with c-Jun and form the AP I complex (see section 1.2.7). 
In a recent report a role for p38 MAPK in c-fos induction has been demonstrated 
using SB 203580 at concentrations similar to the IC5 0  value for the inhibition of p38 
MAPK enzyme activity. However in this study c-fos was induced by UV radiation 
and not by pro-inflammatory cytokines (Hazzalin et el., 1996). MEF2C, a member of 
the myocyte-enhancer factor (MEF2) group of transcription factors, has also been 
identified as a substrate of p38 MAPK (Han gf al., 1997). In monocytes stimulated 
with LPS the transactivation activity of MEF2C is increased through p38 MAPK 
catalysed phosphorylation. A consequence of MEF2C activation is increased c-jun 
gene transcription and evidence suggests that p38 MAPK may regulate the levels of c- 
Jun during infection of inflammation. Another possible mechanism for transcriptional 
control may be mediated by the p38 MAPK substrates, MAPKAPK-2 and MSK1 
which have been shown to phosphorylate CREB (cAMP-responsive element binding 
protein) which binds to the cAMP response element (CRE) within target genes (Deak 
et cd., 1998; Tan et al., 1996).
From the evidence described above it can be proposed that p38 MAPK may regulate 
gene transcription at several levels. At one level p38 MAPK may phosphorylate and 
increase the activity of transcription factors that directly induce the target gene such 
as COX-2, which contains putative binding sites for members of the Ets/TCF, CRE 
and MEF2 families. At another level p38 MAPK may regulate the induction of early 
immediate genes such as c-fos and c-jun whose gene products form the dimeric
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transcription factor complexes, such as AP I, that regulate the transcription of many 
IL-1 inducible genes (see section 1.2.7) (reviewed by Eder, 1997).
1.5.2 Post-transcriptional
There is now a large body of evidence to support a role for p38 MAPK activity in the 
stabilization of mRNAs from a number of different genes within different cell types 
(Ridley et al., 1998; Dean et al., 1999; Miyazawa et al., 1998). Regulation of mRNA 
stability is often mediated by repeat AUUUA sequence motifs located within the 3’ 
untranslated region (3’ UTR) of numerous induced cytokines and protooncogenes 
(Caput etal., 1986; Chen and Shyu, 1994; Chen and Shyu, 1995). The COX-2 gene 
produces two major mRNA transcripts, COX-2 (4.6 kb) and COX-2 (2.8 kb), which 
are derived by alternative polyadenylation site usage (Newton et al., 1997). In the 3’ 
UTR of the most abundant COX-2 transcript, COX-2 (4.6 kb), there are 22 AU-rich 
elements (AREs) that have been recognised as important determinants of mRNA 
stability (Ristimaki et al., 1996). In the case of TNF mRNA, AREs present in the 3’ 
UTR have also been claimed to regulate translation (Han et al., 1990). Recently, 
tristetraprolin ( TI P) the prototype of a class of zinc finger proteins has been shown to 
inhibit TNFa production by destabilizing its mRNA. This effect appeared to result 
from direct binding of TI P to the AU-rich element of the TNFa mRNA (Carballo et 
al., 1998). Several other fram1-activating factors including AUF1 (DeMaria and 
Brewer, 1996) and AUBF (Rajagopalan and Maker, 1994) have also been identified 
that bind to AREs. At present it is still unclear how AREs regulate mRNA stability 
and/or translational inhibition or how ARE binding proteins mediate Selective mRNA 
degradation or protection.
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1.6 Aim of this project
As discussed above specific p38 MAPK inhibitors have implicated p38 MAPK 
activity in the regulation of several IL-1 inducible genes most notably COX-2 (Dean 
et al., 1999; Ridley et al., 1998; Pouliot et al., 1997) (Table 1.2). In addition, the level 
of regulation at which p38 MAPK modulates gene expression appears to be dependent 
on the cell type and stimulus. In view of this, it is highly likely that the effects of p38 
MAPK are mediated by several downstream substrates (some of which may have not 
yet been identified). Therefore the aim of this investigation was to try and identify a 
novel protein substrate or protein interaction that could add to our current 
understanding of pro-inflammatory cytokine signalling and gene regulation by the p38 
MAPK pathway. To do this p38 MAP kinase and its substrate MAPKAPK-2 were 
used as bait in a yeast two-hybrid screen. This method has been previously used 
successfully to identify many of the components involved in the early signalling 
events of IL-1 and TNF (see Figure 1.3). In addition an investigation was also carried 
out to determine the role of MAPKAPK-2 in pro-inflammatory cytokine signalling 
and gene induction. To achieve this HeLa cells were stably transfected with a kinase 
inactive MAPKAPK-2 mutant and MAPKAPK-2 anti-sense RNA HeLa cells were 
chosen for study because of their responsiveness to IL-1 stimulation. Dominant 
negative and anti-sense methods to target and specifically reduce endogenous kinase 
activities have previously been described in this ERK (p42/p44) and INK MAP kinase 
pathways (Pages et al., 1993; Krause et al., 1998).
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Chapter 2
Materials and Methods
2.1 Materials
2.1.1 General chemicals and materials
General laboratory chemicals were purchased from Sigma Chemical Co. Ltd. (Poole, 
Dorset, UK) or BDH Ltd., (Poole, Dorset, UK) unless otherwise stated. Ethanol was 
obtained from Hayman Ltd. (Witham Essex, UK), Biophenol / Tris from Camlab Ltd. 
(Cambridge, UK), Bacto-tryptone, bacto-agar and yeast extract were obtained from 
Difco Ltd., (Detroit, Michigan, USA).
Radiolabelled chemicals [y-32P]-ATP, [32P]-orthophosphate and [35S]- methionine 
were supplied by Amersham Pharmacia Biotech Ltd (Bucks., UK)
Tissue culture media and supplements were obtained from Gibco-BRL (Paisley, 
Scotland). Tissue culture plastics were supplied by Falcon™ (NT, USA).
Restriction enzymes, T4 DNA ligase, and calf intestinal phosphatase were purchased 
from Boehringer Manheim Ltd., (Lewes, East Sussex, UK) or New England Biolabs 
(Beverly, MA, USA).
For the construction of epitope-tagged proteins, the mammalian expression vector 
pcDNA3 (Invitrogen BV, Netherlands) was used. For routine non-expression cloning 
* and sub-cloning the vector pSP73 (Promega Ltd., Southampton, UK) was used. For
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the construction of GST-fusion proteins, pGEX-3X from Pharmacia (St., Albans, 
Herts., UK) was used.
The FireLite™ Dual Firefly and Renilla Luciferase Reporter Gene Assay Kit was 
provided by Packard Bioscience (Netherlands) and the Prostaglandin Ez Monoclonal 
Enzyme Immunoassay Kit was supplied by Cayman Chemical (US).
QIAGEN plasmid Maxi / Midi Kits and SuperFect™ Transfection Reagent were 
obtained from QIAGEN Ltd. (Crawley, UK).
DNA Sequence Kit™ (Big Dye Terminator Cycle Sequencing Ready Reaction) and 
AmpliTaq DNA Polymerase was obtained from PE Applied Biosystems (Foster City, 
CA., USA). Sequence reactions were carried out in a Biometra™ Trio-Thermoblock 
complete with Biometra™ heated lid (Anachem Ltd, Luton, UK) and analysed on a 
373A DNASequencer (PE Applied Biosystems, Foster City, CA, USA). All other 
PCR reactions were done in a Perkin Elmer TCI machine (PE Applied Biosystems, 
Foster City, CA, USA).
Protein gels / Western blot apparatus and See Blue™ pre-stained protein markers 
were obtained from Novex Experimental Technology (San Diego, CA, USA). 
Immobilon™ PVDF transfer membrane was supplied by Millipore Corp. (Bedford, 
MA, USA).
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Horizontal gel electrophoresis equipment was supplied by Bethesda Research 
Laboratories Inc., (Maryland, USA). DNA molecular weight markers (100 bp /I kb 
ladders) were obtained from Gibco-BRL (Paisley, Scotland).
The gene puiser, pulse controller and electroporation cuvettes were obtained from 
BIO-RAD (Hemel Hempstead, Hertfordshire, UK).
Small scale centrifugation was carried out using a benchtop microfuge (Anderman i
centrifuge 5414). Large scale centrifugation was carried out using a Sorvall® RC3B 
or RC5B refrigerated centrifuge.
Gammabind G Sepharose beads were obtained from Pharmacia Biotech (St Albans,
Herts., UK).
2.1.2 Microbiological media
YPD broth 2%(w/v) Bacto-peptone, l%(w/v) Bacto-yeast extract, 2%
dextrose (added separately as 40% stock)
YPD agar 2%(w/v) Bacto-peptone, l%(w/v) Bacto-yeast extract 2%
dextrose (added separately as 40% stock), 2% (w/v) Bacto-agar
SD broth 0.67%(w/v) yeast nitrogen base without amino acids, 2%
dextrose (added separately as 40% stock), pH 5.8
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SD agar 0.67% (w/v) yeast nitrogen base without amino acids, 2%
dextrose (added separately as 40% stock), 2% (w/v) Bacto- 
agar, pH 5.8
LB agar l%(w/v) Bacto-tryptone, 0.5%(w/v) Bacto-yeast extract, 171
mM NaCl, 1.5%(w/v) Bacto-agar
2X TY broth 2%(w/v) Bacto-tryptone, l%(w/v) Bacto-yeast extract, 171 mM
NaCl, pH 7.0
SOC 2%(w/v) Bacto-tryptone, 0.5%(w/v) Bacto-yeast extract, 10
mM NaCl, 25 mM KC1, 10 mM MgCl2, 10 mM MgS04, 20 
mM glucose
2.1.3 Solution and buffer formulations
5X M9 salts 230 mM NazHPO^ 7H20 , 110 mM XH^O^, 42 mM NaCl, 93
mM NH4CI
PBS 120 mM NaCl, 2.7 mM KC1,10 mM phosphate buffered salts
TE 10 mM Tris-HCl pH 7.5, 1 mM EDTA
TAE 40 mM Tris-acetate pH 8.0, 1 mM EDTA
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X-gal stock 50 mg/ml X-gal (5-bromo-4-chloro-3- indolyl-p-D- 
galactopyranoside in N,N- dimethylformamide
10X LiAc 1 M lithium acetate (adjust to pH 7.5 with acetic acid and
autoclave)
10X PCR buffer 500 mM KCU00 mM Tris-HCl pH 8.0,150 mM MgCl2
Z-buffer 60 mM NazHPCV 7H20, 40 mM NaHzPCV H20,
10 mM KC1, MgSCV 7H20  (adjust to pH 7.0 and autoclave)
5X ligation buffer 5 mM ATP, 100 mM DTT, 50 mM MgCl2, 250 mM Tris-HCl
pH 7.4
Z-buffer/Xgal solution
100 ml Z-buffer
0.27 ml p-mercaptoethanol
1.67 ml X-gal stock (50 mg/ml) ç
SX DNA sample loading buffer
glycerol 25%
EDTA 100 mM
Bromophenol blue 0.1 %
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yeast lysis solution
2% Triton X-100 
1% SDS 
100 mM NaCl 
10 mM Tris pH 8.0 
1.0 mM EDTA
5X protein sample buffer
p-mercaptoethanol 5%
SDS 10%
Glycerol 50%
Tris-HCl pH 6.8 100 mM
Bromophenol blue 0.2%
PEG/LiAc solution
Final Cone. To prepare 10 ml
PEG 4000 40% 8 ml of 50% PEG
TE Buffer IX 1 ml of 10X TE
LiAc IX 1 ml of 10X LiAc
10X kinase buffer
Final Cone. To prepare 10 ml
P-glycerophosphate 25 mM 2.5 ml of a 1 M stock
MgClz 25 mM 2.5 ml of a 1 M stock
Hepes pH 7.4 25 mM 2.5 ml of a 1 M stock
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DTT
Na3V0 4
2 mM 0.4 ml of a 0.5 M stock
100 |iM 10 pi of a 1 M stock
m am m aH aii cell lysis buffer
Final Cone.
NP40 1%
EDTA 10 mM
NaCl 0.15 M
Tris-HCl pH 7,5 10 mM
NaF 50 mM
Na3V04 1 mM
Na4Pz0 7  20 mM
H20
protease inhibitor tablet*
* Complete™ Mini protease inhibitor cocktail tablet (Boehringer)
QIAGEN plasmid purification buffers
Buffer PI (Resuspension Buffer) 50 mM Tris-HCl pH 8.0, 10 mM EDTA,
100 pg/ml RNAse A 
Buffer P2 (Lysis Buffer) 200 mM NaOH, 1% SDS
Buffer P3 (Neutralization Buffer) 3.0 M potassium acetate pH 5.5
Buffer QBT (Equilibration Buffer) 750 mM NaCl, 50 mM MOPS pH 7.0,
15% isopropanol, 0.15% Triton X-100 
Buffer QC (Wash Buffer) 1.0 M NaCl, 50 mM MOPS pH 7.0,15%
isopropanol
To prepare 10 ml 
1 ml of a 10% stock 
0.4 ml of a 0.25 mM stock 
1 ml of a 1.5 M stock 
0.1 ml of a 1 M stock 
1 ml of a 0.5 M stock 
0.1 ml of a 0.1 M stock 
0.4 ml of a 0.5 M stock 
6.0 ml
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Buffer QF (Elution Buffer) 1.25 M NaCl, 50 mM Tris-HCl pH 8.5, 15%
isopropanol
Buffer N3* (Neutralization Buffer) contains chaotropic salt 
Buffer PB^ (Optional Wash Buffer) contains chaotropic salt 
Buffer PE* (Wash Buffer)
* The ingredients to the QIAprep Spin buffers N3, PB, PE are withheld at the 
manufacturers' discretion
2.1.4 cDNA and vector sources
Human peripheral blood mononuclear cell (cPBMC) and skeletal muscle cDNA were 
kindly provided by Dr. Patrick Slocombe (Celltech). The human COX-2 promoter (- 
2309 to +37) cloned into the pGL3b Firefly luciferase reporter vector (Promega, 
Southampton,UK) was kindly provided by Dr Andrew Clark (Kennedy Institute of 
Rheumatology, London). The E-selectin promoter (-170 to +52) cloned into the 
pGL3b Firefly luciferase reporter vector was kindly provided by Dr. Breda Twomey 
(Celltech). The pRL-CMV Renilla luciferase reporter vector was also obtained from 
Promega.
2.1.5 Bacterial strains
For the routine propagation of recombinant plasmids and for the purification of 
recombinant glutathione S-transferase (GST) fusion proteins, ultra competent 
Epicurian Coli XL-1 Blue cells (recAl endAl gyrA96 thi-l hsdRll supE44 relAl 
lac[F proAB lac\q ZAM15 TnlO(Tetr)] ), were used (Stratagene Ltd » Cambridge, 
UK).
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To select for Leu\ Ampr transformants in the yeast two-hybrid experiments, 
electrocompetent E.coli HB101 cells, a strain carrying a LeuB mutation ( F  hsd S20 
(re" ms) supEAA aralA galK2 lacYl pro A  rpsL20 (StrR) xyl-5 mil-1 recA13 mcrB 
thi-l leuB6) were used.
2.1.6 Antibodies and recombinant proteins
The anti-human Hsp27 and anti-MAPKAPK-2 (anti-p50) antibodies and the murine 
GST-cleaved MAPKAPK-2 protein were kindly donated by Professor J. Saklatvala 
(Kennedy Institute of Rheumatology, London). Anti-human c-Myc antibodies were 
obtained from UBI. Anti-human COX-2 was obtained from Oxford Biomedical 
Research. GAL4 BD and GAL4 AD monoclonal antibodies were purchased from 
Clontech and the murine anti-FLAG monoclonal antibody was obtained from Kodak 
Scientific Imaging Systems. Anti-human actin was purchased from Santa Cruz 
Biotechnology and the anti-human IL-6, IL-8 and detection antibodies used in the IL- 
6 and EL-8 ELISA were obtained from PharMingen, UK Anti- MAPKAPK-2 
antibodies were obtained from various sources and are discussed in detail in Chapter 
6.
2.1.7 Yeast two-hybrid reagents
An oligo (dT) + random primed human leucocyte MATCHMAKER cDNA library in 
the vector pGADIO was purchased from Clontech (Hants, UK).
Yeast growth media and amino acid dropout supplements (Leu ,Trp ,His, LeuVTrp", 
LeuVTrpTHis" DO) and all other reagents required for the Matchmaker Two-Hybrid 
System were also purchased from Clontech.
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2.1.8 Yeast strains
Strain Genotype Reporters Transformation Markers
SFY526 MATa, ura 3-52, his 3-200, 
ade 2-101, lys 2-801, trp 1-901, 
leu 2-3,112, can', gal 4-542, 
gal 80-538, URA3::GALl-tocZ
lacZ tfpi, teu2
HF7z MATa, ura 3-52, his 3-200, 
lys 2-801, ade 2-101, trp 1-901, 
fctt 2-3,112, gal 4-542, gal 80-538 
LYS2::GALl-fflS3,
URA3::(GAL4 17mers)3-CYCl-tocZ
fflS3, tocZ np7, Zcm2
Table 2.1: Yeast strains used in the two-hybrid study 
2.1.9 Vectors
The cloning and control vectors provided with the MATCHMAKER system used in 
the yeast two-hybrid screen (Chapter 5) and are shown in Table 2.2 below.
»
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Plasmid Description Selection on SD 
medium
References
pAS2-l GAL4(1.147) DNA-BD, 
TRPl,ampr, CYHS2
Trp- Harper et a l, 1993
pGADIO GAL4(768-881)AD,
LEU2,ampr
Leu- Bartel et al., 1993
pGAD424 GAL4(768-881)AD,
LEU2,ampr
Leu- Bartel et al., 1993
pCL-1 wild-type full-length GAL4 
gene, LEU2, ampr
Leu- Fields & Song 1989
pVA3 murine p53(72-39o> 
TRP1, ampr
Trp- Iwabuchi et al., 1993
pTDl SV40 large T-antigen^^.^ 
LEU2, ampr
Leu- U &  Fields 1993
Table 2.2: Cloning vectors used in the yeast two-hybrid study
2.1.10 Oligonucleotides
Oligonucleotides were designed from the database sequences (accession numbers 
indicated below). Only the oligonucleotides that were used for PCR cloning, PCR 
mutagenesis, RT-PCR and DNA/riboprobe amplification are indicated below. 
Sequencing and vector specific oligonucleotides are not shown.
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CSBP2/p38MAP kinase oligonucleotides: (Accession No. L35264)
N5378 (forward)
5 ’ - GCG GGATCC AAA ATG GAC TAC AAG GAC GAC GAT GAC AAG TCT C AG GAG AGG 
Bam HI Start FLAG epitope
CGC ACG TTC TAC CGG CAG G - 3’
N0465 (reverse)
5’ - CAG GGATCC CCT CAC AGTGAA GTGGGATC - 3’
Bam HI
27019 (reverse)
5* - TGG TCT GGA GAG CTT CCT CAC TGC C - 3’
K53R
27020 (forward)
5’ - CGT GTG GCA GTG AGG AAG CTC TCC AG - 3’
K53R
27021 (reverse)
5’ - CAC CAG ATA CAC ATC ATT GAA TTC CTC C - 3’
Eco RI
W0988 (forward)
5* - CCG GGGATCCGT ATG TCT CAG GAG AGG CCC ACG TTC TAC C - 3’
Bam HI
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MAPKAPK-2 oligonucleotides: (Genbank Accession No. U12779)
N3257 (forward)
5* - GCG GGA TCC ACC ATG CTG TCC AAC TCC CAG GG - 3’
Bam HI
N3258 (reverse)
5’- GAG GCC CGG GGT CGA CGG ACA GGA ACA CAG AAT CCT CTG CTC ACA A - 3’
Sma 1/ Sail
P0324 (reverse)
5’- GAG GCC CGG GGT CGA CGG TGG CTC AGT GGG CCA GAG CCT CCA GGG - 3’
Sma I / Sal I
W0989 (forward)
5* - CCG GGGATCCGT CCG CAG CAG TTC CCG CAG TTC CAC - 3*
Bam HI
W9760 (forward)
5’ - GGC AAA GTT TTG CAG ATC TTC AAC AAG AGG ACC CAG GAG AAA TTC GCC CTC
Bgin
AGA ATG CTT CAG - 3’
K93R
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A0488 (forward)
5’ - GCG GAA TTC ATG CTG TCC AAC TCC CAG GGC CAG AGC CCG CCC ACC CCT GCC 
Eco RI
CTG CCG CAC CCC CCG GCG CAG CCG CCG CCG CCG CCC CCG CAG CAG TTC - 3* 
N3256 (reverse)
5’ - GAG ATT CTC AGG CTT GAC ATC Ç - 3’
B5640 (reverse)
5? - ATA GCC AAG CTT TCT AGA TTA ATT CAA GTC CTC TTC A AAT GAG CTT TTG CTC 
Hind m  /Xba I c-Myc epitope
CAT GTG GGC CAG AGC CGC AGC CTC CAG GGC CCG AGC - 3’
MAPKAPK-2 RT-PCR anti-sense 
F6070 (forward)
5' - GTC CTC TIC AGA AAT GAG CTT TTG CTC CAT GTG G - 3' 
c-Myc epitope
F6071 (reverse)
5' - CGC CAT CCT GAA ACT CAC TGA CTT TGG - 3'
MAPK Kinase 6 oligonucleotides: (Genbank Accession No. U39657)
W0990 (forward)
5’ - ATC CGT CGA CCT ATG TCT CAG TCG AAA GGC AAG AAG CG - 3*
Sail
49
V6483 (reverse)
5’ - GCG ATA GTC GAC TTA GTC TCC AAG AAT CAG TTT TAC AAA AGA TG - 3*
Sali
Human Heat Shock Protein 27 oligonucleotides: (Genbank Accession No. 
X54079)
N3984 (forward)
5’ - GAG GGATCC AGC ATG ACC GAG CGC CGC GTC CCC TT - 3’
Bam HI
N3985 (reverse)
5’ - CTG GGA TCC GGG CTA AGG CTT TAC TTG G - 3’
Bam HI
Human polyhomeotic 2 homologue (HPH2) oligonucleotides: (Genbank 
Accession No. U89278)
C4045 (forward)
5’ - GCG AAG CTT ATG GAC TAC AAG GAC GAC GAT GAC AAG CAG GCC ATT GTG 
Hind m  Start FLAG epitope
AAA CCC CAA ATC CTG ACG CAT GTT ATC - 3’
C4047 (reverse)
5’ - GCG GGA TCC GCC CTA GGA GTC CTT GAG CAT GCT GAT - 3*
Bam HI
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D5865 (forward)
5’ - GCG GAT CCA GGC CAT TGT GAA ACC CCA AAT CCT G - 3’
Bam HI
2.1.11 Cell Lines
Human HeLa cells and COS-1 cells were obtained from the European Collection of 
Animal Cell Cultures, ECACC Nos 85060701 and CRL1650 respectively.
2.2 DNA and RNA Methods
2.2.1 PCR amplification of DNA fragments
Typically, PCR reactions were carried out in 50 pi total reaction volumes comprising 
of: 50-200 ng of cDNA or plasmid DNA template, 10 pmoles of each oligonucleotide, 
5 units of AmpliTaq DNA polymerase, 2 pi DMSO, 5 pi 10X PCR buffer, 5 pi of a 
2.5 mM dNTP mix (dATP,dTTP,dCTP and dGTP) and sterile dH20. The reaction 
mixture was overlayed with 2 drops of paraffin oil and amplified for 30 cycles under 
the following conditions 95°CZ1 min, 60°C/1 min, 72°C/1 minute. Oligonucleotides 
were usually designed to have a melting temperature (Tm) of > 60°C. Samples were 
then analysed by agarose gel electrophoresis.
2.2.2 Analysis of DNA fragments by gel electrophoresis
Horizontal, submerged gel electrophoresis was typically carried out on 1 % (w/v) 
agarose gels in TAE buffer containing 25 pg/ml ethidium bromide and 
electrophoresed at 100 V/cm. The DNA bands were visualised under UV light at
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254Mn. Agarose gel electrophoresis was used analytically and preparatively, the latter 
for purification of DNA fragments for cloning.
2.2.3 Purification of DNA fragments from agarose gels
DNA fragments were purified from agarose gels using Geneclean II (Bio 101 Inc,
CA, USA) following the manufacturers instructions. In brief, the desired DNA bands 
were excised from the agarose and incubated for 10 min with 2.5 volumes of sodium 
iodide at 55°C. To each sample, glass milk (5 jil/pg of DNA) was added and mixed by 
rotation at room temperature for 5 min before spinning at 13,000 rpm for 5 seconds. 
The supernatant was discarded and the glassmilk pellet with bound DNA was washed 
three times with 1 ml NEW wash buffer (BiolOl Inc.) and spun at 13,000 rpm for 5 
seconds between each wash. After the supernatant from the final wash was removed, 
the pellet was air dried for 5 min to remove any traces of ethanol The DNA was then 
eluted from the glass beads by resuspending the pellet in 30 ill of distilled water and 
incubating at 55°C for 5 minutes. After a final spin at 13,000 rpm for 1 minute the 
eluted DNA solution was carefully removed.
2.2.4 Analysis of of DNA fragments by restriction enzyme
For general restriction enzyme analysis, 1-2 pg of DNA was incubated in the 
appropriate enzyme buffer with 10 units of restriction enzyme at 37°C* for 1-2 hours. 
Digestions were stopped by adding sample loading buffer and the bands were 
resolved by agarose gel electrophoresis. In cases where the DNA was to be used in 
subsequent sub-cloning procedures the amounts of DNA and enzyme were scaled up 
to 10 |ig and 20 units respectively and incubated for a period of 2-4 hours.
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* Sma I digestions for the construction of GST-AMAPKAPK-2 were carried out at 25 
°C.
2.2.5 Alkaline phosphatase treatment of DNA fragments
Prior to sub-cloning DNA fragments cut with a single restriction enzyme, either the 
vector or the fragment were treated with alkaline phosphatase to prevent self-ligation 
of the fragments or re-ligation of the vector. The reaction was carried out by adding 
alkaline phosphatase (10 U /gg DNA) to an appropriate volume containing 10X 
phosphatase buffer. After incubating at 37°C for 45 min, the DNA was purified once 
by phenol/chloroform/isoamyl alcohol (24:24:1) extraction, followed by a single 
chloroform extraction. The DNA was then precipitated by adding 2.5 volumes of 
100% ethanol and 1/10 volume of 3 M sodium acetate (pH 4.6) and incubated at -20 
°C for 1 hour, followed by micro-centrifugation at maximum speed for 15 minutes. 
The DNA pellet was then washed once in 70% ethanol and resuspended, in an 
appropriate volume of water.
2.2.6 DNA tigations
DNA fragments were ligated using bacteriophage T4 DNA ligase in a total reaction 
volume of 20 |il comprising: 4 gl of 5X ligation buffer, 2 units of T4 DNA ligase, 100 
ng of vector DNA and a 3 Molar excess of insert fragment. Control ligations 
containing only the vector were routinely carried out to determine the transformation 
efficiency. Ligations were incubated at room temperature for a minimum of one hour, 
before transformation into the appropriate competent cells.
53
2.2.7 Transformation of competent E.coli cells
Epicurian® E.coli XL-1 Blue competent cells were transformed following the 
manufacturer instructions. Briefly, 1.7 pi of P-mercaptoethanol was added to 100 |il 
of competent cells and incubated on ice for 10 min. 0.1-50 ng of DNA was added and 
incubated for a further 30 min on ice. Each sample was heat shocked at 42°C for 45 
seconds and chilled on ice for 2 minutes before the addition of 0.9 ml pre-warmed 
SOC medium and incubated at 37°C for 1 hr with constant shaking. 200 pi of each 
sample was plated out onto the appropriate antibiotic plates and incubated at 37°C 
overnight.
Electro-transformation of HB101 cells was carried out in 0.2 cm electroporation 
cuvettes using a Bio-Rad gene puiser and pulse controller. In brief, 40 pi of 
electrocompetent E.coli HB101 cells and 1 pi of plasmid (1-20 ng) in TE buffer were 
mixed and incubated on ice for 1 minute. The gene puiser apparatus was set at 25 pp 
and 2.5 kV and the pulse controller was set at 200 £2. The mixture was then 
transferred into a pre-chilled electroporation cuvette and pulsed. The cuvette was 
removed and 1 ml of SOC medium was immediately added to resuspend the cells.
The cell suspension was transferred to a sterile 15 ml polypropylene tube and allowed 
to recover at 37°C for 1 hr with constant shaking. 200 pi of each transformation were 
plated onto appropriate antibiotic plates and incubated at 37°C overnight.
2.2.8 Isolation of plasmid DNA ( Maxi Protocol)
Large scale preparation of plasmid DNA from 100-200 ml of overnight culture 
(2XTY medium containing 100 pg/ml of ampicillin), was carried out using a 
QIAGEN-tip 500 following the manufacturers instructions. In brief, the cells were
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pelleted by centrifugation at 5,000 rpm for 10 minutes and resuspended in 10 ml of 
buffer PI. 10 ml of buffer P2 was added mixed gently and then incubated at room 
temperature for 5 min. 10 ml of chilled buffer P3 was then added and incubated on ice 
for 20 min. The cell lysate was cleared by centrifugation at 12,000 rpm at 4°C for 30 
min. The supernatant was added to an equilibrated QIAGEN-tip 500 (equilibrated by 
adding 10 ml of buffer QBT) and allowed to flow through by gravity pressure only. 
Following this, the QIAGEN-tip was washed with 2 X 30 ml of buffer QC. The DNA 
was then eluted with 15 ml of buffer QF, mixed with 0.7 volumes of isopropanol 
(10.5 ml) and centrifuged at 7,000 rpm 4°C for 30 minutes. The DNA pellet was air 
dried and resuspended in TE buffer.
2.2.9 Isolation of plasmid using QIAprep spin columns (mini-preps)
Plasmid mini-preps using Qiagen spin columns were used to rapidly purify plasmid 
DNA from recombinant colonies for restriction enzyme analysis following the 
manufacturers instructions. In this method all the centrifugation steps were carried out 
in a bench top centrifuge at maximum speed (13,000 rpm). In brief, 1.5 ml of culture 
was centrifuged for 5 min and the cell pellet was resuspended in 250 gl of buffer PI. 
To this, 250 gl of lysis buffer P2 was added and mixed by gentle inversion. The 
solution was then neutralised by adding 350 gl of buffer P3 and mixing immediately. 
The cell lysate was centrifuged for 10 minutes and the cleared supernatant was added 
to a QIAspin column. The column was placed in a 2 ml collection tube and spun for 
60 sec. The flow through was discarded and 0.5 ml of wash buffer (PB) was added 
and spun for 60 seconds. The column was then washed with 0.75 ml of buffer PE and 
centrifuged for 60 seconds. Finally, the DNA was eluted by adding 50 gl of H20  to
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the column which was then allowed to stand at room temperature for 1 min. 
Centrifuging for a further minute eluted the DNA solution.
2.2.10 Optical density measurement of DNA
The concentration of DNA was determined by optical density measurement in a 
quartz cuvette at 260 run, using a Unicam 5625 UV/VIS spectrometer, assuming an 
OD2 6 0 nm of 1.0 represents a concentration of 50 gg/ml.
2.2.11 Analysis of transformed recombinant colonies by PCR screening
This method was used to rapidly screen colonies for cloned inserts and to determine 
the correct orientation when non-directional cloning was carried out. Individual 
colonies were picked using sterile inoculating needles and mixed with 20 pi of PCR 
reaction mix (see section 2.2.1). To enable the correct orientation of the inserts to be 
determined, the reaction mix contained a sense oligonucleotide complementary to 
vector sequence flanking the multiple cloning sites and an anti-sense oligonucleotide 
designed from the gene sequence. The reaction was overlayed with paraffin oil and 
amplified for 30 cycles under the following conditions 940C/1 min, 55°C/1 min and 
72°C/3 min.
2.2.12 DNA sequencing
DNA sequencing reactions were carried out in 0.5ml thin-bottomed Eppendorf tubes. 
Each reaction comprised of; 3.2 pmol sequencing primers, 0.5-1.0 p.g plasmid DNA, 4 
pi sequencing buffer and 4 pi of reaction premix (Big Dye Terminator Reaction 
Ready, Applied Biosystems). Distilled water was added to a final volume of 20 p i 
The reactions were then thermo-cycled in a Biometra™ Trio-Thermoblock with
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heated lid, for 25 cycles under the following conditions 96°C/30 sec, 50°C/15 sec, 
60°C74 min. The DNA was precipitated by adding 2 pi of 3 M sodium acetate, pH 4.6 
and 50 pi of 95% ethanol The samples were incubated on ice for 10 min and then 
centrifuged at maximum speed on a bench top centrifuge for 15 minutes. The ethanol 
was removed and the pellet was allowed to air dry before resuspending in sample 
loading buffer. Sequence reactions were run on a 373A automated DNA sequencer 
(Applied Biosystems).
2.2.13 Isolation of mRNA
To isolate polyA+ mRNA from HeLa cells the Micro-FastTrack™ Kit (Invitrogen) 
was used. Briefly, cells (1X106) were lysed in a detergent based buffer containing 
RNase/Protein degrader, incubated at 45°C for 15 minutes and then applied directly to 
an oligo (dT) cellulose spin column. DNA, degraded proteins and cellular debris were 
washed off the resin with a high salt buffer (0.5 M). Non-polyadenylated RNAs were 
washed off with a low salt buffer (0.25 M) and polyA+ mRNA is then eluted in the 
absence of salt (10 mM Tris-Cl, pH 7.5).
2.2.14 Synthesis of first-strand cDNA for RT-PCR
First-strand cDNA from mRNA was generated using the cDNA Cycle® Kit 
(Invitrogen). Briefly, 0.01-1 pg of mRNA was mixed with random primers (1 pg), 
heated at 65°C for 10 minutes and then allowed to anneal at room temperature for 2 
minutes. First-strand cDNA was transcribed in a 20 pi reaction volume comprising of: 
AMV reverse transcriptase (5U), 5 X RT buffer, 1 pi of dNTPs (100 mM) and 1 pi of 
80 mM sodium pyrophosphate. The mixture was then incubated at 42°C for 1 hour. 
RNA-cDNA hybrids were denatured by heating at 95°C and cooled rapidly on ice. To
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carry out gene specific PCR amplifications, 2-5 pi of the reverse transcriptase mixture 
was used as template under the conditions described in section 2.2.1.
2.2.15 Ribonuclease protection assays
Ribonuclease protection assays (RPA) were carried out using the Direct Protect™- 
lysate RPA system (Ambion). This method allows direct detection and quantitation of 
target RNA in crude lysates of solid tissue or cultured cells. In brief, cells (1.5 X 106) 
were seeded into 60 mm tissue culture plates and allowed to recover for 5-6 hours. 
Following pre-treatment with inhibitor (2 hrs) and IL-1 (20 ng/ml) for 8 hours the 
cells were lysed in 150 pi of guanidine thiocyanate buffer (GuSCN). Cellular debris 
was pelleted by spinning for 10 minutes at maximum speed in a refrigerated 
microfuge. The supernatant was removed and stored at -20°C until required.
The COX-2 riboprobe was transcribed using T7 polymerase from a 256 bp Cla I
r>
(1549)/ Bst YI (1805) COX-2 restriction enzyme fragment, cloned into pBluescript 
(kindly provided by Dr. AClark, Kennedy Institute of Rheumatology, London). 
Pharmingen supplied the hGAPDH housekeeping control template used for in-vitro 
transcription. In-vitro transcription reactions were typically carried out in a total 
volume of 20 pi comprising: 2 pi of DTT (100 mM), 2 pi of T7 transcription buffer 
(10X), 1 gl RNasin (40U/|il), 1 pi template DNA (0.1-1.0 |ig/|il), 5 |il [a-32P] UTP 
(~800Ci/mmol), 4 pi of ATP, GTP, CTP (2.5 mM each), 2.5 gl of UTP (100 (tM) and 
1 )tl of T7 polymerase (ISU/gl). The reaction was incubated at 37°C for 1 hour 
followed by the addition of 1 pi of RNase-free DNase I and incubated at 37°C for a 
further 30 minutes. Spin columns removed unincorporated nucleotides and the 
reaction was purified once by phenol-chloroform extraction and ethanol precipitated.
58
The RNA pellet was resuspended in 100 |il of TE buffer from which a 1 pi aliquot 
was removed and counted. 5 pi of labelled probe (105 cpm/pl) was hybridised 
overnight with 45 pi of lysate. For each probe two control tubes containing 5 pi of 
probe + 45 pi of lysis buffer were also set up. One tube acted as a control to ensure 
RNase digestion was complete and the other as a minus RNase control Single-strand 
specific ribonuclease cocktail (440 pi HzO, 50 pi buffer, 10 pi RNase cocktail) was 
added to digest unprotected RNA and incubated at 37°C for 30 minutes. 10 pi of 
Proteinase K (20 mg/ml) and 10 pi of 10% sodium sarcosyl were added and incubated 
for 30 minutes at 37°C. Protected fragments were precipitated with isopropanol and 
resuspended in 10 pi of loading buffer. Samples were heated for 5 minutes at 95°C, 
resolved by electrophoresis on a 6% polyacrylamide gel and analysed on a 
phosphorimager.
2.3 Cell Culture and Cell Biology Methods
2.3.1 General cell culture
HeLa and COS-1 cell lines were cultured in DMEM (Dulbeccos Modified Eagles 
Medium) supplemented with 10% (v/v) heat-inactivated foetal calf serum, 2 mM 
glutamine, 50 pg/ml penicillin and 50 mg/ml streptomycin. Stable cell lines were 
maintained in the above medium containing G418 antibiotic at 500 pg/ml Both 
HeLa and COS-1 are adherent cells and were routinely passaged in T175 flasks. To 
remove the cell monolayers 5 ml of trypsin /EOTA in Pucks modified saline solution 
(GIBCO) was added and the cells were incubated at 37°C in 5% CO2  for 5 min. A 
further 5 ml of serum-containing DMEM was added, 1 ml of this was then removed
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and added to 50 ml of fresh serum-containing DMEM. The flask was then incubated 
at 37°C in 5% COz for 3-4 days before passaging again. For long term storage, 
pelleted cells (-2.5 x 106) were resuspended in medium containing 10% (v/v) DMSO, 
aliquoted into freezing vials and stored in liquid nitrogen.
2.3.2 Transient transfection of COS-1 and HeLa Cells
The expression of recombinant proteins in mammalian cells was tested by transiently 
transfecting either COS-1 or HeLa cells. COS-1 cells were transfected as described by 
(Whittle et al., 1987), which is an adaptation of the procedure set out by (Lopata et 
al., 1984). Cells cultured in DMEM, 10% PCS, 2 mM glutamine, 50 ug/ml penicillin 
and 50 mg/ml streptomycin were plated out into 24 well tissue culture plates at a 
density of 2 x 105 cells/ml and allowed to adhere overnight. Cells were washed twice 
with serum-free DMEM and incubated for 6-8 hours at 37°C with a DNA-dextran 
mixture consisting of 1-3 fig DNA in serum-free DMEM buffered with 50 mM Tris- 
HC1 pH 7.5 and 0.2 mg/ml DEAE dextran (Pharmacia) prepared in TBS (25 mM Tris- 
HC1 pH 7.4, 38 mM NaCl, 5 mM KC1,0.5 mM MgCl2, 0.7 mM CaCl2, 0.6 mM 
Na2HPO^). The DNA-dextran complex was removed and the cells were shocked by 
adding 10% (v/v) dimethyl sulphoxide (DMSO) in Hepes buffered saline pH 7.4 (138 
mM NaCl, 5 mM KC1, 6 mM glucose, 0.7 mM Na2HPO^, 21 mM Hepes) and 
incubating at room temperature for 3 minutes. Cells were washed once with serum- 
free DMEM before adding 1 ml of fresh serum-containing medium and incubating at 
37°C in 5% C02. Two days after transfection the cells were harvested in mammalian 
cell lysis buffer and assayed for protein expression by Western immunoblotting (see 
section 2.4.4).
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HeLa cells were transiently transfected using SuperFect™ Transfection Reagent 
(QIAGEN) following the manufacturers protocol with minor modifications. Briefly, 
the cells were seeded at 2 x 105 /ml in a 24 well tissue culture plate and incubated 
overnight to 40-80% confluency. Plasmid DNA (1-3 pg) was diluted in serum-free 
DMEM to give a total volume of 60 pi (in co-transfection experiments 1-1.5 pg of 
each plasmid was added). SuperFect™ transfection Reagent (5 pl/pg DNA) was added 
and mixed by vortexing. The mixture was then allowed to stand at room temperature 
for 10 minutes to allow the formation of transfection complexes. During this time the 
cells were washed once with 1 ml of PBS. Serum containing DMEM (350 pi) was 
added to the reaction tubes containing the transfection complexes, mixed by pipetting 
and added immediately to the cells, which were then incubated for 2-3 hr at 37°C in 
5% COz. The transfection medium was removed and the cells were washed once with 
PBS. Fresh medium (1 ml) was added and the cells were incubated at 37°C in 5% COz 
for 2-3 days.
2.3.3 Large scale transient transfection of COS-1 cells
In some cases, such as for the p38 MAP kinase assays, a larger yield of protein 
material was required. To achieve this a confluent T175 tissue culture flasks was 
transiently transfected as described in section 2.3.2, with the following modifications. 
T175 flasks were seeded with 50 ml of medium containing 2 X 105 cells/ml, 100 pg of 
DNA was added in 10 ml of transfection buffer (serum-free DMEM+DEAE dextran 
in TBS), the cells were shocked by adding 10 ml of 10% DMSO in HBS buffer. 
Finally, the cells were washed twice with PBS and 50 ml of fresh medium was added.
61
2.3.4 Generation of stable cell lines
HeLa cell lines stably expressing c-Myc-tagged MAPKAPK-2 and MAPKAPK-2 
anti-sense message were generated as follows. Cells were transfected as described in 
section 2.3.2, with the following modifications. Cells (2xl(/) were seeded in 60 mm 
plates such that they were only 20-40% confluent on the day of transfection. Plasmid 
DNA (5 fig) was diluted in serum-free DMEM to give a total volume of 150 pJ, into 
which 20 pi of SuperFect™ reagent was added and mixed by vortexing. After the 
formation of transfection complexes (5-10 min) serum-containing DMEM (1 ml) was 
added and the cells were incubated for 2-3 hr. The transfection mixture was then 
removed and the cells were washed 3-4 times with 4 ml of PBS. Fresh medium (3 ml) 
was then added and the cells were incubated at 37°C in 5% CO2 . After 48 hours the 
cells were washed twice with PBS and harvested by trypsinisation. The cells were 
counted and diluted to a density of 5,000 cells/ml in medium containing G418 (500 
pg/ml) and then seeded into 20 x 96-well plates (200 pl/well) and incubated at 37°C 
in 5% CO2 . After 2-3 weeks the plates were examined for wells containing only a 
single G418 resistant colony. Colonies were removed by trypsinisation and inoculated 
into 1 ml of medium containing G418 (500 pg/ml) in 24 well plates and incubated 
until confluent. The colonies were then expanded up into T175 tissue culture flask. 
Isolated clones were screened by Western blotting using an anti-c-Myc polyclonal 
antibody for epitope-tagged MAPKAPK-2 expression (see section 2.4.4) or by RT 
PCR for MAPKAPK-2 anti-sense message (see section 2.2.14). A G418 resistant 
HeLa control cell line transfected with empty pcDNA3 was also generated as 
described above.
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2.3.5 COX-2 reporter gene assays
Cells from the G418 resistant HeLa control cell line (pcDNA3 transfected) were 
seeded at a density of 20,000 cells/well into a 96-well tissue culture plate and 
incubated overnight at 376C in 5% COz. The following day the cells were washed 
once in PBS arid transiently transfected using Superfect™ transfection reagent 
following the manufacturers protocol Briefly, 550 ng of plasmid DNA (comprising of 
500 ng of either COX-2 or E-selectin promoter firefly luciferase reporter gene vectors 
and 50 ng of renilla luciferase reporter gene vector) and 2.5 pi of transfection reagent 
were diluted in 20 pi and 30 pi of serum-free medium respectively. The two mixtures 
were added together and incubated for 5-10 min at room temperature. Serum- 
containing medium (150 pi) was then added and the mixture was added to the washed 
cells and incubated at 37°C in 5% CO2  for 3 hours. The transfection medium was then 
removed and the cells were washed once in PBS before adding 200 pi fresh serum- 
containing medium and incubating for 16 hours. The amounts and volumes described 
above are those required for a single transfection. In all experiments carried out a 
master transfection mix using these amounts and volumes was made and then 
aliquoted accordingly.
The following day the medium was removed and replaced with 100 pi of phenol red 
free medium with or without IL-1 a  (20 ng/ml) and the cells were incubated for a 
further 8 hours. 100 pL of reconstituted LucLite substrate (Packard) was then added 
and incubated for 10 min with gentle agitation. The plate was counted on a 
TopCount™ Microplate Scintillation and Luminescence Counter. To each well 50 pi 
of RenLite substrate was then added and incubated for 30 min before counting again.
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2.3.6 IL-6 and IL-8 ELISA
ELISA assays were carried out to measure the concentration of IL-6 and IL-8 secreted 
into the overlaying tissue culture medium following stimulation of stably transfected 
HeLa cells (10*) with IL-1 a  (20 ng/ml) for 16 hours. In this experiment and also in 
the PGEz ELISA (see section 2.3.7) some of the samples were pre-treated for 2 hours 
with SB 203580 (1 pM) prior to stimulation.
Purified anti-cytokine antibodies were diluted to 1 pg/ml in binding solution (0.1 M 
NazIIPCU, adjusted to to pH 9.0 with 0.1 M NaHzP04), 50 pi was added to the wells 
of an enhanced protein-binding ELISA plate (Nunc Maxisorb) and incubated 
overnight at 4°C. The plates were then blocked by adding 200 pl/well of blocking 
buffer (filtered PBS containing 10% foetal calf serum) and incubated at room 
temperature for 2 hours. The plates were then washed three times in PBS +0.05% 
Tween-20. IL-6 and IL-8 standards and the samples (prepared by diluting in serum- 
free DMEM in doubling dilutions) were added at 100 pl/well and incubated at room 
temperature for 3 hours. The plates were then washed 4 times with PBS +0.05% 
Tween-20. Biotinylated anti-IL6/IL-8 detection antibodies (Pharmingen) were diluted 
to 1 pg/ml in blocking buffer and added at 100 pl/well The plates were incubated for 
1 hour at room temperature and then washed 4 times with PBS +0.05% Tween-20. 
AMDEX™ streptavidin-horseradish peroxidase (HRP) conjugate (Amersham 
Pharmacia Biotech, UK) was diluted (1:2500) in blocking buffer and added at 100 
pl/well and incubated at room temperature for 30 minutes. The plates were washed 4 
times with PBS +0.05% Tween-20 and 100 pl/well of TMB* substrate was added and 
incubated at room temperature for colour development (10-80 minutes). The optical
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density for each well was determined by reading at 405 nm on a Microplate 
Autoreader.
*To make TMB substrate 2 L of P-cyclodextrin buffer (3.3 g sodium acetate, 0.77 ml 
acetic acid, 40 g P-cyclodextrin, 20 ml DMSO and 66.8 jjJ of hydrogen peroxide) was 
mixed with 20 ml of TMB (0.63 g, 21 ml DMSO).
2.3.7 Prostaglandin E2 determination
Prostaglandin E2  (PGE2 ) levels were measured in the overlaying culture medium 
following activation of the cells with IL-1 a  using a PGE2  Immunoassay Kit (Caymen, 
US). The assay is based on the competition between PGE2  and a PGE2 - 
acetylcholinesterase conjugate (PGE2  tracer) for a limited amount of PGE2  
monoclonal antibody. Because the concentration of the PGE2  tracer is held constant 
while the concentration of PGE2  varies, the amount of PGE2  tracer that is able to bind 
to the PGE2  monoclonal antibody will be inversely proportional to the concentration 
of PGE2 in the well The antibody-PGEz complex then binds to a goat anti-mouse 
polyclonal antibody on pre-coated plates. The assay conditions and final PGE2  
concentrations were carried out following the manufacturers protocol The standards 
and samples were diluted in culture medium.
2.4 Protein methods
2.4.1 hmnunopretipitation of epitope-tagged and endogenous proteins
Epitope-tagged and endogenous proteins were immunoprecipitated from either 
transiently or stably transfected cells as follows. Cells were typically lysed in 1 ml of
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ice-cold mammalian cell lysis buffer and cellular debris was pelleted by 
microcentrifugation at 13,000 rpm for 10 min at 4°C. The supernatants were removed 
and pre-cleared by adding 50 pi of a 50% slurry of washed Gammabind G sepharose 
and incubated at 4°C for 1 hour with constant rotation. The samples were centrifuged 
at maximum speed for 15 seconds and the supernatant was carefully removed and 
added to fresh Eppendorf tubes. Antibody was added at the concentration 
recommended by the manufacturer (anti- FLAG (3 pg/ml), anti-c-Myc (5 pg/ml), 
anti-rabbit MAPKAPK-2 (5 pg/ml) or anti-Hsp27(10 pi serum)) and incubated 
overnight at 4°C with gentle rotation. To precipitate the immune complexes, 50 pi of 
a 50% slurry of Gammabind G Sepharose was added and mixed by rotating slowly at 
4°C for 4 hours. The sepharose beads were pelleted by centrifugation at maximum 
speed for 15 seconds and the supernatant was carefully removed. The beads were 
washed once in lysis buffer supplemented to 0.5M NaCl, once in lysis buffer 
containing 0.1% SDS and once in TE containing 0.1% NP40. After the final wash the 
beads were resuspended in the desired volume and 5X sample loading buffer was 
added. Immunoprecipitated proteins used for kinase assays were not resuspended in 
loading buffer, but instead the beads were additionally washed twice and resuspended 
to a 50% slurry in kinase buffer.
2.4.2 Batch purification of epitope-tagged protein
FLAG-tagged p38 MAP kinase used for the SB 203580 titration assay was batch 
purified from transiently transfected COS-1 cells grown in a T175 tissue culture flask 
(see section 2.3.3). The cells were lysed in 25 ml of mammalian cell lysis buffer and 
centrifuged (7000 rpm for 15 min at 4°C) to precipitate the cellular debris. The 
supernatant was removed and pre-cleared by adding 1250 pi of a 50% slurry of
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Gammabind G sepharose and incubated at 4°C with constant rotation for 1 hour. The 
beads were then precipitated by centrifugation (3000 rpm for 5 min at 4°C) and the 
supernatant removed. Anti-FLAG antibody (75 p.g) was added and incubated for a 
minimum of 4 hours with constant rotation at 4°C. The immune complexes were 
precipitated by adding 1250 pi of a 50% slurry of Gammabind G sepharose and 
incubated at 4 °C with constant rotation for 2 hours. The beads were pelleted by 
centrifugation (3000 rpm for 5 min at 4°C), washed twice in lysis buffer and twice in 
kinase buffer and resuspended to 50% before aliquoting into equal volumes.
2.4.3 Preparation of GST-fusion proteins
To prepare GST-AMAPKAPK-2wt, GST-AMAPKAPK-2 K93R, GST-Hsp27 and 
GST-HPH2 fusion proteins, 10 ng of each construct was transformed into ultra 
competent Epicurian Coli XL-1 Blue cells. The transformation mixtures were plated 
onto LB agar plates containing ampicillin (100 pg/ml) and incubated overnight.
Single colonies from each transformed clone were then picked and used to inoculate 
20 ml of 2XTY broth containing ampicillin (100 pg/ml) and incubated overnight. The 
following day 500 ml of pre-warmed 2XTY broth containing antibiotic were 
inoculated with the 20 ml of overnight culture and incubated at 30°C with constant 
shaking (200 rpm), until an ODsoomn = 0.6 - 0.7. Isopropyl-P-D-thiogalactoside 
(IPTG) was added to 0.2 mM and the cells were incubated for a further 4 hours. The 
cells were then pelleted by centrifugation (5000 rpm for 10 min) and resuspended in 
10 ml of PBS supplemented with 1 mM DTT and a Complete™ protease inhibitor 
cocktail tablet. The cells were snap frozen in liquid nitrogen and then thawed at 42 °C. 
The suspension was then sonicated (4X20 seconds) and 0.1% Brij 35 was added. 
Cellular debris was removed by centrifugation (15,000 rpm for 30 min at 4°C) and
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the supernatant was carefully removed and loaded onto a packed glutathione 
sepharose column (Pharmacia Biotech). The column was washed and GST-fusion 
proteins eluted as described in the manufacturers protocol
2.4.4 Immunological detection of proteins (Western blotting)
Whole cell lysates (pre-spun to remove cellular debris) or immunoprecipitated 
proteins bound to sepharose beads were mixed with 5X sample loading buffer, heated 
at 95 °C for 5 minutes and centrifuged at 13,000 rpm for 1 minute. Typically, between 
10-35 pi of each sample was loaded onto either a 10% or 4-20% pre-cast Tris-glycine 
polyacrylamide gel (Novex). Gels were subjected to electrophoresis with appropriate 
molecular weight markers at 100 V/50 mA until the bromophenol blue dye front 
reached the bottom of the gel Samples were transferred onto Millipore nylon 
membrane, pre-wetted in methanol using Novex blotting apparatus in Tris-glycine 
buffer for 2 hours at 30 V/200 mA The success of the transfer could be demonstrated 
by using pre-stained molecular weight markers. The membrane was washed twice in 
water and then blocked in PBS containing 5% Marvel for 1 hour at room temperature 
with constant agitation. The membrane was then incubated with the primary antibody 
diluted in blocking buffer according to the manufacturers instructions. Following 
incubation with primary antibody the membrane was washed three times for 5 
minutes each in PBS and then incubated with the appropriate conjugated secondary 
antibody diluted in blocking buffer according to the manufacturers instructions. 
Finally, the membranes were washed three times for 5 minutes each in PBS+0.05% 
Tween-20 at room temperature followed by rinsing in 3-4 changes of distilled water. 
Proteins were detected using the Peirce enhanced chemiluminescence system and the 
signal was visualised by exposure to X-ray film.
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2.4.5 Immune complex kinase assays
Kinase assays were typically carried out in 50 \il reaction volumes of which 30 pi 
comprised of a 50% slurry of sepharose beads complexed with epitope-tagged protein 
(either c-MycMAPKAPK-2 or FLAGp38 MAP kinase). The remaining volume 
comprised: 2-5 pg of GST-fusion protein substrate(s), radiolabelled [y32?] ATP (5 
pCz), unlabelled ATP (20 pM) and 10X kinase buffer. In the reactions containing SB 
203580, the inhibitor was diluted in DMSO and added in a volume that did not exceed 
1% of the total reaction volume. The reactions were incubated at 37°C for 25 minutes 
and then stopped by the addition of 5X protein loading buffer. The samples 
transferred to nylon membranes (as described in section 2.4.4) and visualised by 
autoradiography.
2.4.6 Metabolic labelling of cells with 32P-orthophosphate
Cells (IX 106) were seeded into 6-well tissue culture plates and incubated overnight. 
The following day the medium was removed and the cells were washed twice in 
serum-free, phosphate-free DMEM. The cells were then incubated in phosphate-free 
DMEM containing 10% dialysed foetal calf serum and lOOpCi/ml 32P- 
orthophosphate. After 5 hours the medium was removed and the cells were washed 
twice in PBS and then lysed in 1 ml of mammalian cell lysis buffer. Endogenous 
Hsp27 was immunoprecipitated using an anti-Hsp27 antibody complexed to 
Gammabind G sepharose as described in section 2.4.1. The samples were transferred 
to nylon membrane as described in section 2.4.4 and phosphorylated Hsp27 was 
visualised by autoradiography. In this experiment, cells were treated with or without 
IL-1 a  (20ng/ml) and SB 203580 (1 pm), which were added 20 minutes and 2 hours 
respectively before lysis.
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2.5 Yeast Two-Hybrid Methods
2.5.1 Plasmid library titering
Prior to screening the human leucocyte MATCHMAKER cDNA library, it was 
amplified to obtain sufficient plasmid for large scale yeast transformations. The high 
titre library stock was thawed and 1 |il was added to 1 ml of pre-warmed LB broth to 
give a 103 dilution. This was then repeated to give a dilution of 10*. From each 
dilution, 1 |il was removed and added to 50 pi of LB broth and spread onto 
prewarmed LB+Amp (100 pg/ml) agar plates. The plates were incubated overnight at 
37 °C and the number of colonies on each plate were counted. The titer of the library 
(cfu/ml) was determined for each dilution factor and an average value of 7.4x10* 
cfu/ml was calculated. Using this value the E.coli transformants were plated to obtain 
at least 2-3X the number of independent clones in the library (~ 2X10*).
2.5.2 Library amplification
Cells were plated onto 30 X (243 x 243 mm) sterile bioassay plates (Nunc) containing 
selective medium (LB+Amp 100 pg/ml) at a density of 70,000 colonies/plate and 
incubated overnight at 37 °C. The following day the colonies were harvested by 
scraping and the plates were washed with LB+Amp. The suspension was incubated at 
37 °C for 2-4 hr with shaking. The cells were then pelleted and plasmid DNA was 
purified using Qiagen 500 columns as described in section 2.2.8.
2.5.3 Transformation of plasmid(s) into competent yeast cells
The LiAc method for preparing yeast competent cells was done following the method 
of (Gietz et al., 1992). The human leucocyte library (GAL4 AD/library ‘hybrid’) was 
co-transformed with the GAL4 BD/MAPKAPK-2 K93R ‘hybrid’ as detailed below
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(the volumes indicated in parenthesis are for small scale yeast transformations with 
either singularly transfected or co transfected plasmids).
Several colonies of yeast HF7z cells, 2-3 mm in diameter, were inoculated into 1 ml 
of YPD broth and vortexed vigorously to disperse the clumps. The suspension was 
then transferred into a flask containing 100 ml (50 ml) of YPD and incubated at 30 °C 
for 16-18 hr with shaking at 250 rpm to stationary phase (OD6oo> 1.5). The culture 
was then diluted into a new flask containing 1 L (300 ml) of YPD to produce an 
O D ^  0.2-0.3 and incubated for 4 hr at 30 °C with shaking at 230 rpm. The cells 
were then pelleted by centrifugation at 4000 rpm for 5 min at room temperature and 
washed in 500 ml (50 ml) of sterile water. The cells were pelleted once again by 
centrifugation and resuspended in 8 ml (1.5 ml) of IX TE/LiAc.
The library DNA and pAS2. l/BDMAPKAPK-2 K93R, 500 juig each (0.1 pg), were 
then mixed with 20 mg (0.1 mg) of herring testes carrier DNA and added to 8 ml (0.1 
ml) of competent yeast cells. Sterile PEG/LiAc solution, 60 ml (0.6 ml), was added 
and mixed by vortexing and the suspension was incubated at 30 °C for 30 min with 
shaking at 200 rpm. The cells were then shocked by adding 7 ml (70 pi) of DMSO 
and mixed by gentle inversion. After incubating the cells at 42 °C for 15 min, they 
were chilled on ice for 5 min, pelleted by centrifugation and resuspended in 10 ml 
(0.5 ml) of TE buffer. 200 pi of cells were spread onto sterile, 135 mm plates (X50) 
containing SD/TrpTLeu/His' and incubated at 30 °C for 7-8 days (for reactions 
involving only single plasmid transformations, the appropriate SD plates were 
prepared). To determine the efficiency of transformation and hence the number of 
colonies screened 10 pi of the transformation mixture was plated onto SD/Trp/Leu
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plates. To check that the co-transformants that survived the HIS3 growth selection 
from the library screening were indeed true His"1" colonies, they were picked using 
sterile inoculating needles and the phenotype was verified again by gridding the 
colonies onto a freshly made SD/Trp/Leu/His master plate.
2.5.4 P-galactosidase colony lift filter assays
Colony lift P-galactosidase filter assays were done on the isolated co-transformants 
growing on the SD/Trp/Leu/His master plate (no more than 2 days old). Cells were 
picked using a sterile inoculating needle and resuspended into 20 |il of TE buffer 10 
|il of this suspension was then spotted onto a 125 mm sterile filter disk (Whatman) 
overlayed on top of a 135 mm SD/Trp/Leu/His plate and incubated for 48 hours at 
30 °C. The cells were permeabilized by lifting the filter and plunging it into liquid 
nitrogen for 30 sec. The filter was then removed, thawed at room temperature and 
placed on top of another filter paper that had been pre-soaked in Z-buffer/X-gal 
solution. Both filters were placed inside a large 135 mm petri dish and incubated at 
room temperature for a maximum for 8 hours. The plate was checked periodically for 
the appearance of blue (LacZ*) signals.
2.5.5 Plasmid isolation from yeast cells
Because transformed yeast may take up several plasmids it was important to isolate 
and check each GAL4AD/library plasmid from each potential HIS"1", lacZ* positive 
transformant. Plasmids were isolated from the yeast cells following a procedure based 
on the methods of (Kaiser and Auer, 1993). This method yields plasmid DNA that is 
suitable for E. coli transformation by electroporation.
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Using a single yeast colony, 2 ml of YPD broth were inoculated and incubated at 30 
°C until the culture was saturated (-16 hr). The cells were then pelleted by 
centrifugation at 14,000 rpm for 5 sec at room temperature. The supernatant was 
removed and the cells were resuspended in 200 pi of lysis solution and vortexed, 
followed by the addition of 200 pi of phenol:chloroforin:isoamyl alcohol (24:24:1) 
and 0.3 g of 425-600 pm glass-beads (Sigma). The mixture was vortexed for 2 min 
and then centrifuged at 14,000 rpm for 5 min at room temperature. The aqueous layer 
was removed and the plasmid(s) were precipitated by adding 1/10 volume 3 M 
NaOAc, pH 5.2 and 2.5 volumes of ethanol. The DNA pellet was washed with 70% 
ethanol and air-dried before resuspending in 20 pi of TE buffer.
To isolate the library component of the heterogenous plasmid preparation, the mixture 
was electroporated into E.coli HB101 cells and the AD/library plasmid was selected 
using its LEU2 selectable marker gene to complement the leuB mutation in this E.coli 
strain. The cells were electroporated as described in section 2.2.7 and plated onto 
SD/Leu, M9 minimal medium plates containing 50 pg/ml ampicillin, 40 pg/ml 
proline and 1 mM thiamine-HCl and incubated overnight at 37 °C. To determine if the 
clone from which the plasmid DNA was prepared contained more than one 
AD/library plasmids, the transformants were PCR screened as described in section 
2.2.11, using oligonucleotides designed to specific vector (pGADIO) sequences 
flanking the multiple cloning sites. Ten colonies were picked from each 
transformation and the insert sizes were determined. Plasmid DNA was prepared as 
described in section 2.2.9 and sequenced from colonies containing different insert 
sizes.
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Chapter 3
Cloning and vector construction
3.1 Introduction
This chapter describes the cloning and construction of epitope-tagged, FLAG-p38 
MAP kinase wild type (wt) and kinase dead mutant (K53R), cMyc-MAPKAP kinase- 
2 (wt) and kinase dead mutant (K93R) and the GST- fusion proteins, Hsp27 and 
truncated (A) MAPKAP kinase-2 (wt) and (K93R) mutant. Epitope-tagged p38 MAP 
kinase and MAPKAP kinase-2 were constructed in the mammalian expression vector, 
pcDNAB (Figure 3.1). GST- fusion proteins were constructed in pGEX-3X (Figure 
3.6) vector and expressed in bacteria. The GST-fusion proteins were used as 
substrates in the kinase assays described in Chapter 4, whilst the kinase dead mutants 
of p38 MAP kinase and MAPKAPK-2 were used to generate GALA binding domain 
(BD) and activation domain (AD) fusion proteins, used in the yeast two-hybrid study 
described in Chapter 5. In addition the MAPKAPK-2 constructs were also used to 
generate stable cell lines described in Chapter 6.
At the time of starting this work the human nucleotide sequence of p38 MAP kinase 
had only recently been described (Lee et al., 1994). The enzyme encoded by this 
sequence was found to be the target of a series of compounds that inhibited the 
production of IL-1 and TNF in-vivo. The gene was cloned from a GM-CSF-stimulated 
monocyte library, using degenerate oligonucleotides designed from peptide sequences 
following tryptic digestion of the purified enzyme. Two cDNAs, that were identical 
except for a small sequence of 25 amino acids between residues 230-255 (Figure 3.2) 
were isolated and named CSBP1 and CSBP2 (cytokine suppressor binding proteins).
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CSBP2 differed by only 2 amino acids from the murine homologue (p38), which had 
previously been described and shown to be rapidly tyrosine phosphorylated by 
hyperosmotic stress and endotoxin (LPS) stimulation of a murine pre-B cell line, 
70Z/3, transfected with the LPS receptor CD 14 (Han et cU., 1993).
MAP kinase activated protein kinase-2 (MAPKAP kinase-2/MAPKAPK-2) is a 
serine/threonine protein kinase that was first purified from rabbit skeletal muscle. It 
was originally identified as an enyzme that could be activated in-vitro by the p42 and 
p44 MAP kinase isoforms and inactivated in-vitro by protein phosphatase 2A (PP2A). 
The nucleotide sequence of rabbit MAPKAP kinase-2 was determined using 
degenerate oligonucleotides derived from peptide sequences of the purified enzyme 
(Stokoe et al., 1992).
The first reported human nucleotide sequence of MAPKAP kinase-2, was obtained by 
screening a human skeletal muscle cDNA library with rabbit cDNA fragments 
generated by PCR amplification using degenerate oligonucleotides designed from the 
rabbit peptide sequences. The largest clone obtained from this library was then 
subsequently used to probe a human teratocarcinoma cDNA library, from which a 
longer clone was isolated. However, the lack of an initiating methionine residue and 
the aberrant molecular weight of this clone when expressed, led to the conclusion that 
it was not a full-length clone (Stokoe et al., 1993). The first full-length clone of 
MAPKAP kinase-2 was isolated from a human HL60 cDNA library also using a 
rabbit DNA probe (Zu et a l, 1994). However, although this clone had an initiating 
methionine at the N- terminal, it differed significantly at the C-terminal from the 
clone described by Stokoe ef al. (1993) (Figure 3.8). The two isoforms, MAPKAPK-2
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a (Stokoe et al.t 1993) and MAPKAPK-2b (Zu et al., 1994), are the products of an 
alternate splicing event at the C-terminus of the same gene and are expressed in high 
levels in both heart and skeletal muscle tissues (Zu et al., 1997).
Mammalian MAPKAP kinase-2 enzymes contain a proline-rich N-terminal domain, a 
catalytic domain, the sequence of which is most closely related to the family of 
calmodulin dependent kinases and a C-terminal domain which contains a putative 
nuclear localization signal (NLS) (Engel et al., 1993; Stokoe et al., 1993). This signal 
motif (-K-R-R-K-K-) is absent in the C-terminal of the shorter splice variant 
described by Zu et al. (1994). In transfected cells, MAPKAPK-2 is predominantly 
located in the nucleus. However, upon cellular stress the protein is rapidly 
translocated to the cytoplasm. This translocation which can be blocked by treatment 
with SB 203580 and leptomycin B appears to be regulated and induced by 
phosphorylation (Engel et al., 1998). In mammalian MAPKAPK-2 enzymes, the 
sequence immediately N-terminal to the catalytic domain contains two potential 
proline rich, SH3-binding domain (-P-P-P-X-P-P-) regions (Stokoe et al., 1993; Engel 
et al., 1993), which are absent in the in the Drosophila homologue, Dm MAPKAPK-2 
(Larochelle and Suter, 1995). By possessing these binding sites MAPKAP kinase-2 
may interact with proteins that contain SH3 domain(s).
The human small heat shock protein (Hsp27) is a metabolically stable protein present 
at low levels in all cells and tissues. Following stimulation by cellular insults such as 
heat shock, UV-irradiation, arsenite and pro-inflammatory cytokines (Rouse et a/., 
1994; Freshney et al., 1994) Hsp27 is rapidly phosphorylated at three serines, the 
major one being Ser 82 and two minor ones Ser 15 and Ser 78 (Landry et a/.,1992).
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The sequence and organisation of human Hsp27 has been described. Hsp27 is a 205 
amino acid polypeptide that shows striking similarity with mammalian cc-crystallin 
(Hickey et al., 1986; Carper et a i, 1990). The amino acid sequence of human Hsp27 
is homologous to the reported sequences of the small heat shock proteins from other 
mammals (Gaestel et a l, 1989; Lavoie et a i,  1990).
3 . 2  R e s u l t s
3.2.1 Cloning of FLAG-tagged p38 MAP kinase
To clone p38 MAP kinase (CSBP2) the following oligonucleotide primers were 
designed, N5378 and N0465, complementary to the terminal 5’ and 3’ sequences 
respectively of p38 MAP kinase. The 5’ oligonucleotide, N5378, contained the FLAG 
epitope (-DYKDDDD-) inserted between codons 1 and 2 of the enzyme as well as a 
Bam HI restriction enzyme site to facilitate cloning. N0465 also contained a Bam HI 
restriction site. CSBP2 was amplified by PCR from a human peripheral blood 
mononuclear cell (PBMC) cDNA library. An amplified fragment o f -1143 bp was gel 
purified, digested with Bam HI and ligated into the mammalian expression vector 
pcDNA3 (Figure 3.1). Transformed colonies were screened by PCR to determine the 
correct orientation using a forward, vector specific oligonucleotide (T7) and a reverse 
p38 MAP kinase specific oligonucleotide. A single clone was sequenced in its entirety 
on both strands using oligonucleotides designed from the published sequence. In 
addition, T7 and SP6 vector specific oligonucleotides were used to sequence the 5’ 
and 3’ ends respectively. The sequence obtained from this clone was the same as that 
described by Lee et al. (1994) and the clone was named pcDNA3/FLAGp38wt 
(Figure 3.2). Because CSBP1 and CSBP2 have identical 5’ and 3’ terminal sequences 
and therefore either enyzme could be potentially amplified, four additional clones
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Figure 3.1: Schematic diagram of the mammalian expression vectors pcDNA3 (A) and 
pcDNA3.1(-) (B). Both vectors are approx. 5.4 kb in size and are identical except, 
pcDNA3.1 (-) lacks the SP6 promoter and contains a more extensive and inverted 
multiple cloning site (MCS). The essential features of both plasmids include: CMV (human 
cytomegalovirus) major intermediate early promoter/enhancer region to drive expression 
of cloned genes; FI origin of replication; SV40 origin for transient episomal replication in 
cells expressing SV40 large T antigen; Neomycin resistance marker, expressed from the 
SV40 early promoter for the selection of stable transformants in the presence of G418; 
Bovine growth hormone (BGH) polyadenylation signal for polyadenylation of transcribed 
mRNAs; ^-lactamase gene to confer ampicillin resistance; ColEl origin of replication from 
pUC19 for high copy number.
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Figure 3.2: Construction of pcDNA3/FLAGp38wt. CSBP2/p38 MAPK was amplified from 
a human peripheral blood mononuclear cell cDNA library using the 5’ oligonucleotide N5378, 
containing the FLAG epitope DYKDDDD, and the 3’ oligonucleotide, N0465. The fragment 
was digested with Bam HI restriction enzyme and cloned into pcDNA3. The above figure 
indicates the amino acid differences between CSBP1 and CSBP2. A unique Eco RI restriction 
site located within the gene is shown above. This site was used to facilitate construction of the 
kinase dead construct.
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were sequenced across the small variable amino acid region (between residues 230- 
255) previously described (Figure 3.2). The sequences of all four clones were 
identical to CSBP2.
3.2.2 Generation of FLAG-tagged p38 kinase dead mutant
To generate a p38 MAP kinase mutant the lysine residue critical for ATP binding was 
mutated by PCR mutagenesis. This residue appears to be invariable at the ATP 
binding sites of protein kinases (Hanks et al., 1988) and has been shown in structural 
studies of p42 MAPK (ERK2) to be essential for ATP binding (Zhang et a l, 1994).
To construct a kinase dead clone, PCR mutagenesis was used. Two complementary 
oligonucleotides, 27020 (forward) and 27019 (reverse), were designed, across the 
ATP binding site. Both oligonucleotides contained the necessary base modifications 
to mutate lysine-53 (K53) to an arginine (R) residue (K53R). In addition, a further 
oligonucleotide, 27021 (reverse), was designed across a unique Eco RI restriction 
enzyme site located within the p38 MAP kinase sequence. Two primary PCR 
reactions were carried out using pcDNA3/FLAGp38wt as template. The first reaction 
involved oligonucleotides N5378 and 27019 to generate a fragment of approximately 
150 bp. The second PCR reaction involved the oligonucleotides 27020 and 27021 to 
generate a similar size fragment. Both PCR products were electrophoresed on a 2 % 
agarose gel and purified to remove any unincorporated oligonucleotides. A secondary 
PCR reaction was then carried out by mixing equimolar amounts (50 ng) of each 
fragment with the oligonucleotides N5378 and 27021 (Figure 3.3). A single fragment 
of 318 bp was amplified, resolved by electrophoresis, purified and digested with Bam 
HI and Eco RI.
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Figure 3.3: Mutation of lysine 53 (K53) at the ATP binding site of p38 MAP kinase by PCR 
mutagenesis.
The fragment was then cloned into Bam HI/Eco RI digested pSP73 (Figure 3.4) to 
produce the intermediate construct pSP73/FLAGp38K53R 5’ (Figure 3.5A). The 
mutation was confirmed by sequencing the fragment on both strands using vector and 
gene specific oligonucleotides.
The complete construct was then generated by 3-way ligation of the mutated fragment 
from pSP73/FLAGp38K53R 5’ with the larger fragment from pcDNA3/FLAGp38wt 
(Figure 3.5B) into Bam HI digested pSP73 (Figure 3.5C). Transformed colonies were 
digested to confirm the integrity of the ligation and a single clone was sequenced on 
both strands using gene specific oligonucleotides. Vector specific oligonucleotides 
(SP6 and T7) were used to sequence the 5’ and 3’ terminal regions. This clone was 
then digested with Bam HI and the fragment was sub-cloned into Bam HI digested 
pcDNA3 to produce pcDNA3/FLAGp38K53R.
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Nde I Hpa I Ori Bgl II Nde I
E  >  13=? eg n *3
Figure 3.4: Schematic diagram of the cloning vector pSP73. pSP73 is a high copy cloning vector, 
2464 base pairs in size. The essential features of the vector include: an E.coli origin of replication (Ori); 
an ampicillin resistance marker for selection in bacteria (Amp); an extensive multiple cloning site; SP6 
and T7 promotors for in-vitro transcription of either strand (as indicated by arrows).
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(A)
EcoRI
Nde I Hpa I Ori Bgl II Nde I
BamHI
K53R
( B )
Bsm  I
^ 1  BGl I n a | Neomycin SV40 pA
Bsm I
BamHI
(C)
Nde I Hpa I Ori Bgl II Nde I
EcoRI 1143bp
J  BamHIBamHI [
K53R
Figure 3.5: Schematic diagram illustrating the construction of kinase dead p38 MAP kinase 
in pSP73. To construct a p38 kinase dead mutant the Eco RI/Bam HI fragment of 
pSP73/FLAGp38K53R 5’ (A) was excised and joined in a 3-way ligation with the Eco RI/Bam HI 
fragment of pcDNA3/FLAGp38wt (B) into Bam HI digested pSP73 to produce pSP73/FLAGp38K53R (C).
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3.2.3 Cloning o f truncated (À) M APKAPK-2 4 0 .4 0 0  as a GST- fusion protein
AMAPKAP kinase-2 was built as a glutathione S-transferase (GST) fusion protein to 
act as a substrate to assess the kinase activities of pcDNA3/FLAGp38wt and 
pcDNA3/FLAGp38K53R (see Chapter 4). As discussed previously two 3’ splice 
variants of MAPKAP kinase-2 have been identified (Stokoe et al., 1993; Zu et al., 
1994). The oligonucleotide primers, P0324 and N3258, were designed to specifically 
bind to the 3’ sequence of each splice variant. Both oligonucleotides contained Sal I 
and Sma I restriction enzyme sites to facilitate cloning. Initially, PCR reactions using 
skeletal muscle and PBMC cDNA as templates were carried out in an attempt to 
amplify a full-length MAPKAPK-2 clone. A common 5’ oligonucleotide (N3257), 
designed across the initiating methionine was used in combination with each of the 
specific 3 ’ oligonucleotides. Unfortunately, no full-length MAPKAPK-2 clone could 
be amplified in either PCR reaction or from either cDNA source.
In previous studies a truncated GST-MAPKAPK-2 fusion protein (GST- 
AMAPKAPK-2) had been shown to be active when incubated and assayed against a 
synthetic peptide designed from the N-terminus of glycogen synthase (Zu et al., 1994; 
Ben-Levy et al., 1995) and with murine Hsp25 (Engel et al., 1995). Consequently 
further PCR reactions were then carried out in an attempt to amplify the largest 
catalytically active fragment. The oligonucleotide primer W0989, complementary to 
amino acids 40-47, was designed containing a Bam HI restriction enzyme site. PCR 
reactions were carried out using this oligonucleotide in combination with each of the 
specific 3 ’ splice variant oligonucleotides (P0324 and N3258). Interestingly, only the 
PCR reactions that contained the 3’oligonucleotide (P0324), complementary to the 
MAPKAPK-2 sequence described by Stokoe et al. (1993), produced an amplified
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Factor X
Figure 3.6: Schematic diagram of the glutathione S -transferase fusion vector pGEX-3X.
The important features of the vector are: a tac promotor for inducible, high level expression; an 
internal lac M gene for use in any E.coli host; a Factor X recognition site for cleavage of the desired 
protein from the fusion product.
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BspMI
Ptac g I u ta t h i o  ne S - 1 ra  n s  feras, lac 1 qOri
BspMI
BamHI
W0989 BglH
P0324P40 K93
Smal
1090bp
Figure 3.7: Construction of GST-AMAPKAPK-2 wt fusion protein (pGEX/GSTAMAPKAPK-2wt). 
AMAPKAPK-2 was amplified from a human peripheral blood mononuclear cell cDNA library using the 
5’ oligonucleotide W0989 and the 3’ oligonucleotide P0324. The fragment was digested with Bam HI 
and Sma I and cloned into pGEX-3X.The above figure indicates the amino acid residue (P40) at which 
AMAPKAPK-2 fuses with GST. The diagram also shows the relative position of the lysine residue (K93) 
at the ATP binding site, with respect to the the unique Bgl II restriction enzyme site which was used to 
facilitate construction of AMAPKAPK-2K93R.
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Figure 3.8: Sequence alignments of MAPKAPK-3 (McLaughlin et éd., 1996), MAPKAPK 2a 
(Stokoe et id.,1993), MAPKAPK 2b (Zu et aL, 1994) and the PBMC clone isolated in this 
study.
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Figure 3.9: Schematic diagram outlining the construction of AMAPKAPK-2K93R. (A) Using the 
oligonucleotides, W9760 and P0324, pGEX/GSTAMAPKAPK-2wt was used as a template to amplify 
a MAPKAPK-2 fragment containing a mutation at the ATP binding site (K93R). The oligonucleotide, 
W9760, contained the necessary nucleotide changes to incorporate this mutation. This oligonucleotide 
also extended upstream across a unique Bgl II site located within the MAPKAPK-2 gene which was 
used to facilitate cloning. (B) pGEX/GSTAMAPKAPK-2wt was digested with Bgl II and Sma I to remove 
the equivalent wild-type fragment. (C) The amplified PCR fragment was digested with Bgl II/ Sma I and 
ligated into the Bgl Il/Sma I digested pGEX/GSTAMAPKAPK-2wt to generate pGEX/GSTAMAPKAPK-2 
K93R.
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fragment. This result was the same from both of the cDNA library sources. The 
fragment was digested with Bam HI and Sma I restriction enzymes, purified and 
cloned into Bam HI/Sma I cut pGEX-3X vector (Figure 3.6). Four clones were 
sequenced in their entirety on both strands using oligonucleotides designed from the 
published sequence. Vector oligonucleotides were designed to sequence the 5’ and 3’ 
terminal regions. A single error free clone was named pGEX/GSTAMAPKAPK-2wt 
(Figure 3.7).
The sequences of all four clones described above were identical to each other. 
However, they differed from the sequence described by Stokoe et al. (1993) at three 
amino acid positions (Figure 3.8). At amino acid position 116 there is an aspartic acid 
to histidine change (D116H), at position 247 there is a leucine to tryptophan change 
(L247W) and finally, at position 248 there is a valine to serine (V248S) change. All of 
the amino acid changes above are conserved in the MAPKAPK-2b sequence 
described by Zu et al. (1994). Interestingly, these changes are also conserved within 
the sequence of MAPKAPK-3/3pK, a recently identified homologue of MAPKAPK-2 
(McLaughlin et al., 1996; Sithanandam et a l, 1996).
3.2.4 Construction of truncated kinase dead AMAPKAPK-2# 4#
Ludwig et al. (1996), demonstrated that the kinase activity of 3pK/MAPKAPK-3 
could be completely abolished by mutation of lysine-73 to methionine (K72M). An 
amino acid alignment of 3pK/MAPKAPK-3 vs MAPKAPK-2 revealed that this lysine 
residue is located at the putative ATP binding site and is conserved in both sequences. 
As a consequence of this an oligonucleotide (W9760) was designed containing the 
necessary nucleotide modifications to mutate the respective lysine of MAPKAPK-2 to
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an arginine residue (K93R). MAPKAP kinase-2 contains a unique Bgl II restriction 
enzyme site upstream of the ATP binding site. Therefore the mutated oligonucleotide 
was extended over this site to facilitate cloning.
PCR reactions with W9760 and the 3’ oligonucleotide P0324 were carried out using 
pGEX/GSTAMAPKAPK-2wt as template (Figure 3.9A). The amplified fragment was 
gel purified and digested with Bgl Il/Sma I. pGEX/GSTAMAPKAPK-2wt was then 
digested with Bgl II and Sma I and gel purified to remove the equivalent wild type 
Bgl Il/Sma I fragment (Figure 3.9B). The amplified mutated fragment was then 
cloned into this construct to produce pGEX/GSTAMAPKAPK-2K93R (Figure 3.9C). 
A single clone was sequenced in its entirety on both strands to confirm the mutation 
and to check for any PCR errors. The activity of the truncated mutant expressed in 
E.coli was evaluated (see Chapter 4) and the mutation was found to completely 
abolish kinase activity. As a consequence of this result a full-length enzyme with this 
mutation was constructed.
3.2.5 Construction of the 5’ terminus of MAPKAPK-2
As discussed above, initial attempts to clone full-length MAPKAPK-2 from a human 
PBMC cDNA library had been unsuccessful. However, PCR reactions using 
oligonucleotides designed around the 5’ terminus of the gene did enable additional 
sequence upstream of the fusion point (P40) of GST-AMAPKAPK (described above) 
to be identified. Thus revealing that longer cDNA messages were present within the 
library. From this information a ‘mega’ 5’ oligonucleotide primer (A0488) was 
constructed containing the initiating methionine and the missing residues of 
MAPKAPK-2 and which also overlapped with the 5’ sequence of the longest message
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identified in the PBMC cDNA library (Figure 3.10). To facilitate cloning the 
oligonucleotide was constructed with an Eco RI restriction enzyme site.
A0488
ATG CTG ICC AAC TCC CAG GGC GAG AGO CCG CCG GTG CCG 
M L S N S Q G Q S P P V P 1 3
TTC CGC GCC CCG GGC CCG CCG CCG CAG CGC CGC ACC CCT 
F P  A P  A P P  P Q P P T P 2 6
GCC CTG CCG CAC CGC CCG GCG CAG CCG CCG CCG CCG CCC 
P A GH
CCG CAG CAG TTC CCG CAG TTC CAC GTC AAG TCC GGC CTG
Q H K G
3 9
5 2
Figure 3.10: N-terminus of MAPKAPK-2 showing the abundant proline rich regions. The length 
of the oligonucleotide, A0488, used to artificially construct a full-length clone is indicated by the bold 
arrow. The 5’ limit of the longest clone isolated from the PBMC cDNA library is indicated in the 
boxed area. The initiating methionine is shown in bold type.
To amplify the 5 -terminus of MAPKAPK-2, PCR reactions using oligonucleotides 
A0488 and N3256 were carried out using human PBMC cDNA as template. N3256 
was designed downstream of the unique Bgl II restriction site that was used to 
construct the truncated MAPKAPK-2 GST-fusion proteins previously described 
(Figure 3.11).
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Figure 3.11: Construction of the 5* terminus of MAPKAPK-2 by PCR amplification.
A PCR product of -580 bp was amplified and gel purified. The fragment was then 
digested with the restriction enzymes Eco RI and Bgl II to produce two fragments of 
331 bp and 249 bp (Figure 3.11). Because the yield from this amplification was poor 
the two fragments were not purified, but instead the mixture was ‘shotgun’ cloned 
into Eco RI/Bgl II digested pSP73. This method captured only the 249 bp fragment 
that contained both the Eco RI and Bgl II sites. Three clones were then sequenced 
using gene and vector specific oligonucleotides. Two of the clones contained 
nucleotide errors located within the oligonucleotide (A0488) sequence, whilst the 
third clone was error free. This intermediate construct was recorded as 
pSP73/MAPKAPK-2 5’ (Figure 3.12A).
3.2.6 Construction of full-length wild-type and kinase dead MAPKAPK-2
To construct the full-length wild type and kinase dead genes, pSP73/MAPKAPK-2 5’ 
was digested with Eco RI and Bgl II to remove the MAPKAPK-2 5’ fragment. 
pGEX/GSTAMAPKAPK-2wt and pGEX/GSTAMAPKAPK-2K93R were digested 
with Bgl II and Sal I to remove the remainder of the gene. The fragments were then
Eco RI ^  A0488 Bgl
 ►
5'
4 -------------  249 bp
580 bp
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Nde I Hpa I Ori Bgl II Nde I
Ml EcoRI
M l
( B )
BamHI IP Sal I/S mal
t t
P4°  K93R
(C)
Nde I Hpa I Ori Bgl II Nde I
BglH
EcoRI |M
t
M l K93R
Figure 3.12: Schematic diagram illustrating the construction of full length MAPKAPK-2K93R into 
pSP73. Full length kinase dead MAPKAPK-2 was constructed by 3-way ligation involving the Eco RI/Bgl n  
fragment of pSP73/MAPKAPK-2 5’ (A) and the Bgl II/Sal I fragment of pGEX/GSTAMAPKAPK-2K93R (B) 
into Eco Rl/Sal I digested pSP73 to generate pSP73/MAPKAPK-2K93R (C). As detailed in the text this method 
was also used to construct full-length MAPKAPK-2wt.
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joined in a 3-way ligation with Eco Rl/Sal I digested pSP73 to produce 
pSP73/MAPKAPK-2wt and pSP73/MAPKAPK-2K93R (Figure 3.12).
3.2.7 Construction of full-length cMyc-tagged wild-type (wt) and kinase dead 
(K93R) MAPKAPK-2
To detect MAPKAPK-2 expression in mammalian cells and to facilitate purification, 
a cMyc epitope tag (-MEQKLISEEDLN-) was incorporated into the 3’ end of the 
sequence. Incorporation of the epitope at the 3’ end of the gene avoided amplification 
of the GC-rich 5’ terminus.
To construct cMyc-tagged wild type and kinase dead genes, PCR reactions using 
oligonucleotides, W0989 (forward) and B5640 (reverse) were carried out using 
pSP73/M APKAPK-2 wt and pSP73/MAPKAPK-2K93R as templates respectively. 
B5640 contained the restriction enzyme sites Xba I and Hind III as well as the cMyc 
epitope sequence. The amplified fragments were digested with Pst I (a unique 
MAPKAPK-2 restriction site downstream of the W0989 priming site) and Hind III. 
The fragments were purified and cloned into pSP73/MAPKAPK-2wt that had been 
digested with Pst I and Hind III to remove the equivalent fragment. Two wild type 
clones and two kinase dead clones were sequenced on both strands using gene and 
vector specific oligonucleotides. A single representative of each clone was designated 
pSP73/cMycMAPKAPK-2wt and pSP73/cMycMAPKAPK-2K93R (Figure 3.13).
The wild type and kinase dead fragments were then removed by digestion with Eco RI 
and Xba I and subcloned into Eco Rl/Xba I digested pcDNA3 to generate the
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(A)
EcoRI
Nde I Hpa I Ori Bgl II Nde I
BglH
Sail
B5640 \
cMyc/Xbal/HindlllK93R
( B )
EcoRI
Nde I Hpa I Ori Bgl II Nde I
PstI
(C)
EcoRI
Nde I Hpa I Ori Bgl II Nde I
PstI
K93R
Figure 3.13: Construction of cMyc-tagged MAPKAPK-2 K93R. A C-terminal cMyc-tagged 
MAPKAPK-2K93R fragment was amplified by PCR using pSP73/MAPKAPK-2K93R as template (A). 
The fragment was digested with Pst I and Hind III. pSP73/MAPKAPK-2wt was also digested with 
Pst I and Hind III and the corresponding fragment was removed (B). The final construct was then 
assembled by ligation (C). As outlined in the text this method was also used to construct full-length 
cMycMAPKAPK-2wL
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(A)
Bsm I
L_
^ i B C . H  p a l  I I on  1  S X ' t i v n Neomvcin
cMyc] XbalEcoRI
Bsm I
( B )
Bsm I
^  BGII Neomvcin
Bsm I
EcoRI | R cMycl Xbal
t
K93R
Figure 3.14: cMyc-tagged MAPKAPK-2 wt (A) and kinase dead (B) genes in the mammalian 
expression vector pcDNA3. pSP73/cMycMAPKAPK-2wt and pSP73/cMycMAPKAPK-2K93R were 
digested with Eco RI and Xba I and the fragments were subcloned into pcDNA3 as described in the text.
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constructs pcDNA3/cMycMAPKAPK-2wt (Figure 3.14A) and 
pcDNA3/cMycMAPKAPK-2K93R (Figure 3.14B).
3.2.8 Construction of MAPKAPK-2 anti-sense (A/S) expressing vector
To construct a vector overexpressing MAPKAPK-2 anti-sense message, 
pcDNA3/cMycMAPKAPK-2wt was digested with Eco RI and Xba I and the fragment 
was purified. This was then cloned in the reverse orientation into Eco RI and Xba I 
digested pcDNA3.1 (Figure 3. IB). The integrity of the construct was checked by 
restriction enzyme digestion and sequenced at the 5’ and 3’terminals using vector 
specific oligonucleotides. This was recorded as pcDNA3/cMycMAPKAPK-2 A/S.
3.2.9 Construction of GST-Hsp27 fusion protein
Hsp27 is an in-vivo substrate of MAPKAPK-2 and was constructed as a GST-fusion 
protein to facilitate purification for in-vitro kinase studies. The sequence of Hsp27 
was obtained from the Genbank database and two oligonucleotide primers (N3984 
and N3985), containing Bam HI restriction sites, were designed from the 5’ and 3’ 
ends of the gene respectively. PCR reactions were carried out using human PBMC 
cDNA as template and a fragment of the correct size (630 bp) was amplified and gel 
purified. This was then digested with Bam HI and cloned into Bam HI digested 
pGEX-3X. Recombinant colonies were screened by PCR to determine the correct 
orientation using vector specific and gene specific oligonucleotides. A single clone 
was sequenced in its entirety on both strands and was identical to that of the published 
sequence. This clone was named pGEX/GSTHsp27 (Figure 3.15).
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BamHI
N3985 BamHI
Figure 3.15: Construction of GST-Hsp27 (pGEX/GSTHsp27). GST-Hsp27 was amplified from 
a human PBMC cDNA library, digested with Bam HI and cloned into the correct reading frame 
of Bam HI digested pGEX-3X.
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3.3 Discussion
The sequence of p38/CSBP2 amplified from the PBMC cDNA library was identical 
the sequence published by Lee et a l (1994). Interestingly, all four clones isolated and 
sequenced from this library all were identified as CSBP2 . This may imply that 
CSBP2 and not CSBP1, is the predominant iso form in these cell types. However, a 
greater number of clones would have to be analysed for this observation to have any 
statistical significance.
The sequences of two iso forms of human MAPKAPK-2 have been published (Stokoe 
et a l, 1993; Zu et a l, 1994). These two isoforms are produced by alternate splicing of 
the same gene and differ extensively at the C-terminals. The longer isoform, 
MAPKAPK-2a, described by Stokoe et a l  (1993) contains a nuclear localization 
signal at the C- terminal which is absent in the shorter MAPKAPK-2b isoform. In 
addition to the gross sequence changes at the C-terminals the two clones also have 
three amino acid differences (a.a. positions 116, 247 and 248) within the conserved 
catalytic region of the enzyme.
The PBMC clone isolated in this chapter was identical at the C-terminus to that 
described by Stokoe et a l (1993). However, this clone had the same three amino acid 
residues changes at the positions indicated above, as those in the sequence described 
by Zu et a l (1994). The three amino acid residues (HI 16, W247 and S248) are also 
conserved in 3pK/MAPKAPK-3, a recently identified homologue of MAPKAPK-2 
(Sithanandam et a l, 1996; McLaughlin et a l, 1996). These enzymes share 72% 
sequence identity at the nucleotide level and 75% at the amino acid level. None of the 
residues described above are crucial for MAPKAPK-2 activation and it is possible
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that in the sequence described by Stokoe et al. (1993) these changes may be 
erroneous.
The reason for the failure to directly amplify full-length MAPKAPK-2 from either the 
skeletal muscle or PBMC cDNA libraries, is probably due to the absence of full- 
length MAPKAPK-2 clones within these libraries. This may be a result of the high 
GC-rich content at the 5’-end of the MAPKAPK-2 mRNA sequence. High GC-rich 
regions contain large regions of symmetry, which may then form stable secondary 
mRNA (hairpin) structures and thereby inhibit full-length first strand cDNA 
synthesis.
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Chapter
Expression and Kinase Activities
4 . 1  I n t r o d u c t i o n
The p38 MAP kinase pathway is predominantly activated by cellular stresses such as: 
bacterial endotoxin (Han et a l,  1994; Lee et a i, 1994), chemical, heat and osmotic 
shock (Rouse et a i, 1994), pro-inflammatory cytokines (IL-1 and TNF) (Freshney et 
aL, 1994) and UV irradiation (Raingeaud et a i, 1995). Activation of p38 MAP kinase 
by any of the above stimuli leads to the rapid phosphorylation and activation of 
MAPKAPK-2, a physiological substrate of p38 MAP kinase, which in turn 
phosphorylates the small heat shock protein Hsp27 (Rouse et aL, 1994; Freshney et 
aL, 1994). Activation of MAPKAPK-2 and phosphorylation of Hsp27 can be blocked 
by the specific p38 MAP kinase inhibitor SB 203580 (Cuenda et aL, 1995).
The p38 MAP kinase and MAPKAPK-2 ATP binding mutants, described in Chapter 
3, were designed to be used as bait in a yeast two-hybrid screen (see Chapter 5) and to 
generate stable cell lines (see Chapter 6). This chapter analyses the transient 
expression and the kinase activities of these constructs prior to their use in the studies 
described above. The FLAG and cMyc epitope-tags incorporated into the constructs 
facilitated purification for in-vitro kinase assays and for detection of expression by 
immunoblotting. In addition, the physiological pathway described above was 
reconstituted in-vitro by incubating immunoprecipitated p38 MAP kinase with GST- 
AMAPKAPK-2 and GST-Hsp27. The sensitivity of p38 MAPK to SB 203580 was 
determined by analysing the phosphorylation of MAPKAPK-2 and Hsp27.
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4.2 Results
4.2.1 Expression of p38 and MAPKAPK-2 in HeLa cells
HeLa cells (2xl05) were transiently transfected with FLAG-tagged p38wt, FLAG- 
tagged p38 K53R, cMyc-tagged MAPKAPK-2wt and cMyc-tagged MAPKAPK-2 
K93R. After 48 hours, the cells were lysed and the relative levels of protein 
expression were investigated by immunoblotting with anti-FLAG or anti-cMyc 
antibodies.
The anti-FLAG antibody detected specific immunoreactive bands of -42 kDa 
corresponding to the correct molecular masses of the FLAG-tagged p38 wild type and 
kinase dead proteins (Figure 4.1 A, lanes 1 and 2). No non-specific binding was 
observed with this antibody as observed in the cells transfected with empty vector 
(Figure 4.1 A, lane 3). Although the relative expression levels of both proteins were 
quite high, expression of the wild type protein was stronger. This relative difference 
in expression was observed in all transient transfection experiments carried out, 
suggesting that the difference was not merely due to the transfection efficiencies of 
each experiment.
The anti-cMyc antibody detected two equally expressed bands representing cMyc- 
tagged MAPKAPK-2 wild type and kinase dead (K93R) proteins (Figure 4. IB, lanes 
1 and 2). Epitope-tagged MAPKAPK-2 proteins migrated with apparent molecular 
masses of -50 kDa which differed slightly from the calculated molecular mass of -45 
kDa. No non-specific binding was observed with this antibody in the control reaction 
transfected with empty vector (Figure 4. IB, lane 3).
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Figure 4.1: Expression of FLAG-tagged p38 wild type and K53R proteins (A) and cMyc-tagged 
MAPKAPK-2 wild type and K93R proteins in HeLa cells (B). HeLa cells (2X105) were transiently 
transfected with 1.5 fig of plasmid DNA. After 48 hours the cells were lysed in 100 pi of lysis buffer. 
Cellular debris was centrifuged and the supernatant removed. 5X sample buffer was added and the 
samples were boiled for 5 minutes.15 pi of sample was resolved by electrophoresis on a 4-20% 
polyacrylamide gel and transferred to nylon membranes.
Panel A: Probed with anti-FLAG murine monoclonal antibody (10 pg/ml). 
fo/M? 7: p38wt Zti/ze 2: p38 K53R tone 3: empty vector
Panel B: Probed with anti-cMyc rabbit polyclonal antibody (1 pg/ml) 
lane 1: MAPKAPK-2 wt lane 2: MAPKAPK-2 K93R lane 3: empty vector
Proteins were visualised with a secondary antibody linked to HRP and enhanced chemiluminescence. 
Arrows indicate the positions of the proteins.
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4.2.2 Expression of GST-ÀMAPKAPK-2 4 0 - 4 0 0  wt, GST-AMAPKAPK-2 4 0 - 4 0 0  K93R 
and GST-Hsp27 in E.coli
Epicurian XL-1 blue E.coli, transformed with GST-AMAPKAPK-2wt, GST- 
AMAPKAPK-2 K93R and GST-Hsp27 were induced with 0.2 mM isopropyl-p-D- 
thiogalactoside (IPTG) for four hours at 30°C. The proteins were affinity purified 
using glutathione sepharose beads and samples of each protein were electrophoresed 
on a 4-20% polyacrylamide gel and visualised by Coomasie staining. To estimate the 
concentrations of each fusion protein, for subsequent kinase assays, titrated 
concentrations of bovine serum albumin (BS A) were also loaded onto the gel (Figure 
4.2).
Truncated MAPKAPK-2 wild type and kinase dead GST-fusion proteins (residues 
40-400) migrated as single bands with apparent molecular masses corresponding to 
their calculated molecular masses (-65 kDa) (Figure 4.2, lanes 1 and 2 respectively). 
GST-Hsp27 migrated with an apparent molecular mass of -50 kDa, which 
corresponded closely to its calculated mass of 52 kDa (Figure 4.2, lane 3). The 
relative level of expression of GST-Hsp27 was weaker than that of GST- 
AMAPKAPK-2 and may be a consequence of the low solubility of GST-Hsp27 when 
expressed in E.coli (see Chapter 5, section 5.3.2). In lanes 2 and 3, the two low 
molecular weight bands probably represent cleaved GST and AMAPKAPK-2, whilst 
in lane 1, the low molecular weight band probably comprises of a doublet of cleaved 
GST and Hsp27 which have similar molecular weights.
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Figure 4.2: Affinity purification of GST-AMAPKAPK-2 and GST-Hsp27 fusion proteins.
E.coli XL-1 blue cells expressing GST- AMAPKAPK-2 wt, GST- AMAPKAPK-2 K93R and 
GST-Hsp27 were induced with IPTG (0.2 mM) for 4 hr and then lysed. GST-fusion proteins were 
purified using glutathione sepharose. 3 pi of each purified sample was loaded and 
electrophoresed on a 4-20% Tris-glycine polyacrylamide gel. The concentrations of GST-Hsp27 
(lane /), GST- AMAPKAPK-2 wt (lane 2) and GST- AMAPKAPK-2 K93R (lane 3) were 
estimated by comparing the amount of protein loaded against titrated concentrations of 
BSA (0.1 -1.0 jig).
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4.2.3 Evaluation of the ATP binding site mutation (K53R) in FLAG-tagged p38 
MAPK
COS-1 cells were transiently transfected with FLAG-tagged p38wt, FLAG-tagged 
p38 K53R or empty vector. After 48 hours, the cells were osmotically stressed by the 
addition of sodium chloride (0.2 M) to the medium for 20 minutes. The cells were 
then lysed and the FLAG-tagged proteins were immunoprecipitated using 
Gammabind G sepharose beads coupled to an anti-FLAG M2 monoclonal antibody. 
The kinase activities were assayed in an immune complex protein kinase assay using 
purified GST-AMAPKAPK-2wt as substrate and analysed by autoradiography. 
Figures 4.3 A and 4.3 B show the results of the above kinase assays when the 
phosphorylated substrate was exposed to X-ray film for 4 hours and 19 hours 
respectively.
As shown in Figures 4.3A and 4.3B, mutation of the lysine residue (K53) at the ATP 
binding site of p38 MAP kinase dramatically reduces the kinase activity of this 
enzyme. After 4 hours exposure there was no visible phosphorylation of GST- 
AMAPKAPK-2wt by the mutated p38 enzyme isolated from stressed cells, whilst the 
wild type p38 protein isolated from stressed cells strongly phosphorylated GST- 
AMAPKAPK-2wt (Figure 4.3 A, lanes 5 and 2 respectively). After 19 hours exposure 
a weak signal was observed in the lane containing the mutated p38 enzyme isolated 
from stressed cells, however, this signal was also observed in the empty vector 
transfected samples and may therefore represent a small degree of 
autophosphorylation of the GST - AM APKAPK-2 wt substrate (Figure 4.3 B, lanes 5, 4 
and 1). These results confirm that mutating lysine 53 to arginine within the ATP 
binding site of p38 MAP kinase inhibits the kinase activity of this enzyme.
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Figure 4.3: Evaluation of the ATP binding site mutation of FLAG-tagged p38 (K53R): 
COS-1 cells were transfected with 1.5 pg of either p38wt, p38 K53R mutant or empty vector. 
Epitope-tagged proteins were immunoprecipitated and incubated in an immune complex kinase 
assay with or without GST-AMAPKAPK-2wt (5 p g ) . The reactions were stopped after 30 
minutes by the addition of 5X sample loading buffer and analysed by SDS-PAGE. Substrate 
phosphorylation was detected by autoradiograpy at 4 hour (A) and 19 hour (B) time intervals.
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4.2.4 Evaluation of the ATP binding site mutation (K93R) in full length cMyc- 
tagged MAPKAPK-2
HeLa cells were transiently transfected with cMyc-tagged MAPKAPK-2wt, cMyc- 
tagged MAPKAPK-2 K93R or empty vector. After 48 hours, the cells were 
osmotically stressed by the addition of sodium chloride (0.2 M) to the medium for 20 
minutes. Control reactions in which sodium chloride was omitted were also carried 
out. The cells were then lysed and the cMyc-tagged proteins were immunoprecipitated 
using Gammabind G sepharose beads coupled to an anti-cMyc antibody. The kinase 
activities were assayed in an immune complex protein kinase assay using purified 
GST-Hsp27 as substrate and analysed by autoradiography. Figures 4.4 A and 4.4 B 
show the results of the above kinase assays when the phosphorylated substrate was 
exposed to X-ray film for 6 hours and 18 hours respectively.
It can be clearly seen, by the level of phosphorylation of GST-Hsp27, that the 
MAPKAPK-2 K93R mutant has significantly reduced kinase activity when compared 
to the wild- type enzyme (Figure 4.4 A, lanes 1 and 2 respectively). Surprisingly, 
there was still a small amount of Hsp27 phosphorylation when compared to the 
control sample transfected with empty vector, which could be due to the non-specific 
binding of kinases to the sepharose beads (Figure 4.4 A, lane 4).
The kinase activities of MAPKAPK-2wt recovered from stressed and unstressed cells 
(Figure 4.4 A, lanes 1 and 5 respectively), and MAPKAPK-2 K93R recovered from 
stressed and unstressed cells (Figure 4.4 A, lanes 2 and 6 respectively) were also 
compared. As expected, the kinase activity of the wild type enzyme, recovered from 
osmotically stressed cells was enhanced. Interestingly, the phosphorylation of GST-
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Hsp27 incubated with MAPKAPK-2 K93R also increased when the cells were 
osmotically shocked. However, there is an increase in non-specific ‘background’ 
signals in the osmotically shocked control sample (Figure 4.4 B, lane 4). This clearly 
indicates that other osmotically induced kinases are non-specifically bound to the 
sepharose beads.
4.2.5 Inhibition of p38 MAP kinase activity by SB 203580
The sensitivity of FLAG-tagged p38 MAP kinase expressed in COS-1 cells to SB 
203580 was investigated. FLAG- tagged p38 MAP kinase was batch purified from 
osmotically shocked cells, using Gammabind G sepharose coupled with anti-FLAG 
antibody. The physiological pathway described in the introduction of this chapter was 
reconstituted by the addition of GST-AMAPKAPK-2wt and GST-Hsp27 to the 
sepharose/FLAG-p38wt complex. SB 203580 was added at different concentrations 
and the sensitivity of p38 MAP kinase to SB 203580 was viewed by the inhibition of 
GST-Hsp27 phosphorylation by MAPKAPK-2 (Figure 4.5).
The results from this experiment clearly show that pre-incubation of FLAG-tagged 
p38 MAP kinase, in-vitro, with SB 203580 prevented the activation of GST- 
ÀMAPKAPK-2 and the subsequent phosphorylation of GST-Hsp27 in a dose 
dependent manner. SB 203580 (0.37 pM) strongly inhibited FLAG-tagged p38 MAP 
kinase activation as indicated by the reduced signal intensities of GST - AM APKAPK- 
2 and GST-AHsp27 (Figure 4.5, lane 4). Although the results in this experiment are 
only qualitative, SB 203580 appears to inhibit p38 MAP kinase with an I C 5 0  of 0.37- 
0.123 pM.
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Figure 4.4: Evaluation of the ATP binding site mutation of cMyc-tagged MAPKAPK-2 
(K93R): HeLa cells were transiently transfected with 1.5 gg of either cMycMAPKAPK-2wt, 
cMycMAPKAPK-2 K93R or empty vector. After 48 hours the cells were treated with or 
without NaCl (0.2 M) for 20 min. The cells were lysed and epitope-tagged protein was 
immunoprecipitated and incubated in an immune complex kinase assay with GST-Hsp27 
(5 |ig). After 30 minutes the reactions were stopped and analysed by SDS-PAGE. Substrate 
phosphorylation was visualised by autoradiography at 6 hour (A) and 18 hour (B) time intervals.
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Figure 4.5: In-vitro inhibition of GST-Hsp27 phosphorylation by SB203580. FLAG-tagged p38 
MAP kinase was transiently expressed and immunoprecipitated from osmotically shocked COS-1 
cells. Immune complex protein kinase assays with GST -AMAPKAPK-2 and GST-Hsp27(5 fig 
each) were carried out containing SB203580 at concentrations ranging from 10000 - 5 nM (lanes 
1-8). Lane 9  represents the DMSO control.
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4.3 Discussion
FLAG-tagged p38 MAP kinase and cMyc-tagged MAPKAPK-2 both expressed well 
in HeLa cells. MAPKAPK-2 migrated with an apparent molecular mass of -50 kDa, 
corresponding to the apparent molecular mass of the Hsp27 kinase reported by 
Freshney et al. (1994) and endogenous MAPKAPK-2 in human PMN cells (Krump et 
al., 1997). The apparent molecular mass of MAPKAPK-2 differs significantly from 
its calculated molecular mass of -45 kDa. The reason for this discrepancy is unclear, 
but the proline rich N-terminal domain may retard the migration of this enzyme 
during electrophoresis. This hypothesis could be checked by expressing MAPKAPK- 
2 lacking the N-terminal domain.
Bacterially expressed wild-type and kinase dead GST-AMAPKAPK-240-400 fusion 
proteins, lacking the N-terminal domain, migrated as single bands with the expected 
molecular masses (-65 kDa). However, Ben-Levy et al. (1995) reported two bands 
with apparent molecular masses of 65 and 62 kDa, when a GST- MAPKAPK-245^00 
fusion protein was expressed and purified from E.coli. Intriguingly, only the 65 kDa 
product could be phosphorylated by p38 MAP kinase. Both the 65 and 62 kDa 
products had the same N-terminal sequence, but the 62 kDa species was truncated at 
the C-terminus by 26 residues, suggesting that the terminal 26 amino acid residues 
may play an important role in permitting phosphorylation by p38 MAP kinase.
In this chapter the catalytically inactive p38 and MAPKAPK-2 enzymes described in 
Chapter 3 were analysed. Mutation of the lysine residues at the ATP binding sites of 
p38 and MAPKAPK-2, lysines 53 and 93 respectively, abolished the kinase activities 
of these enzymes as determined by in-vitro phosphorylation of their substrates.
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In addition, in this chapter it has also been shown that components of the 
physiological p38 MAP kinase signalling pathway can be successfully reconstituted 
in-vitro using immunoprecipitated p38 MAP kinase with GST-AMAPKAPK-2wt and 
GST-Hsp27, thus confirming that the recombinant proteins share the same 
mechanisms of activation with the native enzymes. P38 kinase activity was inhibited 
by SB 203580 with an I C 5 0  value of -0.37-0.123 |iM which corresponded to that 
obtained by Cuenda et al. (1995), who calculated an I C 5 0  of -0.6 |iM, using 
bacterially expressed p38 MAP kinase with MAPKAPK-2 as substrate.
The results in this chapter show that both recombinant p38 MAP kinase and 
MAPKAPK-2 expressed strongly in HeLa cells and that mutation of the ATP binding 
sites of p38 and MAPKAPK-2 completely abolished the catalytic activities of these 
enzymes. In Chapter 5, the results of using these proteins as bait in a yeast two-hybrid 
screen are described, whilst in Chapter 6, the expression of these mutants and their 
effectiveness in producing a dominant effect, by blocking IL-1 signalling in stably 
transfected HeLa cells is investigated.
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Chapter 5
Yeast Two-Hybrid Screen
5.1 Introduction
5.1.1 General Introduction and aim
With the development of the specific inhibitor, SB 203580, p38 MAP kinase has been 
identified as having a uniquely pivotal role in a number of inflammatory and 
immunomodulatory responses. The p38 MAP kinase pathway has been shown to be 
implicated in the production of IL-1 and TNF in LPS stimulated monocytes (Lee et 
a i,  1994), in IL-1 and TNF induced synthesis of IL-6 and granulocyte-macrophage 
colony stimulating factor in fibroblasts (Beyaert et a l, 1996; Ridley et al., 1997), in 
collagen-induced platelet aggregation (Saklatvala et al., 1996), in the transcription of 
interferon-y (IFNy) in CD4+ Thl cells (Rincon et a l, 1998), in IL-2 stimulated 
proliferation of T-cells (Crawley et al., 1997) and in the transcription and translation 
of IL-1 induced collagenase (matrix metalloproteinase 1), stromelysin (matrix 
metalloproteinase 3) and cyclooxygenase-2 (COX-2) in fibroblasts (Ridley et al., 
1997).
The activation of p38 MAP kinase, with the concomitant biological effects, by the 
variety of different physiological stimuli described above suggests there may be many 
yet unidentified proximal and distal components within this pathway. Given the 
obvious therapeutic potential in inhibiting pro-inflammatory cytokine signalling, as 
demonstrated by SB 203580, the search for new activators and substrates within this 
pathway has intensified. With this aim, yeast two-hybrid methodology was employed
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to try to identify a novel protein or interaction using integral members of the p38 
MAP kinase pathway as “bait”. Recent yeast two-hybrid studies have been successful 
in identifying MAPKAPK-3 from a human leucocyte cDNA library, using a 
catalytically inactive p38 MAP kinase mutant (D168A) as bait (McLaughlin et a i, 
1996) and in identifying an interaction between p38 MAP kinase and the transcription 
factor MEF2C (Han et a l, 1997). In the latter study p38 MAP kinase was mutated at 
the dual phosphorylation site and used to screen a human foetal brain library.
In this study we describe the construction of MKK6B, p38 K53R and MAPKAPK-2 
K93R as GAL4 binding domain fusion proteins. The screening of a human leucocyte 
cDNA library with p38 MAP kinase was unsuccessful in identifying any two-hybrid 
interactions. However, a potential two-hybrid interaction was identified using 
MAPKAPK-2 K93R as bait. The results of this screen and the attempts to validate 
this interaction are presented in this chapter.
5.1.2 Yeast two-hybrid methodology
The yeast two-hybrid system is a powerful and sensitive technique that allows protein 
interactions to be detected in-vivo. The technique was developed from the seminal 
suggestion by Fields and Song, (1989) that protein interactions could be detected if 
two potentially interacting proteins were expressed as hybrids. In their suggestion, the 
first protein contains a DNA binding domain and is bound to DNA upstream of a 
reporter gene, the second protein contains an activation domain (Figure 5.1). The 
concept was demonstrated using SNF1 and SNF4, two yeast proteins that interact in- 
vivo. They showed that SNF1 fused to a DNA binding domain and SNF4 fused to an 
activation domain could interact together and activate transcription of a reporter gene.
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Figure 5.1: Schematic diagram demonstrating the basis of the two-hybrid system. (A) The hybrid of 
the GALA DNA-binding domain (bd) and protein X binds to the GAL1 UAS but can not activate transcription 
without the activation domain. (B) The hybrid of the GAIA-activation domain (ad) and protein Y cannot 
localise to the UAS and therefore no transcription occurs. (C) Interaction between the X and Y regions of 
the two hybrid proteins in-vivo reconstitutes GALA function and results in expression of the reporter genes.
This finding was of considerable significance since it demonstrated that transcription 
could be used as a tool to study interactions between proteins not involved in 
transcription.
The commercial development of the two-hybrid system has been facilitated by the 
versatility of yeast promoters and their cfs-acting regulatory elements. All yeast 
structural genes are preceded by a region containing a loosely preserved TATA box, 
located approximately 25 bp upstream of the transcriptional start site. Many genes 
also contain ds-activating elements, regions of DNA that are recognized by 
transcription factors or other rra/zs-acting regulatory proteins. In contrast to 
multicellular organisms yeast c/j -activating elements tend to be closely associated 
with the TATA box (Yoccum, 1987). One type of da-acting transcription element in 
yeast is upstream activating sequences (UAS) which are recognized by specific 
transcriptional activators that enhance transcription from adjacent downstream TATA 
regions (Giniger and Ptashne, 1988). The enhancing effect of UASs is generally 
independent of orientation and they can also be eliminated or modified to change the 
regulation of genes. In addition, there may be more than one copy of a UAS upstream 
of a coding region.
The ‘mix and match’ nature of yeast TATA boxes and upstream activating sequences 
has led to the creation of artificial promoters linked to reporter genes (Heslot and 
Gaillardin, 1992). In most cases, the reporter genes are under the control of a 
promoter comprising a TATA sequence and a UAS derived from a different gene. In 
some cases, both the TATA and UAS are derived from different genes. In this study 
the yeast strains HF7z (Feilotter et a l, 1994) and SFY526 (Harper et a l, 1993) were
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used. Table 5.1 below shows the promoter constructs used to regulate reporter gene 
expression in these strains.
Strain Reporter
gene
Origin of 
UAS
UAS
regulated
by
Origin of 
TATA 
sequence
HF7z HIS3 GAL1 GAL4 GAL1
lacZ UASg 17-mer(x3) GAL4 CYC1
SFY526 lacZ GAL1 GAL4 GAL1
Table 5.1: Promoter constructs of the yeast strains HF7z and SFY526 used in this study (Guthrie 
and Fink 1991).
5.1.3 Reporter genes under the control of GAL4-responsive elements
As shown in Table 5.1, the two-hybrid screen carried out in this study was GAL4 
based (Heslot and Gaillardin, 1992). In yeast, the genes required for galactose 
metabolism are controlled by two regulatory proteins, GAL4 and G ALSO, as well as 
by the carbon source in the medium (Guthrie and Fink, 1991). When galactose is 
present, GAL4 binds to the GAL4-responsive elements within the UASs of several 
genes involved in galactose metabolism, such as GAL1, GAL7 and G ALIO and 
activates transcription (Giniger et a l, 1985). In the absence of galactose, G ALSO 
binds to GAL4 and blocks transcriptional activation. In addition, the presence of 
glucose also represses transcription of the galactose genes (Johnston et a l, 1994). The
f
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tight regulation of the GAL UASs by GAL4 have made it a valuable tool for 
manipulating the expression of reporter genes that are GAL4 DNA-binding domain 
(DNA-BD) dependent. However, the yeast host strain must carry deletions in both the 
gal4 and galSO genes to avoid interference by endogenous GAL4 and G ALSO 
proteins. Mutations in both of these genes abolish glucose repression and induction 
unless a two-hybrid interaction occurs.
In the yeast strain, SFY526, the lacZ reporter gene is under the control of native 
GAL1 UAS and TATA sequences. In the yeast strain, HF7z, the HIS3 reporter gene is 
also under the control of native GAL1 UAS and TATA sequences. However, the lacZ 
reporter gene in HF7z is controlled by a synthetic UASg n -m er (x3) consensus sequence 
and a TATA sequence derived from yeast cytochrome C l (CYC1) gene (Table 5.1) 
(Guthrie and Fink, 1991). Consequently, plasmids encoding potential interacting 
proteins that are LacZ+ in one yeast strain are then isolated and transformed into the 
other yeast strain. Since these two promoters share only GAL4 responsive elements in 
common (the rest of the promoter sequences differ significantly), any positive 
interactions observed in both strains are likely to require binding of the GAL4 DNA- 
binding domain specifically to the GAL4-responsive elements. Expression of lacZ 
from the synthetic promoter in HF7z cells is much weaker than the level of expression 
seen with the intact GAL1 promoter in SFY526 cells. The HIS3 reporter gene in HF7z 
cells is also under the control of the entire GAL1 promoter, leading to tight regulation 
of the HI S3 reporter (Feilotter et a l, 1994).
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5.1.4 Reporter genes under the control of non-GAL4 responsive elements
The LexA- based two-hybrid system is the most common alternative to the GAL4 
dependent system. In this system not only are the TATA sequences and the UAS are 
derived from different genes, but the LexA c/5-acting regulatory elements are derived 
from E.coli (Ebina et a l, 1983). The ‘bait’ protein in this system is constructed as a 
fusion protein with the entire LexA protein. In E.coli LexA normally functions as a 
repressor of SOS genes when it binds to LexA c/5-acting regulatory elements. In the 
two-hybrid system there is no repression because the LexA cis-acting motifs are 
integrated upstream of the TATA and coding region of the reporter genes (Estojak et 
al., 1995).
5.1.5 Application of the yeast two-hybrid system
The sensitivity of the yeast two-hybrid system has made it an invaluable technique in 
all laboratories searching for novel protein interactions. During the last few years 
yeast two-hybrid technology has identified many new proteins and interactions 
including many of those, described in Chapter 1, involved in pro-inflammatory 
cytokine signalling such as; RIP (Hsu et al., 1996), TRAF1/2 (Rothe et al., 1994), 
NIK (Malinin et a l, 1997), TRADD (Hsu et a l, 1995) and IKKa (Regnier et a l, 
1997). These findings have contributed greatly to our understanding of cell signalling 
from the receptor to the nucleus.
Yeast two-hybrid technology can also be used to delineate specific amino acid 
residues or protein domains involved in a given protein interaction. In yeast two- 
hybrid systems, the strength of the reporter gene activation generally correlates with
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the strength of interaction between the two proteins. Using site specific mutagenesis 
and deletion mutants, the essential interacting regions of proteins may be identified.
5 . 2  R e s u l t s
5.2.1 Construction of p38 K53R, MAPKAPK-2 K93R and MKK6B GAL4 
binding domain fusion proteins
In the identification of MAPKAPK-3 by two-hybrid screening with a p38 D168A 
MAP kinase mutant, McLaughin et a l (1996) reported the autonomous activation of 
the HF7z HI S3 reporter gene by a GAL4 BD/p38 wt fusion protein. This activation 
was presumed to be a consequence of the high basal kinase activity of this protein. 
Because of this a catalytically inactive mutant was produced that did not activate the 
HF7z reporter gene. Following a similar approach, a catalytically inactive p38 K53R 
mutant was constructed, as described in Chapter 3, section 3.2.2, to screen a human 
leucocyte cDNA library. To construct a GAL4 BD fusion protein and remove the 
FLAG epitope, pcDNA3/FLAGp38K53R was re-amplified using the oligonucleotide 
primers, W0988 and N0465. The amplified fragment was gel purified, digested with 
Bam HI and cloned into the correct reading frame of the yeast two hybrid cloning 
vector pAS2-l (Figure 5.2B). Transformed colonies were PCR screened to determine 
the correct orientation of the cloned inserts. Two clones were sequenced in their 
entirety on both strands to check for any PCR errors. A single error free clone was 
designated pAS2-l/GAL4BDp38K53R (Figure 5.3).
A full-length MAPKAPK-2 kinase dead GAL4 BD fusion protein was constructed by 
digesting pSP73/MAPKAPK-2 K93R (see Chapter 3, section 3.2.6) with Eco RI and
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Figure 5.2 (A): pGAD424 DNA-Activation Domain Hybrid Cloning vector. pGAD424 is used to generate 
GAL4 activation domain fusion proteins. A Col El origin of replication and ampicillin resistance gene allow 
propagation and selection, respectively, in E.coli; the 2\i origin of replication allows propagation in yeast. 
The LEU2 gene allows selection in yeast host strains which are deficient in leucine biosynthesis.
Figure 5.2 (B): pAS2-l DNA-Binding Domain Hybrid Cloning Vector. pAS2-l generates a GAL4 DNA-BD 
(amino acids 1-147) fusion when the protein of interest is cloned into the MCS in the correct orientation 
and reading frame. pAS2-l carries the wild-type yeast CYHS2, which confers sensitivity to cycloheximide 
(P); transcription is terminated at the ADHl transcription termination signal (T) and targeted to the yeast 
nucleus by nuclear localization sequences. pAS2-l is a shuttle vector that replicates autonomously in 
both E.coli and S.cerevisiae, and carries the bla gene, which confers ampicillin resisitance in E.coli. 
pAS2-l also carries the TRP1 nutritional gene that allows yeast auxotrophs to grow on limiting synthetic 
media.
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Figure 5.3: Construction of GALA BD/p38 K53R fusion protein. (A) pcDNA3/FLAGp38K53R was used as 
template and re-amplified using the oligonucleotides W0988 (forward) and N0465 (reverse). (B) The 
amplified fragment was digested with Bam HI and cloned into the correct reading frame of Bam HI digested 
pAS2-l.
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Figure 5.4: Construction of the GALA BD/MAPKAPK-2 K93R fusion protein. (A) pSP73/MAPKAPK-2K93R 
was digested with the Eco R l and Sal I and cloned into the correct reading frame of Eco Rl/Sal 1 cut 
pAS2-l (B).
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Figure 5.5: Construction of the GAL4 BD/MKK6B fusion protein. MKK6B was amplified from a human PBMC 
cDNA library using the oligonucleotides W0990 (forward) and V6483 (reverse). A fragment of ~1 kb was amplified, 
digested with Sal 1 and cloned into the correct reading frame of Sal 1 digested pAS2-l.
1 2 6
Sal I. The MAPKAPK-2 K93R fragment was then sub-cloned into pAS2-l (Figure 
5.4).
MKK6B was amplified from a human peripheral blood mononuclear cell cDNA 
library (PBMC cDNA) using oligonucleotide primers, W0990 and V6483, designed to 
the 5’ and 3’ terminals off the gene. Both oligonucleotides contained Sal I restriction 
enzyme sites to facilitate cloning. The MKK6B fragment was gel purified and cloned 
into the correct reading frame of pAS2-l. Transformed colonies were PCR screened 
using vector and gene specific oligonucleotides to determine the correct orientation of 
the cloned inserts. Two clones were sequenced in their entirety on both strands using 
oligonucleotides designed from the published sequence of MKK6B (Han et al., 1996; 
Moriguchi et al., 1996). A single error free clone was designated pAS2- 
1/GAL4BDMKK6 (Figure 5.5).
5.2.2 Construction of a GAL4 activation domain /p38 K53R fusion protein
The strength of activation of the HIS3 and LacZ reporter genes in the yeast two-hybrid 
system are directly related to the strength of interaction between the two GAL4 BD 
and GAL4 AD fusion-proteins. The exact nature of the interaction between p38 MAP 
kinase and MKK6B is unknown. However, in a recent report evidence was provided 
of a physical interaction between p38 MAP kinase and MAPKAPK-2 in-vivo (Ben- 
Levy et al., 1998). Because of this p38 K53R was cloned as a GAL4 activation 
domain fusion protein (GAL4 AD) to act as a positive control when co-transformed 
with either MKK6B or MAPKAPK-2 GAL4 BD fusion proteins.
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Figure 5.6: Construction of the GAL4 AD/p38 K53R fusion protein. (A) pAS2-l/GAL4BDp38K53R 
was digested with Bam HI and the insert was subcloned into Bam HI digested pGAD424 (B).
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The GAL4 AD/p38K53R fusion protein was constructed by digesting pAS2- 
l/GAL4BDp38K53R with Bam HI and subcloning the fragment into the correct 
reading frame of pGAD424 (Figure 5.2A). Transformants were PCR screened to 
determine the correct orientation, using gene and vector specific oligonucleotide 
primers. A single clone in the correct orientation was designated 
pGAD424/GAL4ADp38K53R (Figure 5.6).
5.2.3 Validation of the amplified human leucocyte cDNA library
Prior to co-transformation of yeast HF7z cells with the human leucocyte cDNA 
library and the GAL4 fusion constructs the integrity of the amplified library was 
validated by PCR. The results of several PCR reactions in which integral members of 
the p38 MAPK signalling pathway are amplified are shown in Figure 5.7.
MKK6B (Figure 5.7, lane 4), p38 (Figure 5.7, lane 3), AMAPKAPK-2 (Figure 5.7, 
lane 5) and Hsp27 (Figure 5.7, lane 7) were all represented and successfully amplified 
from the library cDNA, producing amplified fragments of the correct size (1143 bp, 
1000 bp, 1100 bp and 630 bp respectively). The attempt to amplify full length 
MAPKAPK-2 was unsuccessful and should have produced an amplified fragment of 
1240 bp (Figure 5.7, lane 6). However, for the reasons discussed in Chapter 3.3, in 
which the attempt to PCR full length MAPKAPK-2 from human PBMC cDNA was 
also unsuccessful, this result was not surprising. The result of this experiment 
confirmed that the full-length genes of several integral components of the p38 MAP 
kinase signalling pathway are represented in this library cDNA preparation.
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Figure 5.7: PCR analysis of the amplified human leucocyte Matchmaker cDNA library, 
demonstrating representation of several integral members of the p38 MAP kinase 
signalling pathway. The integrity of the amplified human leucocyte cDNA library was 
assessed by PCR amplification of relevant enzymes. Library cDNA (0.5 pg/ reaction) 
was used as template to amplify; p38 MAP kinase (lane 3), MKK6B (lane 4), AMAPKAPK-2 
(lane 5) MAPKAPK-2 (lane 6), and Hsp27 (lane 7). lanes 1 and 2 are 1 kb and 100 bp 
molecular weight markers respectively. 20 pi of a 50 pi PCR reaction was loaded and 
electrophoresed on a 1 % agarose gel.
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5.2.4 Yeast phenotype verification and test for autonomous activation of the 
HIS3 and lacZ reporter genes by the GAL4 BD fusion constructs
Prior to transforming the yeast strains with plasmid it was important to check the 
nutritional requirements of the HF7z and SFY526 yeast strains. Colonies from each 
were streaked onto synthetic dropout (SD) agar plates lacking either tryptophan (Trp 
), leucine (Leu ) or histidine(His ). The plates were then incubated at 30 °C and 
examined for growth after 3 days for HF7z and 4-5 days for SFY526. The results 
obtained are indicated in Table 5.3.
SD Medium SFY526 HF7z
-Trp - -
-Leu - -
-His - _*
Table 5.2: Growth results of SFY526 and HF7z on various SD agar plates. The asterisk denotes 
that HF7z grows very slowly on SD/His" plates.
To test for autonomous activation of the HIS3 and lacZ reporter genes, by the GAL4 
BD fusion proteins, the plasmids were separately transformed into yeast HF7z cells 
and plated onto SD/Trp" agar plates. After incubation at 30°C for 3 days single 
colonies from each transformed plasmid were picked and resuspended in 20 pi of TE 
buffer. 10 pi of this suspension was spotted onto sterile filter paper overlayed on a 
SD/Trp" agar plate and incubated for a further 3 days. The filters were lifted and 
assayed for (1-gal activity as described in Chapter 2.5.4. The remaining 10 pi of the 
cell suspension was plated onto SD/His" agar plates, which were incubated for 3 days 
at 30°C. None of the GAL4 BD fusion proteins autonomously activated the lacZ
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Figure 5.8: (3-gal assays to test for autonomous activation of the lacZ reporter gene in 
yeast HF7z cells transformed with GAL4 BD fusion constructs. Competent HF7z cells 
were transformed with 0.5 |ig of plasmid DNA and plated onto synthetic dropout (DO) 
medium, lacking tryptophan (Tip), SD/Trp". The plates were then incubated at 30°C for 3 days 
until colonies appeared. Single, well isolated colonies were picked and resuspended in sterile 
TE buffer and spotted onto sterile filter paper overlayed on SD/Trp" plates. After 48 hours 
incubation, the filter papers were lifted and (3-galactosidase activity was determined by assaying 
the filters in Z buffer/X-gal solution for a maximum of 8 hours.
Expt.A: GAL4 BD/p38 K53R
Expt.B: GAL4 B D/AMAPKAPK-2 wt
Expt.C: GAL4 BD/AMAPKAPK-2 K93R
Expt.D: GAL4 BD/MKK6B
Expt.E: GAL4 B D/M APKAPK-2 wt
Expt.F: GAL4 B D/M APKAPK-2 K93R
132
reporter gene and no growth was observed with any of the transformed plasmids on 
SD/His" agar plates (Figure 5.8). In Figure 5.8, Expts. B and C, the autonomous 
activation results of truncated (A) MAPKAPK-2 wt and K93R GAL4 BD fusion 
proteins are shown. However, these constructs were not progressed any further in this 
study.
5.2.5 Activation of the lacZ reporter gene by interactions between GAL4 
BD/MAPKAPK-2wt/K93R and GAL4 AD/p38 K53R fusion proteins
As discussed, the p38 K53R mutant was constructed as a GAL4 AD fusion protein to 
act as a control for a positive two-hybrid interaction when co-transformed with either 
MKK6B or MAPKAPK-2 GAL4 BD fusion proteins. Plasmids were co-transformed 
into yeast HF7z cells as described in Chapter 2.5.3 and plated onto SD/Trp/Leu agar 
plates. Single isolated colonies were picked and assayed for P-gal activity (Figure
5.9).
As expected, co-transformation of the GAL4 AD/p38 K53R fusion protein with either 
the GAL4 BD/MAPKAPK-2wt or GAL4 BD/M APKAPK-2 K93R fusion proteins 
produced a strong P-gal signal (Figure 5.9, Expts. H and /  respectively). There was no 
visible signal when GAL4 AD/p38 K53R was co-transformed with the empty GAL4 
BD fusion vector, pAS2-l, or when the wild type and kinase dead GAL4 
BD/MAPKAPK-2 fusion proteins were co-transformed with empty GAL4 AD fusion 
vector (Figure 5.9, Expts. G, J and K respectively). Surprisingly, no positive p-gal 
signal was obtained when GAL4 AD/p38 K53R was co-transformed with GAL4 
BD/MKK6B (Figure 5.9, Expt. L). There may be several reasons for the failure of p38 
and MKK6B to interact and activate the lacZ reporter gene. One possible explanation
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Figure 5.9: Positive control protein-protein interactions as determined by (3-gal 
assays of co-transformed yeast HF7z cells. Competent HF7z cells were co-transformed 
with 0.5 pg of DNA from each plasmid and plated onto synthetic dropout (DO) medium, lacking 
tryptophan (Tip) and leucine (Leu),SD/Trp7Leu". The plates were then incubated at 30°C 
for 4-5 days until colonies appeared. Single, well isolated colonies were picked and 
resuspended in sterile TE buffer and spotted onto sterile filter paper overlayed on 
SD/TrpVLeu" plates. After 48 hours incubation, the filter papers were lifted and (3-galactosidase 
activity was determined by assaying the filters in Z buffer/X-gal solution for a maximum 
of 8 hours.
Expt.G: GALA AD/p38 K53R and GALA BD(empty vector)
ExptiH: GALA AD/p38 K53R and GALA BD/M APKAPK-2 wt
Expt.I: GAL4 AD/p38 K53R and GALA BD/MAPKAPK-2 K93R
ExptJ: GALA AD(empty vector) and GALA B D/M APKAPK-2 wt
Expt.K: GALA AD(empty vector) and GALA B D/M APKAPK-2 K93R
Expt.L: GALA AD/p38 K53R and GALA BD/MKK6B
Expt.M: GALA AD(empty vector) and GALA BD/MKK6B
Expt.N: pTDl and pVA3 (positive control see Chapter 2, section 2.1.9)
Expt.O: GALA AD(emply vector) and GALA BD (empty vector)
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may be due to the lack of expression of the GAL4 BD/MKK6B fusion protein. To 
test this, transformed HF7z cells were lysed immunoblotted and probed with a murine 
anti-GALA BD monoclonal antibody. Figure 5.10 shows that the expression of GAL4 
BD/MKK6B (-59 kDa) in yeast HF7z cells was clearly detectable.
GAL4 BD/MKK6B
2  3 4
k D a
—  6 4
-  5 0
Figure 5.10: Expression of GAL4 BD/MKK6B in yeast HF7z cells. Transformed yeast cells were 
lysed and electrophoresed on a 4-20% Tris-glycine gel. The samples were immunoblotted and probed 
with an anti-GAL4 BD monoclonal antibody. Lanes 1 & 2 indicate 40 pi and 10 pi loadings 
respectively of transformed cell lysates. Lanes 3 & 4 represent equivalent loadings, 40 pi and 10 pi 
respectively, of untransformed cell lysates.
Another explanation could be that in yeast the proper post-translational modificatons 
required for native folding, or interactions of some mammalian proteins are not 
provided. This appears not to be the case because Zanke et al. (1996) demonstrated by 
two-hybrid interactions that MKK6 is able to interact with p38 wild type without the 
need of scaffold proteins. It maybe therefore that the success of a positive two-hybrid 
interaction may be determined more by the conformational changes imposed on a 
protein because of specific mutations, rather than any post-translational modifications
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imposed by yeast. Because of its failure to interact with p38 K53R, the GAL4 
BD/MKK6B fusion construct was not used in any further two-hybrid studies.
5.2.6 Two-hybrid screening of a human leucocyte cDNA library with 
MAPKAPK-2 K93R
Competent yeast HF7z cells were co-transformed with pAS2- 
1/GAL4BDMAPKAPK-2K93R and pGAD 10/GAL4AD human leucocyte cDNA 
plasmids (500 p,g each) as described in Chapter 2.5.3. The cells were plated onto 
SD/Trp/His/Leu agar plates and incubated at 30°C for 8 days. In addition, to 
determine the efficiency of co-transformation, the cells were also plated onto SD/Leu" 
/Trp agar plates and incubated at 30°C. After 4 days the colonies were counted and 
the number of independent cDNA clones screened was determined. Seventy-six out of 
the 1.5 X 106 independent cDNA clones screened grew in the absence of histidine 
(His+). Growth on histidine deficient medium alone may not reflect a true two-hybrid 
interaction. Activation of this reporter gene may occur for example due to the 
fortuitous cloning of HIS3 transcriptional activators or other activators that appear to 
require the presence of both types of hybrid, but are not dependent on interaction 
between the hybrid proteins. Consequently, screening for the expression of the second 
reporter gene (/acZ) is necessary.
His+ co-transformants were picked, resuspended in 10 fil of TE buffer and gridded 
onto sterile filter paper overlayed on a SD/Trp /His /Leu agar. After 48 hours the 
colonies were lifted and assayed for (3-galactosidase activity. Thirty of the 76 His+ co­
transformants had detectable (3-galactosidase activity after 8 hours incubation, albeit 
of varying intensities (Figure 5.11). Plasmids were recovered from the His+, LacZ+
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Figure 5.11: P-gal assay of the HIS+ co-transformants ( putative MAPKAPK-2 K93R - interacting 
clones) isolated from a human leucocyte cDNA library screen. A human leucocyte cDNA library, 
pGAD 10/library (500 (ig), was simultaneously co-transformed with pAS2- 1/M APKAPK-2 K93R (500 pg) 
and plated out onto synthetic dropout (SD) medium, lacking tryptophan (Trp), leucine (Leu) and histidine 
(His), SD/Trp/Leu/His The plates were incubated at 30°C for 8 days and then examined for growth. 
Seventy six HIS+ colonies were picked, resuspended in sterile TE buffer and spotted onto sterile 
filter paper overlayed on SD/Trp/Leu /His agar. After 48 hours incubation at 30°C, the filter 
was lifted and assayed for lacZ reporter gene activity in Z buffer/Xgal solution for a maximum of 8 
hours.
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co-transformants and electroporated into Æ.co// HB101 cells. To select for the GALA 
AD/library component cells were plated onto SD/Leu", M9 minimal media containing 
ampicillin (50 pg/ml). Because transformed yeast cells may take up several plasmids, 
several E.coli colonies (10) transformed with plasmid isolated from each His+, LacZ+ 
yeast clone were PCR screened using pGADIO vector specific oligonucleotides and 
the insert sizes were determined. Twenty-six out of the 30 His+, LacZ+ clones 
contained unique inserts. Plasmid DNA was prepared from each and sequenced at the 
5’ terminus with a specific oligonucleotide designed to bind complementary sequence 
in the GALA activation domain. The sequences were analysed using the NCBI 
BLAST nucleotide similarity search tool. Only two clones, pGADIO/AD 1.1 and 
pGAD10/AD46.1, contained protein coding sequence that was correctly fused with 
the GALA activation domain. Both clones encoded partial, overlapping nucleotide 
sequences that shared substantial homology with the human homologue of 
polyhomeotic 2 (HPH2) protein (Gunster et a i, 1997). The remaining clones 
contained sequences of genomic DNA or cDNA sequences in the wrong reading 
frame. The high number of co-transformants that were HIS+ and LacZ+ positive and 
yet did not contain any coding sequence was of some concern. A possible explanation 
as to why unidentifiable or incorrectly fused cDNA messages appeared to activated 
the HIS+ and LacZ? reporter genes is that the ADH terminator can sometimes act as 
cryptic promoter in yeast and initiate transcription in the reverse direction. These 
proteins are usually transcriptional activators which do not require the presence of the 
GAL4 AD in order to activate transcription of the reporter genes (Clontech, personal 
communication). However, plasmid isolated from these clones was not reconstituted, 
as described in Table 5.4, which would have subsequently identified many of these 
co-transformants as false positives.
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5.2.7 Analysis of the HPH2-like clones, pGADlO/ADl.l and pGAD10/AD46.1
Oligonucleotide sequencing primers were designed from the published sequence of 
the HPH2 gene (Gunster et a l, 1997). Both clones, pGADIO/ADI. 1 and 
pGAD10/AD46.1, were sequenced in their entirety on both strands using gene and 
vector specific oligonucleotides. The sequencing results revealed that the longest 
clone, pGADIO/AD 1.1, encoded a protein that was shorter than full the length HPH2 
protein sequence by 138 amino acids at the N-terminus. In Figure 5.12 the amino acid 
f the two clones isolated in this study are shown aligned next to the published 
sequences of HPH2 and HPH1 (a closely related homologue of HPH2) (Gunster et a l, 
1997). To avoid confusion in numbering, since HPH1 and HPH2 are different lengths, 
the amino acid residues in Figure 5.12 are numbered arbitrarily (1-300). From these 
alignments, it can be seen that the clones isolated in this study differed significantly 
from the published HPH2 sequence at three regions between amino acids 23-31, M i­
n i  and 202-337. The differences between the amino acid sequences at these regions 
were the result of a number of nucleotide deletions and insertions (nucleotide 
sequence not shown). The shorter clone, pGAD10/AD46.1 fused with the GAL4 
activation domain at the start of the second variable region (141-171) and was 
identical to the sequence of pGADIO/AD 1.1. To determine if the sequence changes in 
the isolated clones were authentic, HPH2-like was amplified from an independent 
cDNA library. Oligonucleotide primers, D5865 and C4047, were designed to the 5’ 
and 3’ terminal nucleotide sequences of pGADIO/AD 1.1. A fragment of 900 bp was 
amplified from a human peripheral blood mononuclear cell (PBMC) cDNA library 
and cloned into pGEX-3X to generate the construct pGEX/GSTHPH2-like. Sequence 
analysis revealed that this clone contained exactly the same amino acid changes as 
those identified in pGADIO/AD 1.1.
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Figure 5.12: Partial sequence alignments of the published HPH1 and HPH2 amino acid 
sequences (Gunster et al., 1997) against the sequences of the two clones pGADlO/ADl.l 
and pGAD10/AD46.1 isolated in this study. The homology domain regions 1 (1-26) and 2 
(237-301) are indicated by the bold lines
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5.2.8 Reconstitution of the HIS3 and lacZ reporter genes in HF7z cells
To determine whether or not the interaction between MAPKAPK-2 K93R and AD1.1 
was a genuine two-hybrid interaction or a false positive interaction, HF7z cells were 
co-transformed with plasmids expressing the fusion proteins as described in Table 
5.4. The co-transformed cells were plated onto a SD/Trp /Leu agar and assayed for |3-
galactosidase activity. HIS3 activity was determined by growth on SD/TrpVHis/Leu" 
agar plates.
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Expt.
No.
Test Purpose Plasmid 1 
(GAL4 B D/fusion)
Plasmid 2 
(GAL4 
AD/fusion)
Selection
Medium
Expected
P-gal
Result
1 Confirm
phenotype
BD/MAPKAPK-2
K93R
AD/1.1 Leu Tip" +
2
Check for 
autonomous 
activation
BD/No insert 
(pAS2-l) AD/1.1 Leu Tip" -
3 Identify artifactual 
interactions
BD/ p53(72-390)
(pVA3, see Chapter 
2, section 2.1.8)
AD/1.1 Leu" Tip" -
4 Positive control
BD/p53(72-390) 
(pVA3, see Chapter 
2, section 2.1.8)
AD/largeT-Ag 
(pTDl, see 
Chapter 2, 
section 2.1.8)
Leu" Tip" +
5 Positive control BD/MAPKAPK-2
K93R
AD/p38 K53R Leu Tip +
Table 5.3: Reconstitution experiments in HF7z cells. To eliminate the possibility of a false positive 
interaction between MAPKAPK-2 K93R and AD1.1, the above co-transformations were carried out in 
yeast HF7z cells and assayed for P-gal activity (Figure 5.13).
The results of the p-galactosidase assays described above are shown in Figure 5.13. In 
addition, HF7z cells were also separately transformed with pGADIO/AD 1.1 and the 
control plasmid pCL-1, encoding wild type full length GAL4 (see Chapter 2, section
2.1.9). The lack of P-galactosidase activity when HF7z cells are transformed with
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Figure 5.13: Reconstitution of the lac Z  reporter gene by simultaneous co-transformation 
of pGADlO/ADl.l (GAL4 AD/1.1) and pAS2-l/MAPKAPK-2 K93R into yeast HF7z cells.
Competent HF7z cells were co-transformed with 0.5 (ig of each plasmid and plated onto synthetic 
dropout (SD) medium, lacking tryptophan (Trp) and leucine (Leu), SD/Trp/Leu .The plates were 
incubated at 30°C for 4-5 days. Single, well isolated colonies were picked, resuspended in 
sterile TE and spotted onto sterile filter paper overlayed on SD/Trp/Leu agar. After 48 
hours incubation at 30°C, lacZ activity was determined by assaying the filters in Z buffer/X-gal 
solution for a maximum of 8 hours. In addition pGADIO/ADI.1 and pCL-1 were separately 
transformed and plated onto SD/Leu" agar.
Expt.l: GAL4 AD/1.1 and GAL4 BD/MAPKAPK-2 K93R
Expt.2: GAL4 AD/1.1 and pAS2-l (empty vector)
Expt.3: GAL4 AD/1.1 and pVA3
Expt.4: pTDl and pVA3 (positive control see Chapter 2, section 2.1.9)
Expt.5: GAL4 AD/p38 K53R and GAL4 BD/MAPKAPK-2 K93R (positive control)
Expt.6: GAL4 AD/1.1
Expt.7 : pCL-1 (assay control see Chapter 2, section 2.1.9)
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GALA AD/1.1 alone confirms the LacZ phenotype, whilst full length GAL4 acts as a 
positive control for the p-gal assays (Figure 5.13, Expts. 6 and 7 respectively). Co- 
transformation of GAL4 AD/1.1 and GAL4 BD/MAPKAPK-2 K93R into HF7z cells 
produced a weak p-gaT signal, which began to appear after ~5 hours incubation 
(Figure 5.13, Expt. 1). The reactions were incubated for a total of 8 hours at room 
temperature (longer incubation periods can produce false positive signals). At the end 
of this incubation period there was no observed autonomous activation of the lacZ 
reporter gene by GALA AD/1.1 and no activation of the lacZ reporter gene due to 
artifactual interactions between GALA AD/1.1 and an unrelated control GAL4 BD 
fusion protein such as, BD/p53(72-39o> (Figure 5.13, Expt. 2 and 3 respectively). The 
strong p-gal signal observed in Figure 5.13, Expt. 4, is the result of the interaction 
between the control proteins, GALA AD/SV40 large T-antigen(84-708) and GALA 
BD/murine p53<72-390), whilst the signal observed in Figure 5.13, Expt. 5 represents 
the result of the interaction between GALA AD/p38 K53R and GALA 
BD/MAPKAPK-2 K93R.
Activation of the HIS3 reporter gene was also achieved by co-transformation of 
GALA AD/1.1 and GAL4 BD/MAPKAPK-2 K93R into HF7z cells, as indicated by 
growth on histidine deficient media (Figure 5.14, SecnA). As expected HF7z cells co­
transformed with the positive control plasmids encoding; GAL4 AD/p38 K53R and 
GALA BD/MAPKAPK-2 K93R or GALA AD/ SV40 large T-antigen^os) and GALA 
BD/murine p53(72-390) grew on SD/Trp /His /Leu agar plates (Figure 5.14, Sec™ B and 
C respectively), whilst, HF7z cells co-transformed with GAL4 AD empty vector and 
GALA BD empty vector or GAL4 AD/1.1 and GAL4 BD empty vector did not grow 
(Figure 5.14, Sec™ D and E respectively).
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Figure 5.14: Reconstitution of the HIS3 reporter gene by co-transformation of pGADlO/ADl.l (GAL4 AD/1.1) 
and pAS2-l/MAPKAPK-2 K93R into yeast HF7z ceils. Competent yeast cells were co-transformed with 0.5 jag of 
DNA from both plasmids and plated onto synthetic dropout (SD) medium lacking tryptophan (Trp) and leucine 
(Leu), SD/Trp /Leu .The plates were then incubated at 30°C for 4-5 days until colonies appeared. Single, well 
isolated colonies were picked, resuspended in sterile TE buffer and re-streaked onto SD medium also lacking 
histidine (His), SD/Trp/Leu /His". The plates were incubated at 30°C for 4-5 days. Growth after this period of time 
indicated HIS3 reporter gene activity.
Section A: GAL4 AD/1.1 and GALA AD/M APKAPK-2 K93R
Section B: GALA AD/p38 K53R and GALA BD/MAPKAPK-2 K93R
Section C: pTDl and pVA3 (positive control see Chapter 2, section 2.1.9)
Section D: GALA AD (empty vector) and GALA BD (empty vector)
Section E: GALA AD/1.1 and GALA BD (empty vector)
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5.2.9 Reconstitution and activation of the lacZ reporter gene in yeast SFY526 
cells
As a further control to authenticate the interaction between AD 1.1 and MAPKAPK-2 
K93R, the proteins were co-transformed into yeast SFY526 cells (Harper et a l, 1993). 
As discussed in section 5.1.3, these cells contain a lacZ reporter gene under the 
control of a promoter that differs from the promoter of the lacZ reporter gene in HF7z 
cells (see Table 5.1). In HF7z cells the GALA binding elements are synthetically 
designed and the TATA box originates from the yeast cytochrome Cl (CYC1) gene.
In contrast, SFY526 cells contain GALA binding and TATA sequences are derived 
from native GAL1 (Giniger et al., 1985). Since these two promoters share only G ALL 
binding elements and the rest of the promoters differ significantly, a ‘true’ positive 
two-hybrid interaction will activate the lacZ reporter gene in both of these yeast 
strains.
Co-transformation of GALA AD/1.1 and GALA BD/MAPKAPK-2 K93R into 
SFY526 cells resulted in the activation of the lacZ reporter gene as indicated by a 
positive (3-galactosidase signal. The intensity of the P-gal signal in this yeast strain 
was much stronger than that obtained in HF7z cells (Figure 5.15, Expt. 2). This 
increase reflects the difference between the strengths of the two promoters of the lacZ 
reporter genes within these two strains. Co-transformation of SFY526 cells with 
GALA AD/1.1 and G ALL BD empty vector did not result in the activation of lacZ, 
whilst co-transformation with plasmids expressing the positive control fusion 
proteins, GALL AD/p38 K53R and GALL BD/MAPKAPK-2 K93R, resulted in a 
strong p-gal signal (Figure 5.15, Expt. 1 and 3 respectively).
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Figure 5.15: Reconstitution of the lacZ reporter gene by simultaneous co-transformation of 
pGADlO/ADl.l (GAL4 AD/1.1) and pAS2-l/MAPKAPK-2 K93R into yeast SFY526 cells.
Competent SFY526 ceils were co-transformed with 0.5 gg of each plasmid and plated onto synthetic 
dropout (DO) medium, lacking tryptophan (Trp) and leucine (Leu), SD/Trp /Leu . The plates were 
then incubated at 30°C for 4-5 days until colonies appeared. Single, well isolated colonies were picked, 
resuspended in sterile TE buffer and spotted onto sterile filter paper overlayed on SD/-Trp/-Leu agar 
plates. After 48 hours incubation, lacZ activity was determined by assaying the filters in Z buffer/X-gal 
solution for a maximum of 8 hours.
Expt.l: GAL4 AD/1.1 and GAL4 BD (empty vector)
Expt.2: GAL4 AD/1.1 and GALA BD/MAPKAPK-2 K93R
Expt.3: GALA AD/p38 K53R and GALA BD/MAPKAPK-2 K93R (positive control)
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5 . 3  I n d e p e n d e n t  b i o c h e m i c a l  e v a l u a t i o n  o f  t h e  i n t e r a c t i o n  b e t w e e n  
H P H 2 - l i k e  ( A D 1 . 1 )  a n d  M A P K A P K - 2  K 9 3 R
MAPKAPK-2 K93R and HPH2-like interacted and activated HIS3 and lacZ reporter 
gene expression in both HF7z and SFY526 yeast strains. To further characterise and 
verify the interaction identified by two-hybrid methodology, co-immunoprecipitation 
of transiently expressed proteins and in-vitro immune complex kinase assays were 
carried out.
5.3.1 Expression of HPH2-like in HeLa cells and co-expression studies with 
MAPKAPK-2 K93R
To facilitate the detection of transiently expressed HPH2-like protein in HeLa cells, 
an N-terminal FLAG-epitope was incorporated by PCR amplification of 
pGADIO/AD 1.1, using the oligonucleotides C4045 and C4047. The PCR fragment 
was digested with Hind III and Bam HI and cloned into pcDNAS. A single clone was 
sequenced in its entirety on both strands using vector and gene specific 
oligonucleotides and recorded as pcDNA3/FLAGHPH2-like. To test for expression, 
pcDNA3/FLAGHPH2-like was transiently transfected into HeLa cells and detected in 
cell lysates by immunoblotting using an anti-FLAG monoclonal antibody. FLAG- 
tagged HPH2-like expressed strongly in HeLa cells and migrated with an apparent 
molecular weight of -40 kDa. (Figure 5.16, lane 1).
To confirm the association of HPH2-like and MAPKAPK-2 in-vivo HeLa cells were 
transiently co-transfected with pcDNA3/FLAGHPH2-like, 
pcDNA3/cMycMAPKAPK-2 K93R (see Chapter 3, section 3.2.7) and appropriate 
empty vector controls (Figure 5.16). FLAG-tagged p38 wt and the K53R mutant were
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Figure 5.16: Co-immunoprecipitation of FLAG-tagged HPH2 like, p38wt and p38 K53R with
cMyc-tagged MAPKAPK-2 K93R. HeLA cells were transiently co-transfected with 1.5 pg of
DNA of each plasmid. After 48 hours the cells were stimulated with or without IL -la (20 ng/ml)
and incubated for a further 6 hours. The cells were then lysed in 1 ml of lysis buffer and
cMyc-tagged MAPKAPK-2 K93R was immunoprecipitated using a rabbit anti-cMyc polyclonal antibody
(5 pg/ml) complexed to Gammabind G sepharose beads. The beads were washed three times in lysis
buffer, mixed with 50 pi of sample buffer and boiled for 5 minutes. Immunoprecipitated proteins
were resolved by electrophoresis, transferred to nylon membrane and probed with a murine
anti-FLAG monoclonal antibody (10 pg/ml). The proteins were visualised using a secondary
antibody linked to HRP with enhanced chemiluminescence detection. The co-precipitated FLAG-tagged
proteins are indicated by an arrow. The large arrow head indicates the heavy chain of the anti-cMyc antibody
used for immunoprécipitation.
Lane 1:
Lanes 2 and 3: 
Lane 4:
Lanes 5:
Lanes 6 and 7: 
Lanes 8 and 9:
HPH2-like HeLa cell lysate (control) 
MAPKAPK-2 K93R and HPH2-like (+/- IL-1) 
MAPKAPK-2 K93R and pcDNA3 (empty vector) 
p38wt HeLa cell lysate (control)
MAPKAPK-2 K93R and p38wt (+/- IL-1) 
MAPKAPK-2 K93R and p38 K53R (+/- IL-1)
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also co-transfected with cMyc-tagged MAPKAPK-2 K93R to act as positive controls. 
After 48 hrs the cells were treated with or without IL-1 (20 ng/ml) and incubated for a 
further 6 hours. Cells were lysed and MAPKAPK-2 K93R was immunoprecipitated 
with an anti-cMyc antibody (5 fig/ml). The immunoprecipitate was analysed by 
immunoblotting using an anti-FLAG antibody to detect co-precipitated FLAG-HPH2- 
like or FLAG-p38 (Figure 5.16). Immunoprécipitation of MAPKAP-2 K93R with an 
anti-cMyc antibody did not result in co-precipitation of HPH2-like in cells transfected 
with both cDNAs (Figure 5.16, lanes 2 and 3). Furthermore, stimulation with IL-1 (20 
ng/ml) had no detectable influence on this interaction. As expected, p38 wt and the 
K53R mutant co-precipitated with MAPKAPK-2 K93R, but there was no observable 
difference between samples treated with or without IL-1 (Figure 5.16, lanes 6, 7, 8 
and 9 respectively). However, there was a significant difference between the protein 
levels of p38 wt and p38 K53R detected. This difference may be due to the relative 
levels of expression, as demonstrated in Chapter 4, section 4.2.1, or alternatively it 
may represent a difference in the binding affinities of wild type and kinase dead p38 
MAP kinase for MAPKAPK-2 K93R. These interactions appear to be unaffected by 
stimulation with IL L In Figure 5.16, lanes 1 and 5 separately transfected controls of 
FLAG-HPH2-like and FLAG-p38 wt respectively are shown. Lane 4 represents 
MAPKAPK-2 co-transfected with an empty vector control.
5.3.2 In-vitro phosphorylation of GST-HPH2-like by MAPKAPK-2
To determine if HPH2-like was as a substrate of MAPKAPK-2, in-vitro kinase assays 
were carried out. To facilitate this HPH2-like was sub-cloned into a GST-fusion 
vector (pGEX-3X), as described in section 5.2.7. Epicurian XL-1 blue E.coli
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Figure 5.17: Purification of GST-Hsp27 and GST-HPH2-like. Epicurian XL-1 blue E.coli cells expressing 
GST-Hsp27 and GST-HPH2 were induced with IPTG (0.2 mM) for 4 hours and then lysed. GST-fusion 
proteins were purified using glutathione sepharose. Lanes 1 and 2 represent 5 |nl of GST-Hsp27 from 
two soluble glutathione fractions. Lane 3 represents 5 pi from the insoluble GST-Hsp27 pellet. Lanes 4 and 5 
represent 5 pi of GST-HPH2-like from two soluble glutathione elutions Lane 6 represents 5 pi from 
the insoluble GST-Hsp27 pellet
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transformed with GST-HPH2-like and GST-Hsp27 were induced with 0.2 mM 
isopropyl-p-D-thiogalactosidase (IPTG) for four hours at 30°C. The proteins were 
affinity purified using glutathione sepharose beads and examined by electrophoresis 
on a 4-20% Tris-glycine polyacrylamide gel and visualised by staining (Figure 5.17). 
GST-HPH2-like migrated with an apparent molecular mass of 65 kDa whilst GST- 
Hsp27 migrated with a mass of -50 kDa (see Chapter 4, section 4.2.2). The relative 
expression level of GST-Hsp27, albeit very weak, was greater than GST-HPH2-like. 
However both proteins were predominantly insoluble in E.coli. To compare the 
phosphorylation of GST-HPH2-like with GST-Hsp27, in-vitro kinase assays were 
carried out using comparable amounts of substrate. Transiently expressed cMyc- 
tagged MAPKAPK-2wt was recovered from HeLa cells treated with or without NaCl 
(0.2 M) and incubated with purified GST-Hsp27 or GST-HPH2-like, as indicated in 
Figure 5.18. In this experiment HeLa cell lysates transfected with empty vector were 
also processed with or without the addition of precipitating antibody (Figure 5.18, 
lanes 3, 4, 7 and 8). In all cases GammaBind sepharose G was added to the samples.
As expected, the addition of 0.2 M NaCl to the cell culture medium significantly 
induced MAPKAPK-2 activity as observed by increased GST-Hsp27 
phosphorylation. In the absence of NaCl, GST-Hsp27 was only very weakly 
phosphorylated and in the empty vector transfected cells (± anti-cMyc) no 
phosphorylation of GST-Hsp27 was observed. In the GST-HPH2 containing samples, 
NaCl induced kinase activity was also observed however, the apparent molecular 
mass of the phosphorylated product (50 kDa) did not correspond to the size (64 kDa) 
of GST-HPH2 (see Figure 5.17). The possibility of this being a phosphorylated 
breakdown product of GST-HPH2-like protein could not be dismissed. However, the
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Figure 5.18: In-vitro phosphorylation of GST-Hsp27 and GST-HPH2-like by MAPKAPK-2. HeLa 
cells were transiently transfected with MAPKAPK-2 wt {lanes 1,2, 5 and 6) or pcDNA3 empty vector. 
(lanes 3,4, 7 and 8). Cells were incubated for 48 hours and then osmotically shocked with NaCl (0.2M) 
for 20 minutes prior to lysis. Epitope tagged MAPKAPK-2 wt was recovered by immunoprécipitation with 
an anti-cMyc antibody and incubated in an immune complex kinase assay with either GST-Hsp27 or 
GST-HPH2-like proteins.
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assumption that the phosphorylation was MAPKAPK-2 dependent was inconclusive 
because the weakly phosphorylated breakdown product observed in the inactivated 
MAPKAPK-2 sample was also present in the samples devoid of any MAPKAPK-2 
activity (Figure 5.18, lanes 6, 7 and 8). It therefore appears that the kinase activity 
observed in the GST-HPH2-like containing samples might be a consequence of other 
NaCl inducible HeLa cells kinases that are non-specifically bound to the sepharose 
beads. This assumption was supported by the finding that incubation of the same 
amount of GST-HPH2-like protein in a buffered kinase reaction without sepharose 
passed through HeLa cell lysate did not result in GST-HPH2-like phosphorylation 
(data not shown).
5 . 4  D i s c u s s i o n
In this chapter a human leucoctye cDNA library was screened with two integral 
components of the p38 MAP kinase signalling pathway, p38 K53R and MAPKAPK-2 
K93R. Of these, only the MAPKAPK-2 K93R screen resulted in the identification of 
a novel putative two-hybrid interaction. From 1.5 x 106 human leucocytes clones 
screened, two clones that met all the specific criteria for binding to MAPKAPK-2 in 
yeast such as, activation of the lacZ and HIS3 reporter genes in HF7z cells (see 
section 5.2.8) and activation of a modified second lacZ reporter gene in SFY526 cells, 
were isolated (see section 5.2.9). Both clones contained partial, overlapping cDNA 
sequences that shared substantial homology with the recently identified human 
polyhomeotic 2 (HPH2) gene (Gunster et a l, 1997).
HPH2 is the human homologue of the Polyhomeotic (Ph) gene, which belongs to the 
Drosophila Poly comb (PcG) group of genes that are part of the cellular memory
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system responsible for the stable inheritance of gene activity (Franke et a l, 1992).
PcG proteins form large multimeric, chromatin associated protein complexes. In there 
original study Gunster et al (1997) isolated HPH2 from a human leucocyte library by 
two-hybrid screening using Bmil as bait. Bmil is a murine oncogene that shares 
significant sequence homology with Posterior sex combs (Psc). As in Drosophila the 
vertebrate PcG proteins have been shown to be involved in the regulation of homeotic 
genes (van der Lugt et a l, 1996).
The amino acid sequence of the HPH2-like protein isolated in this study differed from 
the published sequence at three regions within the gene (Figure 5.12). Re-cloning and 
sequencing HPH2-like from an independent human peripheral blood mononuclear cell 
cDNA library authenticated these changes. Furthermore, the amino acid sequence of 
homology domain I of the clone isolated in this study shared more homology with the 
same domain from another closely related protein, HPH1, than did the clone isolated 
in the original study (Gunster et a l, 1997). Analysis of the nucleotide sequences from 
the two HPH2-like clones revealed that the published sequence contained several 
nucleotide deletions that altered the reading frame of the gene at the three regions 
identified.
Although the interaction between MAPKAPK-2 K93R and HPH2-like fulfilled all the 
criteria for binding within yeast, the two proteins did not show any kind of interaction 
when tested by two independent biochemical methods, co-expression in mammalian 
cells and in-vitro kinase assays. This raises the question as to whether the result is 
artifactual and that the interaction between MAPKAPK-2 K93R and HPH2-like in 
yeast is a false positive. False positives occur when interactions between different
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proteins detected by the yeast two-hybrid system do not represent an in-vivo 
interaction in the cells in which these proteins are normally found (Fields and 
Stemglanz, 1994). Alternatively the interaction between MAPKAPK-2 K93R and 
HPH2-like may be genuine albeit very weak. Previous studies have used yeast two- 
hybrid technology to detect weak interactions undetectable by other physical methods 
such as co-immunoprecipitation (Li and Fields, 1993; Van Aelst et a l, 1993). Li et al. 
(1993) directly compared the sensitivity of the two-hybrid system to 
immunoprécipitation for the detection of weak interactions and demonstrated that the 
two-hybrid system could detect p53-largeT antigen interactions even with T antigen 
mutants that would no longer co-precipitate with p53. Thus, it is likely that transient 
or weak interactions, not stable in the in-vitro conditions of immunoprécipitation, lead 
to a transcriptional response in-vivo in yeast that activates the lacZ and HISS reporter 
genes. It is clear from this study that if the interaction between MAPKAPK-2 is real 
then HPH2-like is not acting as a phosphorylated substrate since it was not 
phosphorylated in-vitro and in addition it does not contain any recognised 
MAPKAPK-2 phosphorylation motifs (Stokoe et a i, 1993). HPH2 is a nuclear 
chromatin-associated protein that forms large complexes with other largely unknown 
components (Gunster et a i, 1997). MAPKAPK-2 contains a putative nuclear 
localisation signal at it C-terminus (Stokoe et a i, 1993) and recent studies have 
demonstrated that in unstressed cells it is predominantly located in the nucleus and 
following activation it is translocated from the nucleus in a complex with p38 MAP 
kinase (Engel et a i, 1998; Ben-Levy et a l, 1998). Consequently, nuclear 
MAPKAPK-2 may be predominantly inactive and the possibility that MAPKAPK-2 
and HPH2-like interact by binding to each other or as part of a larger complex in the 
nucleus can not be discounted.
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Finally, although the two-hybrid system is a powerful technique for identifying 
proteins that bind to a protein of interest or to delineate residues or domains critical 
for interaction, the success of this technique may be dependent upon many factors 
such as authentic post-translational modifications within yeast. Also, when screening 
with enzymatically active proteins, such as protein kinases, success may be dependent 
upon whether the target protein has been mutated at any residues crucial for its 
biological activity, such as, the ATP binding or phosphorylation sites. In this study 
this was demonstrated by the failure of MKK6B to interact with p38 K53R and 
activate the lacZ reporter gene (see section 5.2.5) even though Zanke et a l (1996) had 
previously demonstrated a two-hybrid interaction with between MKK6 and p38 wild 
type. In addition to this, it also appears that even in successful two-hybrid screens 
there is no guarantee that in the same screen known interacting proteins will also be 
identified. For example when McLaughlin et a l (1996) identified MAPKAPK-3 using 
p38 D168A as bait, they did not isolate MAPKAPK-2 or MKK6. Likewise in this 
study using MAPKAPK-2 as bait we did not isolate p38 or Hsp27. This could reflect 
the cDNA message abundance within a given library however in this study both 
MKK6B and p38 MAP kinase cDNAs were detectable in the human leucocyte cDNA 
library prior to screening.
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Chapter 6
Generation of HeLa cells stably overexpressing 
MAPKAPK-2 kinase dead and anti-sense RNA
6 . 1  I n t r o d u c t i o n
The varied biological properties of IL-1 are due to its ability to induce a wide variety 
of genes (see Chapter 1, Tablel.l). This induction may be a consequence of either 
increased gene transcription or increased mRNA stability (half-life) or both. Many of 
these genes are exquisitely sensitive to IL-1 and are induced only in inflammatory 
disease states. Of these, the increased expression of cyclooxygenase-2 (COX-2), 
phospholipase A2 (PLA2) and inducible nitric oxide synthase (iNOS) are some of the 
most dramatic and their metabolic products are potent pro-inflammatory mediators 
that prolong the biological effects of IL-1 long after activation (reviewed by 
Dinarello, 1996). Cytokines such as IL-8, which is a member of the chemokine 
protein family (Baggiolini, 1998) and IL-6 which initiates the hepatic acute phase 
response are also strongly induced by IL-1 (reviewed by Baumann and Gauldie, 
1994).
In this chapter HeLa cells stably transfected with vectors overexpressing dominant 
negative MAPKAPK-2 (MAPKAPK-2 K93R) and MAPKAPK-2 anti-sense RNA 
were used to investigate the role of MAPKAPK-2 in IL-1 induced COX-2, IL-6 and 
IL-8 synthesis. Dominant negative and anti-sense methods to target and specifically
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reduce endogenous kinase activities have previously been described in the ERK 
(p42/p44), INK and p38 MAP kinase signalling pathways.
Pages et al. (1993) demonstrated by transiently transfecting p44 MAP kinase anti­
sense and p42/44 MAP kinase mutants into fibroblasts that both MAP kinases are 
essential for growth factor stimulated proliferation. Of note in this study was that the 
anti-sense RNA had a more inhibitory effect on the endogenous kinase activity than 
the kinase dead mutants. This was shown to be due to the fact that the p44 MAP 
kinase anti-sense RNA inhibited the endogenous activities of both p42 and p44 MAP 
kinases. Krause et al. (1998) demonstrated that INK is required in IL-1 induced IL-6 
and IL-8 expression in KB cells (Krause et al., 1998). Interestingly, in this study, 
although both methods reduced IL-6 and IL-8 induction the anti-sense effect was 
more pronounced and significantly only the anti-sense had an effect on endogenous 
INK activity as determined by in-vitro kinase assays using GST-Jun as substrate.
Dominant negative studies have previously implicated components from the INK and 
p38 MAP kinase pathways in the IL-1-induction of COX-2 (Guan et a l, 1998a; Guan 
et a i, 1998b). In these studies the efficiency of stably overexpressed JNK1 and p38 
MAP kinase mutants on inhibiting endogenous kinase activities were assessed by 
immunoblotting with phospho-specific antibodies or by immune complex kinase 
assays. No attempts were made to look at the activities of any downstream substrates 
such as MAPKAPK-2. In this chapter evidence is presented suggesting a role for 
MAPKAPK-2 in IL-1 induced COX-2 synthesis. In addition the data presented also 
suggests that MAPKAPK-2 may also have role in IL-1 induced secondary pro- 
inflammatory cytokine production.
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6.2 Results
6.2.1 Generation of stably transfected HeLa cells overexpressing MAPKAPK-2 
K93R and MAPKAPK-2 anti-sense RNA
The vectors pcDNA3/cMycMAPKAPK-2K93R, pcDNA3/MAPKAPK-2 A/S 
(described in Chapter 3, sections 3.2.7 and 3.2.8) and pcDNA3 empty vector were 
stably transfected into HeLa cells as described in Chapter 2, section 2.3.4. 
Overexpression of the epitope-tagged MAPKAPK-2 K93R mutant was verified by 
western blotting using an anti-cMyc antibody. This detected an immunoreactive band 
with an apparent molecular weight of 50 kDa (Figure 6.4B), corresponding to the 
apparent molecular mass of the Hsp27 kinase reported by Freshney et al. (1994) and 
endogenous MAPKAPK-2 in human neutrophils (Krump et a l, 1997). To detect 
colonies overexpressing MAPKAPK-2 anti-sense RNA, RNA was isolated and RT- 
PCR, using oligonucleotides F6071 and F6070 designed to complementary sequences 
within the MAPKAPK-2 gene and to the c-Myc epitope respectively was carried out. 
F6071 and F6070 were designed to amplify a MAPKAPK-2 anti-sense fragment of 
-640 bp. The integrity of mRNA purification and subsequent 1 ^ -strand cDNA 
synthesis was verified using control GAPDH oligonucleotides. The RT-PCR result of 
an isolated MAPKAPK-2 anti-sense expressing clone, in comparison with the 
pcDNAS transfected control cells is shown in Figure 6.1. The MAPKAPK-2 anti­
sense specific oligonucleotides amplified a fragment of the expected size from the 
MAPKAPK-2 anti-sense transfected clone, whilst no signal was obtained from the 
pcDNAS control (Figure 6.1, lanes 1 and 2 respectively). Both clones produced strong 
signals with the GAPDH oligonucleotides (Figure 6.1, lanes 4 and 5 respectively).
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Figure 6.1: Confirmation of MAPKAPK-2 anti-sense overexpression by RT-PCR. RT-PCR was 
carried out using mRNA purified from G418 resistant HeLa colonies transfected with either 
pcDNA3/cMycMAPKAPK-2a A/S or pcDNAS (empty vector). Lanes 1 and 2, represent amplifications 
of anti-sense and empty vector transfected clones respectively, using the oligonucleotides F6070 
and F6071 (see text). Lanes 4 and 5, represent amplifications of anti-sense and empty vector 
transfected clones respectively using GAPDH specific oligonucleotides. Lane 3,100 bp molecular 
weight marker.
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To evaluate the effect of overexpressed anti-sense MAPKAPK-2 RNA on the level of 
endogenous MAPKAPK-2 protein. Western blots were carried out on cell lysate 
preparations (Figure 6.2). As discussed in Chapter 3, two isoforms of MAPKAPK-2, 
MAPKAPK-2a (Stokoe etal., 1993) and MAPKAPK-2b (Zu et al., 1994), generated 
by alternate splicing of the carboxy terminus exist, with the clone used in this study 
corresponding to the former. In addition, a closely related homologue, MAPKAPK-3, 
has been identified (McLaughlin ef al., 1996). In Table 6.1 the anti-MAPKAPK-2a 
antibodies used in this study and the similarities between the respective epitope 
sequences of the two MAPKAPK-2 isoforms and MAPKAPK-3 are illustrated.
Antibody (conc.) Host Epitope Result Source
affinity purified anti-rabbit 
MAPKAPK-2 (1 pg/ml)
sheep MTSALA TMRVDYEQIK 
(residues 356-371)
see Fig.6.2E UBI
#06-534
affinity purified anti-human 
MAPKAPK-2 (4 pg/ml)
rabbit EDKERWEDVKEE/VffSAi 
(residues 344-360)
see Fig.6.2B Stressgen 
# KAP-MA015
affinity purified anti-human 
MAPKAPK-2 (1 pg/ml)
goat
* ****** * 
LLLKRRKKARALEAAALA 
(residues 382-399)
see Fig.6.2D Santa Cruz 
# sc-6221
affinity purified anti-human 
MAPKAPK-2 (1 pg/ml)
rabbit residues 2-66 
(see Chapter 3, Fig. 3.8)
see Fig.6.2A Santa Cruz 
# sc-7871
un-purified anti-human 
MAPKAPK-2 (1:1000)
rabbit GST-AMAPKAPK-2 
see Chapter 3, section 3.2.3
see Fig.6.2C Kennedy Institute 
anti-pôO
Table 6.1: List of polyclonal anti-MAPKAPK-2a antibodies used in this study. Where possible the 
epitope sequences from which the antibodies were raised are indicated. The residues are numbered with 
respect to the MAPKAPK-2/3 sequence alignments indicated in Figure 3.8, Chapter 3. Residues in 
italics represent sequence differences between MAPKAPK-2a and MAPKAPK-2b. Residues marked 
by an asterisk represent differences between MAPKAPK-2a and MAPKAPK-3.
162
HeLa cells expressing MAPKAPK-2 K93R and MAPKAPK-2 anti-sense RNA were 
solubilised in mammalian cell lysis buffer and 100 jig of cytosolic protein was 
resolved by electrophoresis on either a 4-20% or 10% SDS polyacrylamide gel and 
immobilised on nylon membrane (as described in Chapter 2, section 2.4.4). The 
membranes were then incubated overnight with each of the antibodies described in 
Table 6.1 at the concentrations indicated in parentheses. Proteins were visualised by 
chemiluminescence following incubation with the appropriate HRP-conjugated 
secondary antibody (1:5000).
In Figure 6.2, the results of immunoblotting with the antibodies illustrated in Table 
6.1 are shown. Four of the five antibodies tested failed to detect a specific, 
immunoreactive band of the expected size (50 kDa) and significantly they also failed 
to detect an overexpressed product in the lysate from the dominant negative 
expressing cells (Figure 6.2A, B, C and E). However, the Santa Cruz antibody (#sc- 
6221) did detect a weak 50 kDa band from the dominant negative lysate which was 
absent in the control and anti-sense lysates (Figure 6.2D, lane 3). This antibody also 
reacted with several polypeptides within the 47-49 kDa molecular size range. In 
addition a faster band of approximately 42-43 kDa was also detected. Since the 
sequence of the immunogen used to raise this antibody is specific for MAPKAPK-2a 
and not MAPKAPK-2b, but does share some sequence similarity with MAPKAPK-3, 
it is possible that the faster 42-43 kDa could represent MAPKAPK-3 which has been 
reported to migrate in HL60 cells with an apparent molecular mass of 43 kDa 
(Sithanandam et a l, 1996). Alternatively, the products may be the result of non- 
spec ifically bound antibody.
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Figure 6.2: Comparison of commercial and non commercial anti MAPKAPK-2 antibodies to evaluate 
the effect of over-expressed MAPKAPK-2 anti-sense RNA on endogenous MAPKAPK-2 protein levels.
100 |ig of cytosolic protein from the HeLa control cells (pcDNA3 transfected) (lanel) and cells stably expressing 
MAPKAPK-2 anti-sense RNA (lane 2) and MAPKAPK-2 K93R (lane 3) was resolved on a 4-20% SDS 
polyacrylamide gel and transferred to nylon membranes. These were then probed with five different 
MAPKAPK-2 antibodies (see Table 6.1); #sc-7871 (A), #KAP-MA015 (B), anti-p50 (Q ,  #sc-6221 (D) 
and #06-534 (E). Lane 4  represents a cleaved murine MAPKAPK-2 control. The position of the 
over-expressed 50 kDa recombinant protein detected by #sc-6221 (6.2D, lane 3) is indicated by an arrow.
MAPKAPK-2 K93R
1 2 3 4  1 2 3 4  1 2 3 4
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With the exception of the N-terminally derived anti-human MAPKAPK-2 antibody, 
#sc-7871 (Figure 6.2A), all the remaining antibodies were able to detect the purified 
murine GST-cleaved MAPKAPK-2 control. The amino terminus of human 
MAPKAPK-2 is significantly different from its murine homologue, which would 
account for the failure of the N-terminally derived antibody to detect the murine 
recombinant control. In Figure 6.2C, lane 4, several larger bands are detected in the 
murine control sample. These are likely to represent partially or non-spec ifically 
cleaved murine GST-MAPKAPK-2 since the anti-MAPKAPK-2 antibody used in this 
experiment was raised against whole GST-MAPKAPK-2^oo protein.
To confirm that the weak 50 kDa band observed in Figure 6.2C, lane 4 was a product 
of dominant negative MAPKAPK-2 mRNA overexpression, it was important to 
compare the mobility of this product to that of the epitope-tagged dominant negative 
mutant. The experiment was repeated and the samples were resolved on a 10% SDS 
polyacrylamide gel, immunoblotted and probed with the anti -MAPKAPK-2 antibody, 
#sc-6221, and an anti-cMyc antibody. A comparison of the results is shown in Figure 
6.3. From this experiment it can be clearly seen that on a 10% gel, epitope-tagged 
MAPKAPK-2 K93R migrates as a doublet in which the upper band migrates with a 
molecular mass of 50 kDa and the lower band migrates with an apparent molecular 
mass of 48-49 kDa. This experiment was repeated several times and the relative 
amounts of the two bands varied between preparations, suggesting that the 48-49 kDa 
form is a proteolytic fragment. Significantly, the upper band migrated exactly with the 
weak 50 kDa band observed in Figure 6.2C, lane 3, whilst the lower band migrated 
with a molecular mass corresponding to the strongly expressed 47-49 kDa products
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that were detected in all samples when probed with the anti-MAPKAPK-2 (#sc-6221) 
antibody.
k D a
- 5 0
- 3 6
Figure 6.3: Comparison of the relative mobilities of the recombinant MAPKAPK-2 K93R 
proteins as detected using the anti-MAPKAPK-2 (#sc-6221) and anti-cMyc antibodies. 100 fig of
cytosolic protein from HeLa control cells (pcDNA3 transfected) (lanes 1 and 6) and cells stably 
expressing MAPKAPK-2 anti-sense RNA (lanes 2 and 5) and MAPKAPK-2 K93R (lanes 3 and 4) 
was resolved on a 10% SDS polyacrylamide gel and transferred to nylon membranes. These were then 
probed with the anti-MAPKAPK-2 (#sc-6221) and an anti-cMyc antibody. The position of the 
overexpressed recombinant mutant detected by the anti-MAPKAPK-2 antibody is indicated by the 
arrow. Proteins were detected by chemiluminescence.
From the above results the effect of MAPKAPK-2 anti-sense expression upon 
endogenous MAPKAPK-2 levels could not be assessed by western blotting using the 
antibody reagents that were available at the time of this study. However, it was 
possible to detect the dominant negative mutant using one of the anti-MAPKAPK-2 
antibodies, #sc-6221, showing that this antibody could detect MAPKAPK-2 when 
overexpressed. The observation that the recombinant epitope-tagged protein migrates
anti-MAPKAPK-2
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as a doublet as detected by the anti-cMyc antibody suggests that it is likely that 
endogenous MAPKAPK-2 protein will also be proteolytically degraded upon cell 
lysis. Consequently the failure of the anti-MAPKAPK-2 antibody to detect 
endogenous MAPKAPK-2 in the control and anti-sense expressing cells may be 
attributed to the strong non-specific 49 kDa band masking its presence.
6.2.2 Effect of MAPKAPK-2 K93R and MAPKAPK-2 anti-sense overexpression 
on IL-1 induced COX-2 protein production
In recent studies, the overexpression of dominant negative mutants or anti-sense RNA 
has successfully demonstrated a role for the p42/p44 MAP kinases in growth factor 
regulated cellular proliferation (Pages et a l, 1993), for SAPKp in IL-1 induced 
expression of IL-6 and IL-8 in KB cells (Krause et a l, 1998) and for the INK and p38 
MAP kinase pathways in IL-1 P induced COX-2 synthesis (Guan et a l, 1998a).
In this study a dominant negative approach was used to investigate the effect of 
MAPKAPK-2 on IL-1 induced COX-2 protein expression. Stably transfected cells 
were seeded into 6-well plates. Control cells (pcDNA3 transfected) were pre-treated 
with SB 203580 (1 jliM) for 2 hours, after which time the cells were stimulated with 
IL-1 a  (20 ng/ml) for 8 hours as indicated in Figure 6.4. The cells were then lysed in 
equal volumes of buffer and analysed by immunoblotting with an anti-COX-2 
antibody (Figure 6.4A). As expected, in the control cells pre-treated with SB 203580 
the level of COX-2 protein was significantly reduced when compared with the DMSO 
treated control cells. This result demonstrates that p38 MAP kinase is involved in the 
regulation of IL-1 a  induced COX-2 synthesis and as reported by others this induction 
can be inhibited pharmacologically (Ridley et a l, 1997; Pouliot et a l, 1997; Guan et
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DMSO (0.1%) 
IL-1 a
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Figure 6.4: Effect of MAPKAPK-2 K93R and MAPKAPK-2 anti-sense RNA overexpression on IL-1 induced 
COX-2 induction. HeLa cells were stably transfected with pcDNA3/MAPKAPK-2a K93R, pcDNA3/MAPKAPK- 
2a A/S or pcDNA3 (empty vector). Cells were pre-treated with SB203580 (1 fiM) for 2 hours and then stimulated 
with IL-1 a  (20 ng/ml) in the continuous presence of SB 203580 for 8 hours as indicated. Cells were lysed in 500 pi 
of lysis buffer and equal volumes of each sample were loaded onto Tris-glycine 4-20% polyacrylamide gel, resolved 
by electrophoresis and immunoblotted. Panel A, COX-2 protein induction was detected in response to DL-la 
stimulation using an anti-COX-2 antibody. Panel B, epitope-tagged MAPKAPK-2 K93R over-expression was 
detected using an anti-cMyc antibody. Panel C, samples were probed with an anti-actin antibody to show 
comparable loadings.
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a l, 1997). Significantly, the induction of COX-2 by IL-1 a  was completely blocked 
by the dominant negative MAPKAPK-2 K93R mutant and to a lesser extent by the 
MAPKAPK-2 anti-sense RNA. Overexpression of the dominant negative 
MAPKAPK-2 mutant was confirmed by probing with an anti-cMyc antibody (Figure 
6.4B). The degree of COX-2 inhibition caused by overexpression of MAPKAPK-2 
anti-sense RNA was not as great as that observed in the cells pre-treated with SB 
203580, but when compared to the control cells stimulated with IL-1 a  this reduction 
was significant. To ensure that the observed differences in COX-2 protein levels were 
real and not due to variations in sample loading, the samples were probed with an 
anti-actin antibody which is abundant and not induced by IL-1 a. This result 
confirmed comparable loading (Figure 6.4C). Therefore the data presented here 
suggests that the COX-2 protein differences are most likely to be due to the 
overexpression of dominant negative MAPKAPK-2 K93R and MAPKAPK-2 anti­
sense RNA.
6.2.3 Effect of MAPKAPK-2 K93R and MAPKAPK-2 anti-sense overexpression 
on prostaglandin E2 production
To determine whether the reduced COX-2 protein levels correlated with decreased 
prostaglandin production, the amount of PGE2 released into the overlaying culture 
medium was assayed using a competition based ELISA (described in Chapter 2, 
section 2.3.7). To demonstrate the role of p38 MAP kinase in PGE2 synthesis, the 
pcDNA3 transfected control cells were pre-incubated with SB 203580 (1 pM) or 
DMSO for 2hours. The cells were then stimulated for 16 hours with IL-1 a  (20 ng/ml) 
as indicated in Figure 6.5. IL-1 activates cytoplasmic phospholipase A2 (CPLA2), 
which has also been proposed as a substrate of p38 MAP kinase (Borsch-Haubold et
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a i, 1997). However, the concentration of SB 203580 (1 |iM) used in this study has 
previously been shown to have no effect upon arachidonate release from IL-la- 
stimulated HeLa cells (Ridley et al., 1998) or thromboxane release in collagen 
stimulated platelets (Saklatvala et a i, 1996) indicating that neither cPLAz or 
cyclooxygenase are directly inhibited by SB 203580 at this concentration.
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Figure 6.5: Inhibition of IL-la induced prostaglandin Ez (PGE2) production in HeLa cells 
overexpressing dominant negative and anti-sense MAPKAPK-2 RNA. Control cells (pcDNA3 
transfected) were also pre-incubated with SB 203580 (IfiM) or DMSO (0.1%) for 2 hours followed by 
treatment with DL-la (20 ng/ml) for 16 hours. The overlaying culture medium was removed and PGE2 
levels were assayed. No PGE2 measurements in the absence of IL -la were taken for the control cells 
treated with SB 203580 or DMSO. The above diagram is a representative of three experiments. Data 
points are mean +/-SD of triplicate readings.
IL-1 is a potent stimulant of prostaglandin production and as expected stimulation of 
the cells in the control reactions, pcDNA3 and pcDNA3+DMSO (annotated as DMSO 
in Figure 6.5), produced large amounts of PGEz (-13 and 10 ng/ml respectively). In 
contrast, the amounts of PGEz produced by stimulated cells overexpressing dominant 
negative MAPKAPK-2 ( <1 ng/ml) and MAPKAPK-2 anti-sense RNA (~4 ng/ml)
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were significantly less, indicating that in these cells IL -la  induced PGE2 synthesis 
was severely impaired. In fact, PGE2 induction in the stimulated dominant negative 
expressing cells was less than twice that of the unstimulated dominant negative 
expressing cells. This result reflected the level of COX-2 protein induced by IL -la  
within these cells (Figure 6.4A). SB 203580 (1 pM) reduced the level of PGE2 in the 
pcDNAS transfected control cells by -80%, which was comparable to the percentage 
inhibition (66%), at 1 pM SB 203580 in HeLa cells, observed by Ridley et al. (1998). 
No PGE2 measurements were made for unstimulated pcDNAS control cells with SB 
203580 or DMSO. The relative trend of these data supported the differences in COX- 
2 protein levels as observed by antibody detection and confirmed that the inhibition of 
COX-2 protein synthesis correlated with decreased production of PGE2 synthesis.
6.2.4 Effect of MAPKAPK-2 K93R and MAPKAPK-2 anti-sense overexpression 
on DL-la induced COX-2 transcription
To investigate the mechanism by which the overexpression of dominant negative 
MAPKAPK-2 or MAPKAPK-2 anti-sense RNA may be inhibiting COX-2 protein 
synthesis, the level of COX-2 mRNA within these cells was examined by COX-2 
RNAase protection assays. Cells (1.5x10*) growing in 60 mm tissue culture plates 
were pre-treated with or without SB 203580 (1 pM) or DMSO (0.1%) for 2 hours and 
then stimulated for 8 hours with IL -la  (20 ng/ml) (see Figure 6.5). RPA assays using 
a 256 bp COX-2 riboprobe and a control GAPDH riboprobe were carried out as 
described in Chapter 2, section 2.2.15. The results were then analysed by 
autoradiography (Figure 6.6A) and quantified in a phosphorimager (Figure 6.6B). IL- 
l a  treatment strongly induced COX-2 mRNA (10 fold increase) in the pcDNA3 
control cells. SB 203580 (1 pM) inhibited IL -la  induction of COX-2 mRNA by
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-62% which was in close agreement with the percentage inhibition (72%) of COX-2 
mRNA in LPS-stimulated monocytes at the same concentration of inhibitor (Dean et 
aL, 1999). The addition of DMSO (0.1%) as a control for the inhibitor had no effect 
upon the level of induction. Overexpression of MAPKAPK-2 K93R and MAPKAPK- 
2 anti-sense RNA significantly inhibited the induction of COX-2 mRNA by IL-la. As 
predicted from the IL -la  induced COX-2 protein levels (Figure 6.4A) overexpression 
of MAPKAPK-2 K93R dramatically reduced the level of COX-2 mRNA. In these 
cells the induced level of COX-2 mRNA was inhibited about 93% and there was also 
~2-fold reduction in the basal or uninduced level of COX-2 mRNA when compared to 
the pcDNAS control cells. MAPKAPK-2 anti-sense inhibited the IL -la  induced level 
of COX-2 mRNA by 86% when compared to the control cells. There was also a ~2- 
fold reduction in the basal level of COX-2 mRNA in these cells, which was 
comparable to the level of COX-2 mRNA in the MAPKAPK-2 K93R expressing 
cells. Interestingly, the IL -la  induced level of COX-2 mRNA from the anti-sense 
expressing cells was -2.5- fold lower than from SB 203580 treated cells. This result 
differed from the observed levels of COX-2 protein between these samples in which 
pre-treatment with SB 203580 (1 pM) had a more pronounced effect on COX-2 
protein inhibition. This discrepancy may be a result of experimental variation. The 
results obtained in this experiment clearly demonstrate that IL -la  induced COX-2 
mRNA synthesis is inhibited by overexpressing MAPKAPK-2 K93R and 
MAPKAPK-2 anti-sense RNA and that this effect could be due to decreased 
transcription and/or reduced mRNA stability.
An attempt to look at the role of MAPKAPK-2 on COX-2 transcription by using a 
COX-2 reporter gene (described in Chapter 2, section 2.3.5) was carried out.
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However, IL -la  did not significantly increase the transcription (<2-fold) of a 
transiently transfected COX-2 luciferase reporter gene in the pcDNAS control cells 
and therefore the MAPKAPK-2 K93R and anti-sense expressing cells were not 
transfected with this reporter plasmid. In contrast the transcription of an IL -la  
responsive control plasmid containing an E-selectin minimal promoter was increased 
by ~500-fold in transiently transfected pcDNAS control cells (Figure 6.7). The latter 
result served to confirm the integrity of the IL -la  signalling pathway within these 
cells after transfection.
6000
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Figure 6.7: Effect of IL-la stimulation on the induced transcription of a COX-2/luciferase 
reporter plasmid, CP(-2309/+37) pGL3b, in transiently transfected pcDNA3 control cells. Cells 
(2xl04) were transiently transfected in 96 well plates with 50 ng of renilla luciferase* and 500 ng of a 
firefly luciferase reporter plasmid containing -2300 bp of upstream COX-2 promoter sequence or a 
firefly luciferase reporter plasmid containing 170 bp of upstream E-selectin promoter sequence, ES (- 
170/+52) pGL3b. Cells were stimulated with IL-la (20 ng/ml) for 8 hours and then assayed for 
luciferase. The above diagram is a representative of three experiments. Data points are mean +/-SD of 
triplicate readings, * -see text.
Thus IL -la  strongly induced COX-2 protein and mRNA in the pcDNAS control cells 
(Figures 6.4B and 6.6 respectively) but did not significantly increase the transcription
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of the COX-2 reporter gene (Figure 6.7). These results suggest that IL -la  induced 
COX-2 synthesis in HeLa cells is not due to increased transcriptional activity, but is 
mediated by post-transcriptional events, of which the stability of COX-2 mRNA has 
been previously described (Pouliot et a l, 1997; Dean et a l, 1999; Ridley et a l,  1998). 
Interestingly, in this experiment the rate of transcription of the control renilla 
luciferase vector, containing the hCMV promoter, increased following stimulation 
with IL-1 suggesting that this promoter is responsive to IL-1. As a consequence 
normalising the results between the unstimulated and stimulated samples was not 
possible, however, the relative counts for renilla luciferase between the unstimulated 
and stimulated samples from each transfection were similar.
6.2.5 Effect of MAPKAPK-2 K93R and MAPKAPK-2 anti-sense overexpression 
on Hsp27 phosphorylation in-situ and in-vitro
Hsp27 is a recognised physiological substrate of MAPKAPK-2 (Cuenda et a l, 1995). 
An investigation as to whether or not overexpressed MAPKAPK-2 K93R and 
MAPKAPK-2 anti-sense had a dominant negative effect and blocked IL -la  induced 
Hsp27 phosphorylation in-situ was carried out. Cells were seeded into 6-well tissue 
culture plates and labelled with [32P]-orthophosphate as described in Chapter 2, 
section 2.4.6. As indicated in Figure 6.8, pcDNA transfected cells were pre-treated 
with or without SB 203580 (IpM) or DMSO (0.1%) for 2 hours prior to stimulation 
with IL -la  (20 ng/ml) for 20 minutes. Endogenous Hsp27 was immunoprecipitated as 
described in Chapter 2, section 2.4.1, using an anti-Hsp27 antibody. Samples were 
resolved by electrophoresis on a 4-20% SDS polyacrylamide gel, transferred to nylon 
membrane and analysed by autoradiography (Figure 6.8A and B). As expected SB 
203580 (1 pM) significantly inhibited the IL-1 induced phosphorylation of
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endogenous Hsp27 when compared to cells treated with DMSO vehicle. There was no 
significant inhibition of Hsp27 phosphorylation in cells overexpressing MAPKAPK-2 
anti-sense RNA when compared to the pcDNAS control cells and although a degree 
of inhibition was observed in the dominant negative expressing cells in this 
experiment, subsequent assays demonstrated that this was probably a result of 
experimental variation. These data suggest that overexpressing MAPKAPK-2 K93R 
and MAPKAPK-2 anti-sense is not sufficient to block the endogenous 
phosphorylation of Hsp27 and that other IL -la  induced Hsp27 kinases are likely to 
be present in HeLa cells. This assumption is supported by a recent study in which four 
major inducible Hsp27 kinases in HeLa cell lysates were identified. One was 
subsequently identified as PRAK, which in the same study was also identified as a 
substrate of p38 MAP kinase. A second was identified by western blot analysis as 
MAPKAPK-2 whilst the two remaining kinase activities were not identified (New et 
al., 1998). In a separate study another p38 MAP kinase substrate, MAPKAPK-3, was 
identified and phosphorylated Hsp27 in-vivo (Sithanandam et al., 1996; McLaughlin 
et a l, 1996). The effectiveness of SB 203580 (1 pM) at blocking endogenous Hsp27 
phosphorylation is probably due to the fact that the known major inducible Hsp27 
kinases are substrates of p38 MAP kinase. From these findings it is clear that Hsp27 
can be phosphorylated by a number of known and unknown kinases and that 
overexpressing a mutant or anti-sense form of one of these kinases, MAPKAPK-2, is 
not by itself effective at blocking Hsp27 phosphorylation in-situ.
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Figure 6.8: Effect of overexpressed MAPKAPK-2 K93R and MAPKAPK-2 anti-sense RNA (A/S) 
on inhibiting Hsp27 phosphorylation in-situ. Labelled cells (106) were incubated for 2 hours with or 
without SB203580 (1 pM) and DMSO vehicle prior to stimulation with IL -la (20 ng/nl) for 20 minutes. 
Endogenous Hsp27 was immunoprecipitated from cell lysates, resolved by electrophoresis and 
transferred to nylon membrane. Hsp27phosphorylation was visualised by autoradiography. The 
images from two exposure times 2 hours (A) and 16 hours (B) are shown.
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Next, to investigate whether overexpressed MAPKAPK-2 K93R or MAPKAPK-2 
anti-sense RNA interfered with endogenous MAPKAPK-2 activation induced by IL-1 
stimulation, in-vitro kinase assays using GST-Hsp27 as substrate were carried out. 
Cells (106) were seeded into 6-well tissue culture plates and pre-incubated, as 
indicated in Figure 6.8C, with or without SB 203580 (1 pM) or DMSO for 2 hours 
prior to stimulation with IL -la  (20 ng/ml). Cells were then lysed and endogenous and 
mutant MAPKAPK-2 enzymes were immunoprecipitated using two different anti- 
MAPKAPK-2 antibodies, #06-534 (Figure 6.9A) and #sc-6221 (Figure 6.9B). In-vitro 
kinase assays were carried out as described in Chapter 2, section 2.4.5. The samples 
were resolved by electrophoresis, transferred to nylon membrane and analysed by 
autoradiography (Figure 6.9A and B). As expected, in both experiments pre­
incubation of the pcDNA3 control cells with SB 203580 (1 pM) completely inhibited 
GST-Hsp27 phosphorylation, indicating that endogenous MAPKAPK-2 activation by 
p38 MAP kinase was inhibited in these cells. However, a comparison of the results 
from both experiments indicated no significant difference in Hsp27 phosphorylation 
that could be attributed to overexpression of dominant negative MAPKAPK-2 or 
MAPKAPK-2 anti-sense RNA. This may be explained by the fact that the epitope 
sequences used to raise the two precipitating anti-MAPKAPK-2 antibodies, share 
homology with the Hsp27 kinase MAPKAPK-3 (see Table 6.1). These experiments 
suggest that overexpressed dominant negative MAPKAPK-2 or MAPKAPK-2 anti­
sense RNA does not measurably interfere with the activation of endogenous 
MAPKAPK-2. However, it can not be ruled out that in these assays the activity of 
MAPKAPK-3 is also being measured and that this may mask any dominant negative 
effect on endogenous MAPKAPK-2 activity. Since, MAPKAPK-3 is activated upon
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Figure 6.9: Effect of overexpressed MAPKAPK-2 K93R and MAPKAPK-2 anti-sense RNA (A/S) on 
endogenous MAPKAPK-2 activity. Cells (106) were incubated with or without SB 203580 (1 fiM) or DMSO 
vehicle prior to stimulation with IL -la  (20 ng/ml) for 20 minutes. MAPKAPK-2 was immunoprecipitated with 
two different anti-MAPKAPK-2 antibodies #06-534 (A) and #sc-6221 (B) and incubated with GST-Hsp27 
(3 pg) in an in-vitro kinase assay. Phosphorylated GST-Hsp27 was analysed by autoradiography.
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phosphorylation by p38 MAPK pre-treatment with SB 203580 would inhibit any 
activity contributed by this enzyme in the kinase assays.
6.2.6 Effect of MAPKAPK-2 K93R and MAPKAPK-2 anti-sense overexpression 
on IL -la  induced IL-6 and IL-8 production
IL-6 and IL-8 are two important mediators induced by IL-1. Secreted IL-6 and IL-8 
were assayed from the overlaying culture medium from cells pre-treated with or 
without SB 203580 (1 (iM) or DMSO (0.1%) vehicle for 2 hours prior to stimulation 
with IL -la  (20 ng/ml) for 16 hours. Due to the variability of the levels of IL -la  
induced IL-6 and IL-8 produced in this study, the results from four separate IL-6 
(Figure 6.10) and IL-8 (Figure 6.11) assays are shown for discussion. As expected IL- 
l a  induced the levels of both IL-6 and IL-8 in the pcDNA3 control cells and in the 
absence of IL -la  there was no significant production of either cytokine. Analysis of 
the IL-8 assay results revealed that SB 203580 caused partial inhibition in three out of 
four experiments when compared to the DMSO treated control cells. This results 
contrasts with that seen by Ridley et al. (1998) who reported that IL -la  had little or 
no effect on IL-8 production in human gingival fibroblasts and HUVEC cells. 
However, in a more recent report Suzuki et al. (2000) demonstrated that SB 203580 
inhibited IL-1 (3 and TNFa induced IL-8 production in a dose dependent manner, in 
rheumatoid synovial fibroblasts. Overexpression of MAPKAPK-2 anti-sense RNA 
had no significant inhibitory effect in three of the four experiments whilst the 
dominant negative MAPKAPK-2 mutant had no apparent inhibitory effect in all 
experiments.
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Figure 6.10: Effect of MAPKAPK-2 K93R and MAPKAPK-2 anti-sense RNA overexpression 
on IL -la  induced IL-6 secretion in HeLa cells. Cells were pre-treated for 2 hours with or 
without 1 |iM SB203580 or DMSO vehicle prior to stimulation with DL-la (20 ng/ml) for 16 hours. 
The overlaying culture medium was removed and assayed by specific IL-6 ELISA. IL-6 values 
were not determined for unstimulated DMSO or SB203580 samples. The above figure shows the 
results from duplicate samples from four separate experiments. Unstimulated □  , stimulated 0
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Figure 6.11: Effect of MAPKAPK-2 K93R and MAPKAPK-2 anti-sense RNA overexpression 
on IL-la induced EL-8 secretion in HeLa cells. Cells were pre-treated for 2 hours with or 
without 1 pM SB203580 or DMSO vehicle prior to stimulation with IL -la (20 ng/ml) for 16 hours. 
The overlaying culture medium was removed and assayed by specific IL-8 ELISA. IL-8 values 
were not determined for unstimulated DMSO or SB203580 samples. The above figure shows the 
results from duplicate samples from four separate experiments. Unstimulated □  , stimulated U
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SB 203580 has been shown by several workers to inhibit both TNF and IL-1 induced 
IL-6 production in several cell types (Ridley et a l, 1997; Miyazawa et a l, 1998; 
Suzuki et a l, 2000). In this study SB 203580 inhibited IL -la  induced IL-6 production 
in two of the four experiments when compared to the DMSO treated control cells. 
Significantly, overexpressed MAPKAPK-2 anti sense RNA dramatically reduced the 
levels of IL-6 in all experiments when compared to the pcDNA3 transfected control 
cells. In all cases this reduction was lower than that observed using SB 203580. The 
results from cells overexpressing dominant negative MAPKAPK-2 were slightly 
ambiguous. In two of the experiments elevated levels of IL-6 were observed, whilst in 
the other two experiments significant inhibitory effects were observed. As indicated 
above the high degree of variability observed in the production of IL-6 and IL-8 in 
these assays has made these results difficult to interpret. However, it is clear that 
HeLa cells overexpressing MAPKAPK-2 anti-sense RNA had a reproducible and 
significant inhibitory effect on IL -la  induced IL-6 when compared to the pcDNA3 
transfected control cells.
6 . 3  D i s c u s s i o n
In this chapter evidence has been presented suggesting a role for MAPKAPK-2 in the 
regulation of IL -la  induced COX-2 synthesis. HeLa cells stably transfected with 
either a catalytically inactive MAPKAPK-2 mutant or a MAPKAPK-2 anti-sense 
RNA construct showed significant inhibition of IL -la  induced cyclooxygenase 2 
(COX-2) protein synthesis and prostaglandin production. In both cases the inhibition 
of COX-2 protein correlated with an inhibition of COX-2 mRNA synthesis. In 
addition to the above findings overexpressed MAPKAPK-2 antisense RNA 
significantly inhibited IL -la  induced IL-6 production, suggesting a role for
183
MAPKAPK-2 in IL-1 induced cytokine production. Although it is possible that the 
results obtained from these cell lines are due to other genetic changes in other 
signalling pathways, the fact that these cell lines show Hsp27 phosphorylation in 
response to IL-1 confirms that the IL-1 receptor response is intact. In addition the fact 
that two independent approaches to modify the MAPKAPK-2 phenotype gave similar 
results on COX-2 synthesis suggests that a specific effect has been obtained
The exact mechanisms of inhibition by anti-sense and dominant negative mutants are 
unclear. Inhibition by anti-sense RNA is presumed to be due to decreased endogenous 
enzyme activity that is a consequence of reduced MAPKAPK-2 mRNA. By contrast 
the overexpressed MAPKAPK-2 K93R mutant may inhibit the function of 
endogenous MAPKAPK-2 by several different theoretical mechanisms such as; by 
binding to p38 MAP kinase and interfering with its activation by MKK6, by 
competing with endogenous enzyme for activation by p38 MAP kinase or by binding 
to downstream substrates and preventing their phosphorylation or subcellular 
targeting. From this we can speculate that MAPKAPK-2 anti-sense RNA affects IL- 
l a  induced COX-2 and IL-6 synthesis by reducing the activity of endogenous 
MAPKAPK-2 on all downstream substrates involved in the regulation of these genes. 
In contrast, the MAPKAPK-2 mutant may differentially regulate the induction of 
these genes by binding specific downstream substrates of the endogenous enzyme. 
The conformational change imposed upon MAPKAPK-2 K93R as a result of the ATP 
binding site mutation may allow it to preferentially sequester and bind a downstream 
substrate that is specific for COX-2, therefore explaining the dramatic inhibition of 
induction of this gene.
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The role of Hsp27 in pro-inflammatory cytokine signalling is unclear. Although not 
conclusive the data presented in this chapter suggests that Hsp27 is not involved in 
pro-inflammatory cytokine induced COX-2 and IL-6 synthesis. This notion is also 
supported by the finding that in L929 cells that lack Hsp25, the murine homologue of 
Hsp27, TNF signalling is unaffected, excluding a role of murine Hsp25 (Hsp27) in 
TNF action (Beyaert et a l, 1996).
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Chapter 7
General Discussion
At the start of this thesis p38 MAP kinase had only recently been described (Han et a l, 
1994). The link between p38 MAP kinase and the response of cells to pro-inflammatory 
cytokines was first established by Saklatvala and co-workers who showed that IL-1 
activates a protein kinase cascade that results in the phosphorylation of the small heat 
shock protein, Hsp27, probably by MAPKAPK-2 (Freshney et a l, 1994). Subsequently 
workers at SmithKline Beecham showed that p38 MAPK was the target of a series of 
pyridinyl imidazole compounds which inhibited the production of pro-inflammatory 
cytokines (Lee et a l, 1994). As a consequence of these findings this project was 
undertaken with two inter-related aims. First, to try and identify additional novel enzyme 
components or interactions within the cytokine signalling pathway and second to 
examine the role of the p38 substrate MAPKAPK-2 in pro-inflammatory cytokine 
signalling. Using a PCR based strategy the enzymes described above were successfully 
cloned, mutated and epitope-tagged as described in Chapter 3. In Chapter 4, 
reconstitution experiments in-vitro confirmed loss of kinase activity in the recombinant 
p38 MAPK and MAPKAPK-2 enzymes, as a result of mutating the conserved lysine 
residues at their respective ATP binding sites. Following the successful outcome of these 
studies the enzymes were expressed as GAL4 binding domain fusion proteins and used as 
bait in a yeast two-hybrid screen. In Chapter 5, a novel protein interaction between 
MAPKAPK-2 and a human polyhomeotic 2-like protein (HPH2-like) is described.
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Analysis of the HPH2-like protein revealed that there was no obvious connection with the 
p38 MAPK pathway and the significance of the interaction was unclear. It is interesting 
to note that in this study MAPKAPK-2 K93R did not detect p38 MAPK or Hsp27. In 
Chapter 6, the results form HeLa cells stably expressing dominant negative MAPKAPK- 
2 and MAPKAPK-2 anti-sense RNA suggest that MAPKAPK-2 is involved in IL -la  
induced COX-2 synthesis and possibly IL-6 synthesis. Although not conclusive, evidence 
from these cell lines also suggests that Hsp27 is not involved in pro-inflammatory 
cytokine induced gene expression since its phosphorylation in-situ was not noticeably 
affected.
At the time of completion of this study evidence from MAPKAPK-2 knockout mice 
indicated that MAPKAPK-2 plays an important role in gene regulation (Kotylarov et a l, 
1999). In these animals circulatory TNF levels were reduced by 90%. This was shown to 
be due to reduced protein and not decreased amounts of TNF mRNA. In addition these 
animals also had an increased resistance to LPS challenge. In contrast. Northern blot 
analysis of various cytokines in isolated spleen cells from LPS stimulated animals 
showed significantly reduced levels of IL-6 mRNA implying a role for MAPKAPK-2 in 
transcription or mRNA stability or both. In the MAPKAPK-2^ mice the effect of 
MAPKAPK-2 on COX-2 was not examined. Consequently it would be interesting to test 
the IL -la  induced COX-2 response in, for example, fibroblasts isolated from these 
animals.
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Although many unanswered questions have arisen from this work, the results provide a 
new focus for future studies. One important topic will be to identify the downstream 
substrates of MAPKAPK-2. Although yeast two-hybrid methodology was tested in this 
study, the failure to detect any known MAPKAPK-2 proteins indicate that the success of 
this technique may be determined by many factors, such as the choice of bait protein, 
conformation changes imposed by mutagenesis or the cDNA source. More recently 
proteomic studies have being used identify new proteins in-situ. This technique could be 
employed to look for phosphoprotein differences between the HeLa control and 
MAPKAPK-2 mutant cell lines. Current evidence using a tetracycline-controlled 
expression system in HeLa cells suggests MAPKAPK-2 may regulate gene synthesis in 
part by stabilising mRNA (Winzen et a i, 1999). In this report, constitutively active 
murine MAPKAPK-2 stabilised a p-globin reporter mRNA containing IL-8 3 -UTR 
sequences, whereas a dominant negative MAPKAPK-2 mutant interfered with MKK6 
induced stabilisation. To search for novel downstream substrates of MAPKAPK-2 
techniques such as the RNA-protein hybrid technology may be more successful than 
protein-protein interactions. This system allows the detection of interactions between 
known RNA bait for example, COX-2 or IL-6 and a potential RNA binding protein. Such 
studies may identify proteins involved in controlling pro-inflammatory cytokine induced 
gene synthesis and thus provide therapeutic opportunity for controlling inflammatory 
diseases.
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